[go: up one dir, main page]

WO2025117544A1 - Engineered omega guide molecule and iscb compositions, systems, and methods of use thereof - Google Patents

Engineered omega guide molecule and iscb compositions, systems, and methods of use thereof Download PDF

Info

Publication number
WO2025117544A1
WO2025117544A1 PCT/US2024/057461 US2024057461W WO2025117544A1 WO 2025117544 A1 WO2025117544 A1 WO 2025117544A1 US 2024057461 W US2024057461 W US 2024057461W WO 2025117544 A1 WO2025117544 A1 WO 2025117544A1
Authority
WO
WIPO (PCT)
Prior art keywords
swa
systems
compositions
com com
engineered
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
PCT/US2024/057461
Other languages
French (fr)
Inventor
Feng Zhang
Han ALTAE-TRAN
Soumya KANNAN
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Massachusetts Institute of Technology
Broad Institute Inc
Original Assignee
Massachusetts Institute of Technology
Broad Institute Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Massachusetts Institute of Technology, Broad Institute Inc filed Critical Massachusetts Institute of Technology
Publication of WO2025117544A1 publication Critical patent/WO2025117544A1/en
Pending legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/22—Ribonucleases [RNase]; Deoxyribonucleases [DNase]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/20—Type of nucleic acid involving clustered regularly interspaced short palindromic repeats [CRISPR]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/351—Conjugate
    • C12N2310/3519—Fusion with another nucleic acid

Definitions

  • ene seuuee .. are arence aren -o- re re-o- -o- re re-o- nosarone eanree saeurueeence aren -o- re re-o- -o- re re-o- nosarone eanree saeurueeence aren -o- re re-o- -o- re re-o- nosarone eanree saeurueeence aren -o- re re-o- -o- re re-o- nosarone eanree saeurueeence aren -o- re re-o- -o- re re-o- nosarone eanree saeurueeence aren -o- re re-o- -o- nosarone eanree saeurueeence aren -o-

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Absorbent Articles And Supports Therefor (AREA)
  • Prostheses (AREA)
  • Materials For Medical Uses (AREA)

Abstract

The present disclosure provides engineered OMEGA guide molecules, trans-oligonucleotide activated OMEGA guide systems, and compositions and systems comprising engineered IscB polypeptides. Methods of modifying target polynucleotides using the compositions and systems described herein are also provided.

Description

, , - , , .. ... . ,, .,, , , . . . ,, -. _., , , . , , . . - , . . , , . , , , ’ ,’ , , . , . ,’,’, . ,. , . . , , . ,’,’, . , . ., , . . , , ’ ’ .’ , , , , , , , , , , ,,,,,, ,, ,,, , , , , , , . , , , , , , ’ . , , ’ , , . ,- - , . . ,’ ’ ’ . , ’ ,. ’- . , , , , . , . . , , -, . , , . , , , , , , . -. ,, . - ., ,, . , . . ,. , . , - , - - . . . , , -- . , , ,,, . , , , ,, . , , , ,, , . -, . , , . , , , ,- , , ,, , . , , , , , , , , , ,, , , ,, , , , , , , , , , , , ,,, ,,,,,,,,,,,,,, , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , ,, ,, ,, ,, ,, ,, ,, ,, ,, ,, ,, ,, ,, ,, , , , , , , ,, , , , ,, ,, ,, ,, , , ,, , , , , , ,, , , , , , , ,, ,, ,,,,,,, , , , , , ,, , , , , ,, ,, ,, ,, , ,, , , , , ,. , , , , , , , ,, , , , ,, ,, ,, , , , , ,,, , , , , , ,,,, ,, ,, ,,, ,, ,, , , , , , , , , ,, , , ,, ,, ,, ,, , , , ,, , , , , , , ,,, ,, ,, ,, , , , ,, ,, ,, ,, , , , ,,,,,, ,, , . , , , , , ,, , ,,,,,,, , , , , , ,, , , , , ,, ,, ,, ,, , ,, , , , , , , , . , , , ,, . , , , - . ., . , , ., - , , , - - , . , . - , - , . , , ., , , - , . , . - , . , . , , .. , , , ., , - , , . . , - , , , . , , .- – . ´´´.. . ´. . ´ . . ´, ~ . . .. ´ . - . -, .. . ´ . . ´ . . ´ .- – . ´ -, . ´ -´ . . –-. . . . - -. . . - -, , , -,-, , , ,-, -, , -, -, , -,, . – , - . . .-.- .- – . .-.- . – .-.- . .-. - . – - . . .-.- . – - . .-.- .– – . .- , , - ..- ,, . . -, . 1. . ***.. -- - . . ,=. *., **., . , =.. -.– – -. ., - . . . - - . . ,, . ,. - . . - . - - . . . . - . , -, , ., -, - , =. *., **., ***. - - -. ., -,, =. - - - . - - ,. -, -- - . . - - . ..– – . . . . , ’ ., ’ ,- . ,. ’’ ′. . , =. . . - .. – – , =. . . . . - - - . - . - , =. - . - , =. - .- , =. , . -. . ,.- , =. . . = , .– – . . - . . . . . ... . - ..– – - - . . ,. . . ,-., - -. . .– – . 1 . , -- , . . .1 . . - .. . ,. , , .. – . . , . ,. , . , . - , , . , .– – . . , - -. . . . . - . - .– . . – -- . -, , , . - - - - . . . . ., =. . - - . ,--, .– - . ..–- – __ . - -. . - - . - . . . , -. . .- -- . - . -. - . -. . - , ,- . - - - - . . - - - . . ..– – ----- - ,- - . , -- ----- - . . -- , , - , ,, . . .– – ---- .- . - - . -- .– – ’ . . - - . ′ ’’ .′ . . - --. . . ′ - , ., .– – . -- - . , =. - .- - . , =. - - , =. . . .. , . ,,n ,. .t , , . .... ,.. , .. . n, ,. .. ,. , .. . , . , , , . ., . ., , . , ,.,.,. ,.,..,, , ,..n ,. ,, “”, “”, “” , . “ ” “ ”. , , . “” “, . , , ” , -. , , -, ,- ,- . , “” “, “ ” ” , , . . “ ”. , ,, , , , , , ,,, , , , , , , , ,,, , , , ,,, ,, , , , , ,, . , , . “ ,” . , “ ,,” “ ” , , , , , ,. . ,, . . . “ ”, “ ,” . ,” , “ “ . , ” ,” “ ,” “ , . ,, , , . , , , .. , . , , , ,.. ”,,. , , “ “ - . ,”...,, ,.,, . , , , . “. ,, , , “ ”, , , “ ”, .. . ,, , , .” , , . ., , ,,-.- - - . ,, . , , , , , -. , , , . . , , ’ , . - ., . ,.. . . “ ,” “. .., ,” “ ,” “ ” . “ . , . ” - . _ . , ,,,,,,,,,,,,,,,,,,,,,,,, ,,,,,,,,,,,,,, ,,,,,,,,,,,,,,,,,,,,,,,,,, ,,, ,,,,,,,,,,,,,,, .,,,,,,,,,,,,, ., ,, ’ . ,- - , -, . . - . . , , . ,..,,,. ,, , , .,,,..,,,, ,, ,,., ,..,,,, ,. .,,, ,..,,,,, ., , ,..,,,,,, , ,,,,,,,,,,,,,,, ,,,,,,,,,,, ,,,,,,,,,,,,,,,,,,,,,,,,, ,, ,,,,,,,,,,,,,,,,,,,,,,,,,, ,,,,,,,, ,,,,, ,, ,,,,,,,,,,, ,,,,,,,,,,,,,,,,,,,,,,,,,, , , . . , _ , _ _ . _ . , . , . “ , ’’ . -” . ,. , . ,.., , , , . , , , , . - ., , , . , . , . , , . , . , . . , ’ ,’ _ ,,,,,,,,,,.,,,,,,’ ’ . ,,,,, ,,,,,,, ,,,,, , ’, ,,,,,,,,,,,,, ’,,,,,,,,.,,,,,,,,,, . ,. , . . “ ” .., , , .., . , , ,, . - . , ,.., , ,. . ,. , . , , . . , , . , ., , , - . . , , , , , , . - ,. ,.., ,, . ’ , ,.., -, , – ,. ,., ., ,– ,..,,.., , , – ., , . , , , ,,- , , . - , . , ,. – ., , , ., ., ,’- , ,– ,- , - ., - –, – , , –,, -, , , , ., -’ – , – , , , – ., , , , , .,–,, –.,,, , – ,., .,, , –., , , –,, , – -’ ,, , , – ., – ., , , – ., ,,-, .,., ,,, – , -- , , – , – ., ,. . , ,. ,.., . , ,,–. - ., . , , , . - ...,, - . . , . . , . , , . ,. , . .’, ’, ’. . , . , ’ , .. . , , . , ,. - — ,..., “ ” -. , , ., .- , - ’, . , ’, . . , . , , . , . . , . , , . ,. -. ., .,. , , , , ., ,,, - . , ’,, ’, ’. . ’. , , , ,.., . , . , . , - ,- - ., .., , , , -- — , . — ’. ’, ’ , ’ . , . ,- . - -.’, ’, . , ’ ’. , ,,..., . , . , , . , , _ . , - . , “ ” , . . , , ,,,, ,, ,,,,,,, ,, ,,,,, ,, , , , , ,,,, ,., , ., ,, , , . , .. , . , , . , _ . , - . , - . , , . .- ,- - . .- , .., “ ”, . - ’ . . , “ ” . ,’ ,,,,,.,., , ’,,, . ,,,,,,,,,,,, ’ ,.’ ’ ’.-. .-. - , . , .., , ,, ,. ’ . ..-. , , ’ ,,,. ’ , , ,,,, . . , . , ’ . ’ , . . , , , , . , . , , . ., , , . -, . . , , , , , , . , . , . - . ,., ,. ., , , . ,– ,-. , . . , , , . , ,, ,, ,, ,. , . , , , . ., , , , . . , ,, , . , , , , . , . , , . .,, , . , , , . . .- ,, . -, ,.,,., , . , , ,.., , . , , , ,, ,, , , , , , , , ,, ,, , , , . , , , , . , , , , , , , , , , , , , , ,, ,, -, -, , ,- ,- , - , . , ,- . -’- ’- .,.... . -.,,...... - -’- .,’-. . ’’ “’’” . - “- ”.., - - -, ., - “ - , “” . , , “”“” , “”” - “” “”. . “” ,- - - “” “” “’”’ “”. ’ , - - ’ . . “ ,”,..,- ,.., “ ” , “ . , ” “ .” , ,,,,,,.,, . , ,, . ,, , . , . , . ,, , , , , ,, , , ,,,,, ,. , .,, ,,,,,,,,.,, ,-- - , ,, - .., ., , ,,, , , . ..-, . .-. - , .- , , , . - , .., , , - , , , , . , . - , - ,. . ., . , , , ,- , , - , ,- , - , . , , . , ,- , , , . . -- ,, . -, ,.,.,, , ., , . ,.., , , , , , , , , , , , , ,, , , , ,, , , , , , . , ,. , , , , , , , , , , ,, ,, , , ,- , , , , , , , - - - ,. - . ’-, ’- ,- - , .,.... .,..... - -’- .,’- . -. . - . .,. . . , , , . .. - -. ,..- . ,.. ,. -,,. ,. ,.. ,.. ,. . ,.. ,.. ,.. , - . , ,,–. - , . ,’-, ,,,,,,,. .’- ,,, ,,,,,, , ,,,,, . ,,, , . - . . , . , . , . , - . ,, ,, ,, ,, , - ,. , - .- , - , .- - , , - ,.- . , , - . ., - , ′ ′, '-- , , . . , '-,- ,'-- - , , , , ,- . ′ , , ′-- ,′-- .- ,′-- ′ . , , , ,. - .- .,, , -, . ., . , - . - .,.. - ., , ..,.,,, - ., ,.,, . ---. . . . , ,’ , ,, ,’ , , , . ., ,. . -. , . ,.. ,-, ’ ’ ’ , .’- ., ,’- ’-- ,’-- ’’ ’ ,- , ’-- ’ , .,. .. -.’ .’ . ,’--,’- - ., , , - . , , , , ’ ’. , , , , , , . . , , , , . .,,, , , .. - . , .. , , , . , ,,, - , ... - , . ., . ., - ..... -- ,., ,., . . - -’ , ., - ’- - ’.... - , . -- .,’.- .,.... ,. -. . , ..,, - , , . , , - , , ..,, , , , , .., , , , . .., , , , , , ., , , ,, , , , ,, , , -, , ,, ., . , , , .., - . - . ., , - .- ., , . .. , , . , ,. , , , “ .” ,--. ,,, . " ." , ., . -. “ ." - , ,.. " -.” ,, . , -.. , .", .., .-,. . . " , , .. " , ." . . - - , , ,.., , , ,. , , , . , , , , , . , , , , . ., , , , -- . , , . . . - , ,. , , , . . , , , .. , , . . . - ., . . . . ,. - ,-. . .., .. .,. - ,.., .. ... , .., - - ,.., .. . . - . , , ,, , - , , . . .- . , - ,.., , . ,. - , . , , . , . , . , , , .. , . , , ‘. ’ . , “. ” . , , . ,,., . ,- , . , . . , . , . . , , , ,,. , ... . . ,,.. . , . , , ,. , , , , ,, ,, ,,,,, ,, ,, ,, ,, , , , , , . , . . . . , . . , , . , “” ,. , , . , . . , , , , . , . . , “ ” . . ,... ' , , . ,.,. ,. " ", . . , , , ,. , , ., " " . .,.,.-. .,.,.-..,.,.- . , , , , , .. , . , -. , , -. . ... .. .. , ., . , , . , , , . . . - . - , , , -,. , , - , , ,. ., ,, . . , , , . . . - . - , . . , , . - . - , , . , , , . , . . ’ ,, “ ” “ ” ’ , .., - . , ’. “ ”. “ “ ” . ”, ,. . ,., , . , . . , , - ,.., - , . . . , , - . , , , ., . , - . ,- . , , , . -.. ∼ ′- ., , , ′–- .,.,. ∼ ., ,- . , , .., – . .., , . ., ,- . .,., , ,–. , ,. - . , . , . - ., - - ,- ,,, . , - - . , - -- . , . , , . , - , -,,-, - . . - .- , . . , ., “ - - ., ,” - . . . , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , . , , , , , -- ,. , ,- , - ,- - . - ,- ,- , . , , –
Figure imgf000053_0001
Figure imgf000054_0001
_ ,,_ . . _ . . . . , . . , , , , , , , , , ,, ,, ,, ,, ,, ,, ,, ,, ,, , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , ,, ,, ,, ,, ,, ,, ,, ,, , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , ,, ,, ,, ,, ,, ,, ,, ,, ,, ,, , , , , , , , , , , , , , ,, , , , , , , , , , , , , , ,, , , , , , , , , , , , , , ,, , , , , , , , , , , , , , ,, , , , , , , , , , , , , , ,, , , , , , , , , , , , , , ,, , , , , , , , , , , , , , ,, , , , , , , , , , , , , , ,, , , , , , , , , , , , , , ,, , , , , , , , , , , , , , ,, , , , , , , , , , , , , , ,, , ,, , , , , , , , , , , , ,, , , , , , , , , , , , , , , ,, , , , , , , , , , , , , , ,, , , , , , , , , , , , , , ,, ,, , , , , ., , , ,,,,,,, ,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,, ,,,,,,,,,,,,,,,,,,,,,,,,,,,, ,,,,,,, ,,,,,,, ,, ,,,,,,,,,,,, ,,,,,,,,,,,,,,,,,,,,,,,,,,,, ,,,,,, ,,,,,,,, , ,,,,,,,,,,,,, ,,,,,,,,,,,,,,,,,,,,,,,,,,,, ,,,,,,,,,,,,,,,,,,,,,,,,,,,, ,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,, ,,,,,,,,,,,,,, ,,,,,,,,,,,,,, ,,,,,,,,,,,,,, ,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,, ,,,,,,,,,,,,,, ,,,,,,,,,,,,,, ,,,,,,,,,,,,,, ,,,,,,,,,,,,,, ,,,,,,,,,,,,,, ,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,, ,,,,,,,,,, , , , ,,,,,, ,,,,,,,,,, , , , , , , ,,,,,,,,,,,,,,,,, ,,,,,,,,,,,,,,,, ,,,,,,,,,,,,,,,,, ,,,,,,,,,,,,,,,, ,,,,,,,,,,,,,,,,, ,,,,,,,,,,,,,,,, ,,,,,,,,,,,,,,,,, ,,,,,,,,,,,,,,,, ,,,,,,,,,,,,,,,,, ,,,,,,,,,,,,,,,, ,,,,,,,,,,,,,,,,, ,,,,,,,,,,,,,,,, ,,,,,,,,,,,,,,,,, ,,,,,,,,,,,,,,,,,, ,,,,,,,,,,,,,,,,,,, ,,,,,,,,,,,,,,,,,, ,,,,,,,,,,,,,,,,,,, ,,,,,,,,,,,,,,,,,, ,,,,,,,,,,,,,,,,,,, ,,,,,,,, , ,, ,,,,,,,, ,,,,,,,,,,,,,,,,,,, ,,,,,,,,,,,,,,,,,, ,,,,,,,,,,,,,,,,,,, ,,,,,,,,,,,,,,,,,, ,,,,,,,,,,,,,,,,,,, ,,,,,,,, , , ,,,,,,,, ,,,,,,,,,,,,,,,,,,,,,,,,, , . . , ~ , . , , , , . - -, -,.- . - , .- . , - . , . , , .. ,, , , , , – . , , , ,. , – . , , , ,. , , , . –,. , - , ,.. ,. .,–. , ~, . . - . . ~ - , , -, , - , - , , , - , . .
,.., -, - -. , . . ., , , ,, ,, , , ,. , , , , - , . -- , - . - -,.- ,, , , , , , - ,. ,- , , , - . , - , - . , ,, ,, , , - ,. ,, - , . - -, .- ,, , , , , , -, ., , , , ,, .., - - ,, ., - ,, - - ,. – , ,-- , .. - - , ., -. - , , -.. , .., , - . , . , .- , - - , -.-- , . , ’ - - -. - .., .., . , , ,. , , , . , - . , - –. - - , , ,, . .., . . -, , , , , . , , . , ,, , , , , , .. - , , . , - . , , - . - . . -, , . , .- . .- . ., , - , ,. , ,, , , , , ., ,, ,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,, ,,,,, -,,, , . ,,,,,,,,,.,,,,,, ,,,,, - . , ,,, - , . ,.. ,,, , , .-. . -, . - , , , , , , , , , .,, ,,,,,,,,,, ,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,, ,,,,,,,,,,,,,, ,, .,.. , . - ,.. ,..- ., . -. ,. . . . - . , , , , ,. . , .-. . . , , .,,,,,, ~,, .,,,,,,,,, ,,,,,,,,,,,,,,,,,,,,,,,,,.,,,,,,,,,, . - . . - , ,.-., -,.-, . . , -,,,,,,,,,, ,,,, , ,..,, - .. . . ,. , , “ , ” . , . - . , - . , , .. , ,. , . .. , , . , . , . , ,. “ ” “ ” “ ” .... “ ” . , , , , . , ,__ – , . – , . - . , , , , , , . , -, ., -, _, _,- _. . . . , , ,.., , . . , . ,. , , , , , , , , , ,. , ,, , , . , , , , , , , . .... , ,” , “... –, . - . , , . , - - - . ..,. . - ., , , . , , ,.,, ,, ,, , , ,. , . , ,. , , , , ,, ,, , , . , . , ,. , , , , , , , ,. , , , ,, . .., , ,, , . ,-–, - – – , –. , . - , . , . . , . ,, ,, , , , , , , , . - - . , . , . - , - , , ,- . ., , ,. . , , . . , , . , . . ,. , . , , . , .,. , . , ., ,.., . -, _ , - . . , , , . , . , ,,,, , , ., . ,, ,, . .. , 2+. . . , ,-,,, . ., , , . “” - . . -. , . . . . . -. , . “ .” .., , . - , , , .- _ , . , ’, , . ’ . . ,,,,,, . . , , , .., , . . , . , , . . . ..,. , . , , ., , , , , , . , , , , , , , ,, , , , . .., , , , . - - . _ , ,. ,. , , . . . , , , . , . , ,2+, , , , , . - . 2+, . , , , . - , , _ - ,. ,. . . ,., ,,,..,. , ,. , - . . . , - ’-. . “ . , .”,.,.,..,,.,. -,...,. .,. ,. ,. . ,. ,. , ,. - . . , , , . . . ..,. , . - . - _, . , . , , ,.,., -, - -.. . , , . , .. . . . . . , , - , . -- . , - . , - - .- - - - . , - - . - . -, - , .. . , .,, - - -,,,, - - ,. – , , ,-- , ., . . . , .., , , , , - . . . . , . , , -. - . , - . , , - . , -. - ., , . . , , . - , , _ , .- , , , . , , - , . - . . , . . , . , , . ., - , ,’ ’ ,..,. , . , - - , . .. , . ., , - - ., .,..., -, . , .,- , , , . _, ,. , , . , . , - -,- , _ ,- ,- , -,-, - . _ , , - ,- __, - -,- __, __, - _, - - , , , - _ - _,- , _, _ - _ - __, __, __, - - __ - __, __, , - _ - ,-, __, _, , _ . . . ,, - .. , . , , . . , , . . , - -, - -, -- , -. , , , - ,. . - , . - .., , , , , . . -. .- . .. - . - , . - ., .., , - , , , ,. - - , . - - , . , , , , , . , , , , ,,,- ,,, ,,,,,,,,,,,,,,, ,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,, . ,,,,,,,,,,, , .,. , - .. ,..- . ., . -. , ,.. - . . . , , , - . . - - - ,. . - , ,-- . . - , - .. ,- . , . , , . , . , ..,. . , . ..,, , ., , , . ..,,, . , ..,, . ., , . , . ,..,, , - . ,.., . , . , , . . -,.-,.- , .. - ,,,. ,,,,,,,,, ,,,,,, ,,, , , , _, ,_, , . . , , , , ., , , _ _ _ , , -. , . , , _ __ _ . , , , _ , _ . _, _ -_ _, , ,,,., , , _, _ ,., _, _ , , . _ , . , _ , _ _ . _ _ _. _ , . , ,_ _ , . , , , , . , _ _ . _ _ , , , , ._ _, . _ _, ., , , , ,_ _ . , _ , . _ , . , , . , , _ _ _ , . , _ , . _ _ , , , . , . _ _, , , , , , , _ _ . , _ _ , , , , ,_ , . _ ,, , , , , ,. , _ _ , , . , _ , , _ , , , . , . , _ _ , ,, , , _ _ , , . , , , ,. , _ _ , , , , _ _, , . _ , , , _ , . _ _ ,., , , , , _ _ , , _ , , ,,. ,_ , , , ,. , . _ _ _ ,_ _. , . , _ , _ _ . _ _ . , . _ _ _ , _ . _ ,_ . _ , _ _. _ , . _ , _ . . _ , _ , _, _ . _ _ . _ , _ . . , _, _ . “ ” “ . ” . , . ”, , “ . , _. _ , , . ,. , , , , , . . ,, - , -. ., , . , . . . , . , , - .- , . - . , , ,-- . , ,,, . , , , ,, . , , , , , . , -, . , , . , ,- , , , , ,, , . , , , , , ,, , , ,, , , , , , , , , , , , , , , , ,,, , , , , , , , , , , , , ,,,,, , , , , , , , , , , , ,,,,,, , , , ,, , , , , , , , ,, ,, ,, , ,, ,, , , , , , , , , , , , , ,,,,, , , , , , , , , , , , ,, ,, ,, , , , , , , , , , , , ,, ,, ,, ,, ,, ,, , , , , , , , , , , , ,, ,, ,, , , , , , , , , , , , ,,,,, , , , , , , , , , , , ,, ,, ,, ,, ,, ,, ,. , , , , , , , , , , , , , , , , ,, , , , , , , , , , ,, , , , , , , , , ,, , , , , , , , , , ,, , ,, ,,,,,,,,,,,,, ,, ,,,, ,, ,, ,,,,,,,,,,, ,, ,, ,, , , , , , , , , ,, , , , , , , , , , , _, ., , , , , , , ,, , , , , , , , , , ,,, , ,, , ,, , ,,,,, ,,, ,,, ,, ,, ,, ,, _, ., ,, , , . . ,. , . . ,, ,, , . ,,-, , , . - ,. . , , - - . . , - - - “ , , ”.. , , -,.. , - . ,, , , , ,, , ,, ., , , .., ,.., .. , .., , . - ,- , ,- . , .. . ,, , . . , - .., . - → →. , ., - . - , ., . , . , . . , , , . .. “ -”. , .., “ -,.., .,, . . - - . , - . .. -,.., - .- , -.., - ,- , . .., - , - , .. ., .., - , , - , , , ., .., - ,- ,.., - , . , ,.- .-, , – • • , - ,., - . . . - .,, - -- ., - ... - --, ., , ... - , .,- , . , , , . . , , , , - , ..., , ,. , . . . “ ” . ,.. , , . - ’ , ’ .. , , , . , , . . , , , , ,, -. - - , , -- . , , - .. - ,..,- . , . , .., ,.., - . , . , . , , . , - , - , . , , ,, , ,,.., ,., - - , .-- -. . , - - , . - . .-- , . ,- , , . , , , , , . - , . . . ,.., ,.., - . - ’- , - . ’ .’’ , ’ - ,.., , . - - - - .., -- - , . .. . ---, . .., , -, - , , , , , , , ,,,,,, , , , , ,, , , ,,,,,,,, , , , , , , , , , , ., , , - ”, .,., “--- . “ -. ” , , . , , , .. . - , , . , - , . . , - - - - -. , - - - - - . , -- , . . “ , , - ,” , . - . . , . ,’ , . . , . , . , . , , .. ., . ., , ,, , . ., , . . , , “ ” .., . “- ” “ ” . . , . “ ” - ., , “ ” . “ . ”,, .., . “” “,” , ., .., ′, ′ ′ , , . . , ′, , , , ′ “”′, “.”. , , , , “” - ′ ′, . , - . “-- . - ”,- , ., ,. . .. “ ” , . . - . - . “. “ ”” . , . “ ” , . . . . . - -- - - . - - , - -. -- - - - ,. , , - - , - , , - , , . , . . , . - - - . , - . , “ ” , . . . , . . , , . ... ..-. -,. .. , ... - , . - ., . , . ., , ,, , , , , ,,, , , . , ,,, , ,, , . , , , .., , ., . -. , ...---, -... . . . - ., . ., ..- .. . . --- .. - . .-. . - . . . -- .. ... . - . . . . . . - ... .- -- .. . . . ... - ... ... - . .. . - - - .. . . -.... -- . .... ,,- - . ., . , - . . . , .., . , , , ., . . . , ,, . , , , , , , , , , . . , , ,, , , . , , , ,, , , , , ,,, ,, ,. , ,, . , - , ,.., , , .., , . . , , , , - , . , . , - “- -,” . , . ,. - ,, . , , ,, , , , . .., . . . , , . - . - ′-.-′′--′. - - ∼- . - - ∼-- . . - - - - ., . , -, , - -. , , . ,, , . . ,., ,,..,.., ,.., ,.., ,., ,. -, .,.,–. , , . . - , , . - , --, , , --, , , . -, , - . , , , , . . , , , . . , . - – ,, . . ,. . , ,.., . . , .., . , “” “”, ,. ,, . ., “”, ,, . ,.., .., , , - . . , ,, . - ,, , ,. - ,, , . . , - . , , . , ,. -, - - , . ,. - ,. . ,, - ,- - , . , . , - , , .,., ., , ,- . , . - , - , . . ,, .. , - -- . - . .... - -. . - - .... .- ... ,- ... , ,. , . ., - . . . , , - ,- - . - . , ,. - - - . ., -, ’ . - , ’ . - ’ . ,..., . , , ’, ,’ , .,,,, , , ,..,,,,, ,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,, -,,,,,,,,,, . - . - . - . , , - . -. . - , , - . - - .- ,. . -, . ’ . , . .. , - - - , . -- . , , . , , .., , . ,, - , , , , . , ,. -, - ,.,,,,,,,-, .,. '- - , ,, , - . . ,. --. , - --. .,--- , ., , - . . , . -, - . , - - . . , -. , . ,.., .., . . , - . , , , . - - , . , . , , - , - , , - . . . . . , , , , . . , ’ . ., . . , . . - , .., , , .., .. ,, . , ’ ’. . ,- . . . ,.- . . . -, , ”. “. - - . ,- , , ,, .., .. - . ..,, ,. , .. -, - . , “” . , . , . , , . ,.., , . , - . , ., . , . ,, - , . -- - , ,.., — – . - ,. . . , , ,., , ,.., . .- . ,,-. . . - , . - -. , - , .. , - - . - . , - - , , - . .. , ,,- . , . , . . , “ ”, , “ ” . -, . - , . . ., , ‘ –... , , - ..,.. -.,- ’’ . , , . . , , , -., , . - . .. ... , . , – , , , . . , . ..,– .,, - “ ” . . . ~ , , . . -- -. . .,. .,. ,,, ,,, , . ,, , ,,,,,, , , . . . , . , , . .,,.,,.,,., .. , . . --- , , ,.. , .., . , , , ,, , .. ,, ′- -′ ., -, -- . -.. , , , , , . . , , , , . - , , ,.., . . , , - . ,, .., ,.- , , , . , . - ,.., , - - ,. , - ., . , - , ,, ,, , , , . , , . . -.-...-... ., ... , , , , - ., , , , - - , ,. . , -.-. .. - ,. - -. .. , -. , ,.., - . , .- , . , ,.. .,..,,. - _ - . . , -. .,.. ., .. , , , , , . ., ., , ” “.-- - , , ..,. - . - , - - , , , . , , , , , .- , . ,.., . ., - , ,,.,...., ,, ., .. . , .- ,, . ,. , . ,, - .,.., ., , . , , . , . , . , . . , ,, , , . . , . . “ ,” . ,.., - - - . - , -- .. .. , .., , ,.., . .., ., . ,, - . . - ..,. , .., . , . , -, . , . ., , - . , - - ′ ′ ′ ., - , ′ ′ ′ . , . ,. , , , ,, , , ′- ., - . , . , . , , , , ., , ,, - , - . . . , ′, ′ ′ ′ . , ′ -, , . , . - ,.., ’ - . . .., . . , , , , ’ - . . . , ' . , ' -.., ’ . ,. . . ., , . . . , . , . ., ., ,, .., -, .. - -, - . , , ,- ..., . ,, .. , .- , , .., ''. , −, −, . −, −, , ,. , ,, , ,. ,, , , , , , , ,, , , , -, , ,- , - , . , , ., , .., . .., - -- , . . , - , - ..- . , , , . , , . . , , , , ,, -- . , , - - - -. ., , ,..,- . . - , . , -..,,.., . ,. . , , . - , .. “-” - , ... - ..,, ....,, ...,. ,,,, ....,, ....,, ....,, , . , . . ., ,, . , ,. - –. ,, , , . . , . - ′- . , . , . , , ., , , , . . - . , , . , - , . -- ., . , . , - . , - . , - - - - - - - - - , - , -- - . “” - - - . , , . . . . -- -- . , .., “ ” , . - , - “” ′ ′ . - “-” . ..., . - - -... ,,, .. , - - . , - - , -. , ,. - - .., , .., , .. , - . , . -, , - ,, . . - , - . .., - - , -,, . - , , ,. , , , . - ,°™ , , ,′ , , , ″ , , , , ,- ′,′-, , , - , , , , , , - , , , -° , , , , , , , , ,, , , - , . . , .., . , “ , ..”. , .., . . . , , . - -. - .., , . , , , , ,, , , , , , .., , , , , - ,.., , , , . - , , ., , .. ... . .. - . , , ., , , , - , .-, -, ..,, , .., ,.., - -, .., - , .., .., , , , ,,, , , ,, ,,, , .., ,.., , , , , , , , , , , , , , , ,, , , , , - , , , ,,, -- ,-.,, . . ,.,., ,. . .-.- ,, . ,.., ., . . ,..,–. , ,,, , , .. - – - . -, . . . , . ,-.., , ,.,. ,, . . ,-..,., , - . .,.., . , . , ,. . . – . - – - - , , , . . . - . – , , , . . .. -. , -, , ., .., .,..., -., . ., .,- - ., - . . – .- ,. ,, . ., , , , , , . - -. . . ,.., ,., , ,, , . – . . . , , ,..,, , -, , . - . – ,.,- . , . . – , .. . – ,- , ,. , , , , ,. . - . . .-, -,.., , . – . , . . , .- .-.. -–, , . ,..., –. , , ,.., , ., , , -, .- . – ,- , , , . . . ..,. –- -, - , , . .-. . , . ., ,, , . ' ,. ,., ,.., , . - , - . - . , , ., , , , ,,- . ..,, . , ., , , , , , , ..,, , -- , -- , , . - .. ,, , ,, , - . , -- .. , , . ,, , , ,, ,,, ,.., , . -. - , - , , . , ,, , - , , - , - . , - - , , - ..““ ”, ”,““ ”, “ ”, - - ”, . – .. “- - ”, ”, . , , ., , , . - . , . -, , . . . , , , , . , . , , ,. , .., . , , . . “ “ ”, “ ”, “ ”, “ ” , ” . - , , ,. - - . , , , , , , , - , ,, , , -, ,,, ., , , ,,.., -- , -, , ., , , , . . , . . - . “ ”, ,., . “ ” “ ” . “- .” “, ” . “ ” - - . ,,, .., -,,,,, ...,,, ” “ “ . ,,,,,,,,,,,,” ,,,,,,,,,,,,,,,,, ,,, .,, , ” , “ , - - . , . , .- - , ,”, , “.. . , “ ” . , , . . , - , , . , . , , “ “ ” . .” “ “”” . ,, , , , ., , , , , ., , “ , ,” “ ” , - . , . - . , , " " “ ” . , , “ ,.” . “ ”, “,” “ . . ” , , , , ,. , , . , , , “ ” . , “ , ” ” “ .. , . , , , .. ,. , . , .. , ,, , , , . , - . , . , . , ’ . ,,’ .. , . , . , , . , . , ,.., .., , - . , , . ,, ,- , , - . ,,.., ,, , , , . , .., ,,,, ,,,,,, . . , , , . . , , , “ . ” . ,., .. . ”. “. . . , , ..,,,,,,,,,,,,, , . , ,., . , - . ., , ,, .,,.,–, ., , . , , ,, - ,. . - ,., . ., ., ., .. -,– ...-.,,, . , ,.., , , , ,.., .. , , . , . . , ., . .,,.., . . - . ,, ,.., . , - -. ,.., , ., . . , . , ,, ., . , , , ,.., ..,..–. , . ., , , . , . , , .., .,.., . ., . - ,.., -. - , -. - ,. , . . ,. ,.., . . – , .. .– ,.. , . ,.., –. ,.. . . ,.., – , .., ,.., , . , ., ,, , . . , ,.., . , , - , , , , ,- . , , , . , ,, , , .., .. , . . , ,- , .., . . , , . .., ., , , , , , , , ,, ., ,, , .. ,.., . .., , .., ,,, ,-, -,..,, , , ...,–, , ,... . , , , . . , . . - – .. , , ,. ,.. ,.. ,...,.,.,. ,.,.. ,,–. .-, , , . . . , - , - , . - , , , .., ,. . ,., . ..., ..,- , ,. . , - . .,, . . , , ..,, , ,. .., .. , , , , , , , .., ..., , , , , , , , , , , , ., , , , , ..,. , , , . . ,.., , . , . .., .., , , . ,..,,, , , , , . .., , ,,, . .. .., , , . , ,, ,. ,,, . ,.., . , - , ,. , , , - , , . ,- . . . “ , ” , .. . , , . , ..,, , - . , , , , , , , . . . .., - , , - ., , ,, , ..,, - ., . - , , - - , ..,,,.,,, ..,,,, ..,,,,,, , ,,, , , . , , . , , , , , ., - , - . , , ..., - . , , . . , , . . , , , . , ,..., , , , . . -, -, - -, -, -, -, .., , -. ,, , , . -, , . -- -, -,-. - ,.,.. . , - - -.-. .-.- -.-.-
Figure imgf000142_0001
, . , . . - .,, ,,. . , , . . , . , ,, , - . . . - . , , - . ,,- ,.. - , – - -, . - . . , . , , ,, - - . , . ,,.., . . . .,- . ,- , . .., .,,.., .. -., , , ., , ..,, , ,. , ,.., .., . .., ,- ..,- . - . , ,. ,- , ,- , - ,, - . . ,.., . , .., , ,, , . . . . ..,.., , .. , - , ,- -- ,,- -,-,--- --,- --- -,- - ,--,-,"- -,- -- - - - - - - ,-- , ,- -- -- , ,..,., -,.. ,- - . , , , . , . , ,-,..,- . , - - - . , , , ,- -.- --, ,.. , , . , -- . , , , .-., , . , , ,- , , -,- -,- , - --,, . , ,- -- -- . - , ,- --- , ,.., , -- ,,-- -- -,- -- - . , , , . - .. 2+ - , - ,,- .., . , .., , -
, . . . ., , , . , . ,.., ., - , . -, , ,, . - . -. , , -, , -- , , , , - .,,.. . , , , .. , –. – , . , . - , .., .. . - ., . . , -. - . . ,.., ., . ,.. ,.., , . , . ' – ,.™. , –. ,. , . . , , - ' , . ,.. , - –. . ,, - .., . - - , , , . , , . . , - . , . , , .- ,.., ., .. . . , . ...... ,. , , . -..... , , ' ., . , .., . ,.– . ,..–. .,. . - . - - , , . . .., . ,.., ..,.., , , - , , - -,, . - ., , - - -.. –,... .– , - - . - .. , , , . , . , , ,.. -– ,.. –. .. . . –., , .. ,.. , ., .. –. , . , , , , . , , ., .,.. .- - -,.,, . - ,., , ., . -. . .,., . , ,., . ... . - -. , -, , - . . . .- ,- - , - - , . , , ......,,.. ., . -.- . , . , . ,, , , . . , . - , , . . - - , . ,-,. . , . , , . , , , . ,, , - , - - ,, ,. . . ,,.. ,. ., . , - , , , , - . , , - . . ,, , , ,, . , , , , -, - -, , . ,,., ,, , . , , , , . , - , , . , , . ,,, , , , - ., - , - , , , , , , , , , ,. , ,..,, , . , ,, , -, , , -. . .-., ,,,,,,,,,,,, ” “ .., ,,,,,, ,,,,,, , , . , , , , , , . , , - . , , . , ,, . ,.., - .. “ - ” - - . ., - . . . ., ..., - , .., . , , , - . , , . , , . , , , , . . . , ,.., - .. “ - ” - - . ., - . . , , , . . , , , .. , ,,, , .. , , , , ,, , ,, , , , , ,, , , , , , , ., .-, -, .--, -, .-, .-, -, .-, -,, --, -, -, -, - ,. , , ,, , , , ,, ,, , ,, ,. , , ,, .-, .--, -, ,.-, -, .-, -, -,, .--,, -,- -, - , , -. , , . . , , , , , - , ,.. , . ,,.. ,. ., . , - , , , . ,, - . ,,, - . , , ,, . , , , , -, ,. ,- - , , , , . , , . ,,, , , . , - . ,, , , . ,, , , , - , ,. - - ,. - . , - .., -,.,, , - , . ,.-., , , -, . . , - . , , ..- , . , , . , . . . .., - . .., . , . . , . . , ,,. . , ,,, . ,,, , , , ,, . , ,,, ,,,,,,,,,,,,,,,,,, , , , , . , . , , . . , . ,., , , ., ..., , - , . . - . , - . - .., ., ,, - , - , , . - . .- , , . . .., , , ., - ,.. . ., - “ - ” . - . - ., - .. .- . , , . .., - .., , , , , - - . ., , - - - .. ,. ,, - , , . - , - .- . . . - . , . - . " ," - . , , ,. ,,,,,,,,,,. , ,,,,,,, ,,,,, ,,,,,,,,, . ,,,,,, ,, " , - - . ," , , , - , . . , , , . , , , ,., - . . . , , - , . , - , , . , . , . , , , .. , , ,.., . , . - , - . , . ,,,,,,, , . ,,,,,, . , ,,,,,,,,, .., . ,,,,,,, ,,,,,,,,, ,, . ,,, , , , , . . ,, . , - . , . , , , . ,.,.,.., , , , , . , , '' - ,.., ,-. - . . ., , , - - ,.., . , , . ,. , , , ., . ,,,,,,,,,,,, -,-, . -,-, -,, -, --,,--,,--,,-, -, -, -, - ,-,.-,-,, -, -, -, -,- -,-, - -, -, -, -, -, -, -,,--,,--,, -- , ,. , ,, , , , ,, . , - -' ' , , . ,.., . ,.' , ',,,,,,,,.,,,,,' , ' ' . ,,, ' ' .,' ,' ,,,,,,,,,,, ' ' ,,,,, ,' . . . ,' . ,,' '. ' , - . - ,,,,',',,, . ,.., . , ' , , ,.., . . ,, . , . , . . .., ,, ,., , . ., , , , - , , .-. - - ,.- . - - - , - .., , , , - , . - , , ,. , , .- , - . , . , - , . . - , ,.., -- ,. . , , , . , , . - ,, -, , . , , -. . , -, , ,, -, . - ,.., ,.., . , .., ..,, ,,,,, , , ,,, . , , , - - ,,,,, ..., ,,,,, -, ,,,,,,,,, , . ,. , -., - , , . . - , , , , . - . , .. , . , - , , ,, . , . , , , . ..., , ., - . . ,.,., . , . ,, ” , ’ , . . , ,.., . , . , . ,, , . , ,- - . , , .- , . . , , -, , , ,. , , , , , - .. -. ...... - ,..,. - , - , , - , . . .- , , . , “ ”, . , , ,, , . , , , , . ,, , ., , ,- , . , . , . . , . , . . , , . . , - . , , , - . , , . , . , . ,.., . . , . , . , . , , . . . . , , . ,- . , -- . . .., , . . , . , ™, . , . - .. , . - -, . - ,, ,, , , , , , , , ,, , , , , , . , , , , . - . - ., - ..,- , .. .,,. . , . , , . , . . . ., .,, , ,, , . , ,. -, , . ., .. , - . , , , , , , . , , , . ,- , , , , . . . , . . - . , . , . . . , . , ., . . ., , . , , , .- , . , . , , . . , . . , “ ” ,,, ..,, , , , - ., , - . . - .., , ,. , , . - - .- .-. , -. - - - . , . , - . . . . , ,, , . -’ ,’ ,. . , , , - . . . . .- ,,,,,,,, , .,., ,., ,.,,.,.,., ,., -.,,., ,., ,., ,.,,., ,,..,,.,, . . , . , . . .. . . . . , ,. . - - - , , ,, . - , - .. - , ,, , , .. . ,- , , - , , , , . . , , , . , , . . , . . . . . . . , . . . . . ,., ,., - - ., , ,.,,., , . ., ,., ,., ,., ,.,.,. .–. . - - - . , ,., ., , . -, . , , , - ., .,, , . - “ , . - ., , , , . , , . . , . , . ,. , . , , ,. , .., - . , . . , , .. . .., . ,.., . . .., - .., . . . . , . , . ,, . , , , . . , — , , , . .. , , ,. . . - .. , . . . . . . , , . , . . - , , . ,, , . .. . . .. ‘ ’. . . , - . , . . ,,, ,, ., , , . . , . , , , , ,, , , , , . . . . , , ,. , . . , . . . . . , . . , , . . . ,.. -.., ,., ,.., , , ,..,,., ,., , ,., ,., .., ,.., ,..,,., ,., . , ,., ,.,,,,., ,.., ,.. . .. , . . “ ” . - , . . , , ,. . . , . . . ,.., ,. .., , . , , .., , . , . .., , ,, ,.., , ,. , . , , , , , . , , ,, . , . . .. . , ,,, ,.. , , ..,, , , , , , ., - , , , ..., , ., , , , , ,- -- , .,.,-,- , , ,., , , , , . . , , -, , .., - .., “” . , , . ,, , . .., - , , , , , ,. ,, , ., , , ,-,, . , , , , , . ...,, “” “”.., . . . . , - - , , - - , , ,- , , , , . , - - - . ,,.,. , ,., ,., ..- , -, ... . - . . . , . -. - . . , ’ . - . , . . , ,.., ,,- ,. , . , -, ,.., . - . , . , , . , . . , , , . , ,, ., , , . , ,.., , . . , , , .. - , . , . - , . . , ,, , , . , ., . , . , ,,, ,,. ,, , , , , , , , , . . , , . , ., , , ., , , .,,, , . , ,,, . , , , . , , , . . , , , , , . .,, ,. ,, . , , . , -- -.-., , , . , , , , . , , , . ,, ,, , , , , . . . , , . , .-, , , - , , , , , - , , , , , , , , , , , , ,, , , , , , ,, , , , , ,, ,- , ’ , , , , , , , ,, , , , , ’ , , , , , , , , , , , , , - , , , , ,, , , , , , , , , , - ’ , -, , ,, , , , ,, , ,, , , , , , , , , , ,, , , , , ,, , ,, ,- , , , , , , , , , , . , , , , , . ,. , , , , ,.., . , , , , . , , . . .. , , ., , ‘ ’ , , , “.., .” ,, ,.., , . , . , ,.., , . , , ,.., , , . ‘ ’ “ ,.” ,. , , . , . , .., , .., .., . , , , .., , , . , . . , , , , - -- - . . ,-, , , , - . - - , , , ,,,,,,,,,,,,,,,,,,,,, .,,,,, ,,, ,,,,,,.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,, ,,,,.,,,,,,,,,,. ,, ,,,,,, , , ,, . ,,,,,, ,,,,, , , ,, , , ,,. ,,, ,, ,, ,,, ,,,, ,,,,,, , ,,,,,,,,,,,,,,,,,,,,,,,,,,,, ,,,,,,,,,,,,, , ,,,,,,,,,,, ,,, ,,,,,,,,, ,,,,, . , , , , , , .., . , , ,,,, - , . . , , - , , , , . , ,. , -, ,- - . -, , - .., .,, , , ,- ,. - . , , . .,,,,,,,,, -,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,, ,,,,,,,,,,,,,,,,,,,,,,,,,,,,, ,,,,,,,,,,, ,,,, ,,,,,,, ,,,,,,,, ,,,,,,,,,,,,,,,,,,,,,,,,,,,,,, ,,,,,,,,,,,,,, , ,,,,,,,,,, ,,,,, ,,,,, ,,,,,,,,, , ,,,,,,,,,,,,,, ,,,,,,,,,,,,,,,,,,,,,,,,,,,,,, ,,,,,,, ,,,,,,, ,,, ,,,,,,,,,,,, ,,,,,,,,,,,,,,,,,,,,,,,,,,,,,, ,,,,,,,,, ,,,,, ,,,,, ,,,,,,,,,, ,,,,,,,,,,,,,,,,,,,,,,,,,,,,,, ,,,,,,,,,,,, ,,, ,,,,,,,, ,,,,,,, ,,,,,,,,,,,,,,,,,,,,,,,,,,,,,, ,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,, ,,,,,, ,,,, ,, . - , . , - , , , . . ,. , ,.., - ,, , , ,...,., . , ,,,, . , .,., ,,,,, - - , ..., , -,,,,,,,, ,.,,,,,,,,,,, - - , - , . . - , - , - . . . . - . . , , , .. ,,,,,, , , . ,,,,,, , ,.. , , , , , , , , , , , , , , , , . , . , , ,, , . , , . , , . , . , , ., , ,, , , , . , . , , , , , , . , ., , , , ,. , , , , , , ,, ,,, . , , , , ,. , , , , , , ., , , ,, , , ,. , , ,. , , , , , , . , , ,..,. . . , ,,, , “ , - .. . - ,,” , , , , . , , , , , “ , , , - ..,, .” - - - . -, “ , “”, , – , . . , , - - , “ - ., ” .- . . . . ,. “ . . ” –. , .. ,. , , , , . . , .. . .. . . . . -. “ ”, , . ,.., “” , , . , , , , ,, , , -, - ,. , ,-, -,,.., ,, , ,. , ,,,-, ,- , ,., ,,-,, ,. -, -, -,- -, , , , , , -. . - -. -. . , , . , - - . , . , . , , . ,., - , .., , “ - –, - , ,” . , . . , - . ,.., , ,, . , , . . , , , , , , . . , . , . .- , “ --- . .” . -. , . , . , . , , .., , “ - . - -, , ,”, . –, ., , , - - . . - . , , " - - -. - ." . ,. -, . - - , , , , ...., . , ,., . -., .. ,. , , , . , . . ,..,, ,.,., ,.., - ..., ,, , .., .. ., , , .,....,, ,.. . . , .... , ,,, , . . , , ,.., ,..., .,. -, . , , ,, , , ,.., . ..., , , , . .., . , . , , , . , .., , ,.. ,,.., . , , , , .., , , , ,.. , , , , , ,, ' ,, .., ' .,.. . ,.. . ,... ., . ,.., .,,.,, ,, - , ,-.,. -. - ,.., - .., , - . . - , . . .., . ,, , .., - , .., -. , , - , , , . , . , . . , , , . ,.., ., ,-. - . . - - . ,, . . , . . , - . . - . . , , ,, . , , . ,,– . , .. ,.. . , , ., - - , .- -- . ,, . , - , . “” - , . , ’ .. , , - . , - - – . , - . – , .- ,- – . - ,- - . , , ,, . , - , . , , – , . ,- . . , , . , , , .. , , - . - . , - , - - , , . , . . , , – . , , . - , ,, . , . , , , . , , . , , , , . . . , , , - ,,- , , , , , - , - - ,, , , , , , , , , . ., , . ., , , . , , - - , - . .,, . -, . . , . . , , . , , , ,.–.1 . ,.–. . , , .. ,. .. –.,. . ., – , . , , . . , - . ., , ,.., - ,, , , – . . . , . ,., - , 11 11 1 . . , , - - , , . , . - - , - . , . ,, - . -, . - - - -. , , , , ,, ,., . , , , , –, - , . - , , .. , . , , , ,. . - . , , , ., , . , ,..,- ,..,-, ., , ,14,.,.. .. ,. - . ,., . , , , . . , , , , . , , , . , , . -- - . , . , . , , - , - ,-. , ,. , , , . , , . , , , , , . , “ ” - - , . -- .. , , , . ,,,,,,,,,,,,,,,,,,. ,,,,,,,,,,,,, ,,,,,,,,, , , ,,,,, ,,,, ,,,,,,,,,,,,,,,,,,,,,,,,,,,,, ,,,, , . , . ,,,,,, - .., . , – . , . ., . ., 1 1 ,,– , . .. , , 14 1 . . , , , . , , – . , , . , , .,., , , . ,- ,.., ,.. , - . ., . - , . ' , . . ,. ’ . .-., - , - , , -- - . . - . .. - ..,- ,- . , ,.,, ., -,- -, , . - - , , ,. . . .,. -----, , . - - -.- --- –, . - . . –, . , - , ., , . ., . . . , - –, .. . - , , , .. .,,, , ., , ,.,.,.,.,.- , ,.,.,.– ,.,. - ., .,.,. – . ., , ,., , .- ., , ,.,.,,.., , ., , ,., - ,.,. - ., ., , ,.,,.,.,.,.- ., , ,. . - , ,.. - ., ,.,.,.,.,.- . ., , ,. - ,..– ., , ,.,. .,.- ,., , ,,., ,., ., , - ,.,.,..,.- , , ,.,. - ,. ,.- ., , ,.,.,-.,..- ., , ,. . , . , , , . , . ‘ ” . - . . -. .. ,. , . . , . , , ,. ,. , -, ,. , -, - ,. -, -,, - ., ., ,.. . . , , . –, . - . . ., . , . , . ,. , , . , , , ,.., ,. . , . , , , , .— , , , . , , , , . . ,..,–, . . .,., –, . . , , , . ,. , , , , ,. ., , , ., , . . , . , . , , . , ,. , , , , , , , . , ., , .., , ,, , , . , ., “”, “, ” “ ” ,.., ., . , "" "- - ", . , - ., . . ,., . –., . - ., ., – – ., . – - ., , ,- , - . , ., ,.., ., - . ,, - - . . , , , ,..,,..,-, ,.,, , .,., ...- - . ..,, - , ,.- . – .. , -. - , - ,.., ,., -– ,..,, ., –, - ., , . - , . .. - , , , , - - , - - - - - - - - -- -, - , - - - - --, , - - , - - - - , , , , - - - - - - - - - - - -- , - - , , - , - - -- - - - - , - - -- - , - - , - , - -- - -- - , - - - - - - - , - -- ,- -, - - -, - - , , , -- - - - - - - - - - - - -- - - ,- --- - - - - - - -, -, ,, - ---- -- -- , -, -, - , , - - - - . -, - . -, . -, - . -, . , , , , ' ,, , , ,, ,., - ,, , , - , , , , , , , , -, , ,. , , , . , , , - - , , , - , ,, ,- , - , ,..,. , . , . , . , , , , . , ,, ,- , , , , -, ,. , . - ,, , , , -, ., , , ,, , ,. ,, , , . , .., , , . ,.., - - . ,, , .. ,.,, ,,,., ,, ,, , , .. ,. , , , , , - , ,,, ,, .. .,, ,, ,, ,, ,, ,,, ,, , , . , - , ..,. - , , , , - . . , -, . , - .. , , , , ,,, , -, , . , . , , , , ,,, .. . . , , , , ,, ,,,,, , , , , ,, , , , . , . . ,, - , . . - .- , - , , .. - , .,,.- .. .,, .. .,, ,- , ,-,, ,, ,,-,, -,-, .. .,, , , ,, ,-,, . ,,-,- , - , , ,- ,-, ,-, , - , .. - --- - - . .,, .. .,,.....,., , , ,, ,,,, ,, . , , . , , ,- , , - - , , , ,-, , ,, -,,, , ,-, , , , -, , , , , , , , , ,, , , , , , , , , -,, ,, ,, -,, ,, ,, ,, ,, , , , , , ,, , ,, ,-, , , , , , , , ,, , , ,-, , . , -, , , , -, , , .,. .., , - ,, , , , ,,. - , , -, - , _, -. ,, ,,. , , - ,, ,,. , ,- - ,. , - , - , - - , ., . . - - . - – , , ., - . - , , - . -, - _ , - . - ., ’ – . - - - ’ , ., , - ,.., , , .., , - - - - ., , – , - ., - –.- - - - - ,. . -, , , , . . , , - , -- , , , . , , , _ , - - ., , - - . . . ,. , , - -- - -. , . - -- - ,---- - -- - --- - - , .- , , , , - . - .- , , , - - . . ,, ,, , , , , , , , , , . , , , ., - ., , . . -., - - , , - , ' ... - - . ., .. - - ., ., . , - . -. .- ., ,. - ., ,, . ,.., , , . , , - . , ,. ,, - . ., , - . , , ,- - ..,- . - . ,,. - .. - . ,, .. . -. ,,.. . . - . , , . , .., ,, , ,,., , . .., - - , , , . , ,. , , , , - . , .., .,.., , , , ,, , , ,,,, . ,- - . , ,.., , . , , ., , , - . ., “ , ” - . . , , . - , ,, , , , -,, ,, ,,,,, ,,, .. ,. . - , , ,, . - , , , , - . , - - - . , -- -., - - - -. , , -. , - . ,.., ., - ., . , . . .., ., - - - .-.,., , -. . - ,. - . - , - ., , .., ,...... - , ,–, - . - ,.,, . ., -, ’ , .. ... , - .., ,. - ,.., , –.. .. - . - , , , - ,, , , , . . .,-- ., . – ... . - . .,.., . , , . -, ., . .., ., , - ,.., ., - - .. .’.. , . ., , , - , , , , , , , , , ,, . , , , . , , .. ... ,. - , . , . , .. ,, . , , .. .. , , ., , ,. . . , , - ,. , - .. . ,.., , , . - . .. . – ., . , , , - .,- - . - , -., , " , , - ., , "-- -. . - , ..,, .--. , . - ,. - ., , - ., - , ,- - , , - “ ” . , , .. , .. - , , - , - .., , - - , - - , - - , - - - - , - . , ,, , .. , , . . , - . . - . - ... , . , , , -, , , - . , , , , , , , . , .. -, ‘ ’ . .., , - , -, - , - , - .- ,, , .,- - . - , - - . , . , . - -,- . , , . , , , , ., . . , , , . ,- - , . , , - -- . , , , . , - . ,, . -. ,, ' . , . , . , , ., , . , , , - - , . , . - , ,. , , , , , -- - , . , - - . -. -,. , - . , , , , , , , , -. - - . ,.,--.- ..-, - - , , . ,-, .,.., . - . . - . - . ,., . , , , , , ,. , , , , , , ,, , , ,,,,,,,,, ,, ,,, ,, ,,,,, ,,,, ,,,, , , , , , -,, -,, , , , , , ,-, , , , , , , --, --. . , , , , - .. -, , -, -, , , . , ,-, -,-, -, ,., .,, , -, - , , , -, -,,- - , ,. - , , , . , , , , , - - , - , , . , , ,,,,-, , , , , , , , , , , , ’ ,, , , , , , , - , , ,, , - , -. ., , , - - , ,, - - ’ , , - .., , , - . - - , , , .. , - -. -, - , - ,- , ,, . , - . , , , , ,, - ,, , , , , , , , , , ,, ,, . , - , , - , , ,-- - - - , . , -, , ,, ,, ,, ,, ,,, ,,,.. .,,,, ,, ,, ,, , ,, ,, . ,,. . , . . . . , . , . . , , . , , ...,. ,.. , ., . , . , " . , ," ,, , , , . - ,.., ,, , . , - . , . . , , ,, , , . , . ., , , , . ,, , , , , . , . . . “- , - '” . , , , ,,-,,- . , . , ™ . , ,, , , , ., , , , ,- - ..,™- , - . , . , , ,, . , ,,, . . . ,, , , . , , .. . . , , , , , . , , - , ,.., - . , , , , . , ,, ™. “ ” ..,- . ., - , , - , . - , , ., . ,. ,.., . . , , .., . ,, ..,, , , . ., . . ,. , ,,,,,,,,,,, ,,, . . , , . , , ..,, ,- ,, .. , ,. .., . . , . , . , . , . , , . .. , ° , , −° , . −°. . , - - . , . , - . . ,- , , , , - .. . ,,. - , .... , ,,. ,, ,., , .., . ,., . -. - .,-. . -, ,. . - .. , .,- . , . . - , . , . - , , ., ,™,,, ™ , , ™ , ™,™ , , , .. . . . , . , . -,- . , , ,-, --,, - -,-,--,--, .-- , . -., . . , . , , . .. , ,,, . . .. . - -,-,-,-,-,-, - -,-,-,-,,-,-,,-, -, -, .,-. .,,, . . ,.. .. . , , , .. , , - . . , . , , - , - , ., , - . . ,, , - - , , - , ,- . , , - , , , -- ., . . . , , . . , ,.., -, -- - ,.., , , . . 2. , , . , . , , ,, , , . . , , , , . , , , - . . - . . , , ,,
Figure imgf000247_0001
a ccaacrrumcauueaares, ear vaveosns, ,, ,, ,, , ,,
Figure imgf000248_0001
, , ,, , , , , , , , ,
Figure imgf000249_0001
,,,,,,,,,, se,e , ,
Figure imgf000250_0001
me caaennsa ccoeroec raee ancou cmaa manr e,c cea uerr,ac an os aornm aosca n, oemocmaa, ,, ,, , ,, ,, ,, , ,
Figure imgf000251_0001
,,,,,, -,,, ,,, , , , , , , , ,
Figure imgf000252_0001
,,, ,,,,,,,,, , , ,.,, , , - , , ,,, ,
Figure imgf000253_0001
,,,,,,,:,, -,, , , , , ,,
Figure imgf000254_0001
one-rosro ee ,,,,,,,,,,,,,, , , .e
Figure imgf000255_0001
sn unnr anrro eoommmeee, n, ane roomnrac eenonna- reurrac-on nn , ,
Figure imgf000256_0001
, c mounsnceusvo,es e,eese,a ,,, ,,,,,,,, e, e,
Figure imgf000257_0001
arnu'ssease o saeaasesoron aasrroouns-esranna, rusvaoencaesreae muase, enoase, - ,
Figure imgf000258_0001
era,s , an reae ee a,e,e,n-es,enme,mse,ae,, e.ar,,, a,n,.,,, , , o , -.
Figure imgf000259_0001
ne.rao.mn'mscaeroasreavseeowoes asneases asronesnaons, sn ,,xc,,,,,, , ,, ,, ,
Figure imgf000260_0001
, ,,, ,,,,,,,,, , ,, , ,e,
Figure imgf000261_0001
uscuarro musce s snnrroo,mmee, an,aroe,aux-am, , , , , ,
Figure imgf000262_0001
oonannrome maurscouuso – , , an reearro, eucsesve,eea, , ,, ,
Figure imgf000263_0001
raer- nrome s ru aensrseoc emu nu,ocs ocreea eeon o reon o sor arm o ravenne, cromosome,ncun , , , ,, n
Figure imgf000264_0001
, a,,,,,,,, ,,,,, ,, , , , , ,, ,, , a
Figure imgf000265_0001
nrerearaxas a.u., , noceomeaa , a , ,, ,,
Figure imgf000266_0001
, arous – seeon aoss,, om,,,, ,, urner'snrome o ,
Figure imgf000267_0002
, , , , . , . , ,, . .
Figure imgf000267_0001
nan
Figure imgf000268_0001
xonauancenan
Figure imgf000269_0001
oossnan
Figure imgf000270_0001
nan
Figure imgf000271_0001
r nan
Figure imgf000272_0001
eacoesass
Figure imgf000273_0001
noesaoosmosae
Figure imgf000274_0001
- nan
Figure imgf000275_0001
cvaon
Figure imgf000276_0001
morocessn
Figure imgf000277_0001
reacaoosncc rcaanmmnan
Figure imgf000278_0001
aunaamnaceeocsenoress
Figure imgf000279_0001
, , ,,, - , . , , , , , , , ,,, , , . .. , , ., ,- , ,.. - , -, ,... - , , –, . , , . ,-, , , ,, , , , , ,. , , , , ... , .. , ... , . ,. . ,. , ... ,. ,. , , . ,. ,. , . . , ... , . , , . ... , .... ,. . .. , ... , ,. . , ... , ...... ,, . . ..., , .... , . , ... ,. , ..... , ,... .,... ,,.. ,,. .,.. . , . . , . . , , .. ,. .,. ,.. ,. , . , . ,... , ,. . , ... , ,.. ,. , . . , -, , , - , , - , - , - . , , , .. , .. , , , , - .,. – ,, ., , .. , .. , ... , , .. , . , , , . , .. - ,, , .. -, .. , , , , , , .. , .. , .. , . , - , . , .. , . , .. , . ,, , , , , , .. ,, . , , , ... , ... ,,. ,. , ... ... ,. , . , ,, ... . , ,, ,, . , , , , .. , , , ,.. , .. ... ,, , , , ,, - , .,,,,,, . , , , , , ,.,..,,. , , ...... ,. ,. ., ., , . ... , .... , , ... , . , ...... , ,., ..., , , .. , , , . , ,... ... ... , , .. ... , , ., , .,.. ,. , , ,. ,. , .. ... , ,.. , ,...... , ,, ,... ... ,, ........ , , .,.. , . ... ... , ., ... , , .. ,, ..,. , , ,. . , ... ... ., .. , ., .... , ,, ...... , ... , .. , , ... ., , ... , . , ... , .. , ... ... , , . , ... , . .. , , , , ... , , , ,.. ..., ,, ..... , ... , . , ., . ... ... , .. , , .. , ... ,. , , , .. ., . ... , , ..... , , ...... , ... , ., ... , ..... . -, , , , ,, , ,, , , , , . - . , , ., -. , ,. , . , , , ., . , , , , ,,, , , , , , . ’ .., , , , ’ ’ .’ ..,, , , , ’ . ’ .,,. , , , , ,, , .. , , ,- , , - , , - , , , , , ,, , , , - , ’ , , , . , . , , . , . , , , , ,,, ,, ,, ,, ,, ,, , , , , , , , , , ,, ,, ,, ,, , , , , , , , , , ,,, ,, , , ,- , ,-,,,-,, ,-- -, .. , ,, , , , . .. ,, “ , “ , ”, ” ”, “ ”, “ “ ”., “ ”, “ ”, “ ”, . ,, , ,, ,, , , . , . . . , . , . , . , , , . , - - , . , , , , . , . , ,, , , , ,,,, . , . . - , . , . , , . . , . ,. , - . . , ,- - - , ., , . . , , , , , , , , ,, ,.., , ,, , , , , , .,, , . , . , .. , . ,, , . , ,, . , . . , , , - .., .. - .. .., .. - ,- .. ,..,. .. , ,.-, . ,.-, - , ., , ,...,-,.-.,.-,- ..,- , ,.-, - .., ., , ,.- . . .., . , - ., ,, ,. - , .., . , ,,.. - . , ,. . , ,.-,, . -, ,. .., ., ,. - . , ,.-- ., ,.- . , , .., ,. , ,,., ,. . , . ., , . , , , ,,, - , , . , , . - , -, , , . , . , , - . , , , - . , ., . , . , , , , ,.- , .., , , .. , , . , , . , , , , , , , , , , , , , , , - , , , , . , . . - . - , ,. , . , , . . , . ,, . , . . , , , ,. , . , ,. ,, , , , , , ,. , ,, , ,. , ,, , , , . , , , . , , , , ,, , , , - - , , , , -, , ,, . , , , , , , , , , - -, , , , - , ,, . ,,, , , , , , - - , ,, ,, - , ,,. ,, ,, , , , , - , -, , , -, , ,, , , . , , , , , , , , , , , .., - , , , , ,- - , . , -, , - ,- - . - , . - ,- ,, , , , -, , - ,, . , ,, . “,..,” - . , , ,.., - ,,, - . , ,. ., . . ,, , ., “ .”. ., , ,. , ,- , - ,. , -- .- , - , , , -- . -- . - , - . - , - .. ., - , ., , , . , , , , ., , , ,, . , , , , , ,, , . . , , , , , ., , . . , , , , . , , . , , , , , , , ,, . - . . , , , , , , , , , , , , , , , , , .. , , . ,, ,, , , . ,, , , , .- . , , , , - . - , , . , - , . , . , , , , , , , . , , , , , , , -. . ., ,.. , . , ., ,, .. . , ., ,. , .. , . ,, , . . ., ,. , , . . , , . , . , . , , , , . . , . , . , , , ., , - , , , , , , , , , , , , , , , , , , , ,,, , , , , , , , , , , , , , ,. , . , , ,.. . . . , ,.-. . , , . . ,. . , . ,. . , ,. , . , , , . , , . , . , , - . . ,. , . , , , ,, , , , ,. -, .. , . , . . , , . .., , , , . . , - , ..,- ,. -,-, - , - . , .-, , - - - .., . , . , . . ., . . , . , . , . , . , . , , .., , . . . . , , , , ,,. - . - , ., , , , , - . , -, , , - - ,. , , , ,, , , , ,, , , , , , , , ,, , , , , , , , , , , , , , ,, , ,, , . , , . , , , . , , - , . ., , , . , ,, , .. ,- , , - . . , ., . , , , , -, .- , . , , , , . . , , , . , , ., , ,, ’ . , . -, ,-. , , , . , , , , , , - . , , - - . , , . , . , . . , - ,. , . , . . , ,. , , ,.. - ,, , ,. , . ,-, . , , , , . - , ., , . ‘ ’ . , , . , , , . , ,, . , . , . , , , , . ., . , . ,. , -, --.,-,,-,-,-,-,-,-,-. , ., , . , . ,, ,- ,..,. ,,-. ,... , . , - . , - ,..- ,.,. ,..,. . ,. , - ,..,. , ,, - . , , . , - . , , , , , , . , , . , ., , , , , , . - . ., . , , . , ,, , . , , . , , , , . , . , , , . - , , . ,. , - , . , . ,. , , . . , . , ,.. . - , , - - , , . ,,.-. -.- , , ., , -. . . - . , - , , . , , ,. ,, , –, ., , . . - -. • . . .. ' ,, . , , ' , ' , - -, ,, ,’ , , ' ,.- , , . , , . , , .., , , , , . - . , , , , . .., , , , , . , , , , . ,.., , “ , “ - ,” , . --- . , “ - ,” - ,” ,- , . .. ,” “ , “- –. -, “ ,” . -.-. -. ,” , , ., “ ,” - . . , “ - . , . , , . -,, . . ,, - - . . ,-, “ - ,” . , , , . “ - ” .. “ ” , , . , , . , , ,., , .., .., , , , . . , , , . , . , , - . , , , . ,., ..., -. . . , ’, ,.., . .,.... ........ , . , , , , . , “” , , . . , , , , , , , , , , ,, , , , , , , , , , , , , , , , , , , , ,, ,, ,, ,, ,, ,, ,, ,, ,, ,, ,, ,, ,, , , , , ,,, , ,, , , , , , , , , , , ,.., , ,, , , , , ,. ,, , ,, - , ,, ,, , , , , , , , , , , , , ,, ,, ,, ,, , , , , , , , , , , ,, ,,,, ,, ,,, ,, ,,,,, , , , , , , , , ,, , , , , , , , , ,, , ,,,,, , ,, , , , , , . ,, , , ., .., ,.., , ..,., , ,, , , ..,..,, , ..,, ,,, , ,, ...,, , .., .., , , , ,, , , , , , , , , , , ,,,, ,, ,, , , ’ , , , , , , ,,,,,, ,, ,, ,,, , ,,,,,,,, ,, ,, ,, ,, ,, , , , , , ,,,, ,, , , , , , , ,, , ,,, , ,, , , , , , , , ,, , , , , , , , , ,,, , , , ,, , , , , , ,, , , ,,, ,,,,,., , , , , , "" " .." , ,, , , , , ,- . , , , , , , , , ,, ,, , ,, ,, ,, , , , , , , ,, ,, ,, . ,, ,, ,, , . , . , . , . " . ". ,, - - , - , - . , , ., , ,- . , , , ., . -,- -. , ., -,- ,., , , , , .-,. - , , - , , ,., . , - , , - .., , .- - - . - - , , -- - , . , . , ,. , . , . , . , - , , , . , ' , - . ' , . , , , . . ., . , .., . . - .., ,., , .. - . . , .., . , , , , . , . , , ., ,, , . ’ -,, , , ,, ,.. .., ,., ,.., , .. ,, ,- , - - . . , , - , . ., , , , - . , . , , - .. . , . , ., . , , , . , , . ,, , ,, , ,- , , . , ,- , , . , .., , , . -,, , -, .., .., , .., , , - ,..,- , , .., , ,.., ,, -, , - ,., ,, , , .., , , , , , , , , , , , , , , , , , - , - , ., - , , , , ,,....,, . - , , . , , . . , , , . -. , , - ..,, ,.., - , -, , , , - , , - , , ,.., , . ,. , - ,, - , ,, , , , .., ,-, . -, -,- , . , . , , , ., ,, , ,.., . , ,,.., . . ,.., , , , , . , . , ,.,. , . , , , , , , , , . - . , ,.,.–. ,- , , , , .., ,.-.,-, , ..,- , , ,, ..,.., ,, ,.., , , , , , , , - , , .., , , , , , , ,, , , , , . ,. , , , , , - , , . . , . , , , .., , . , , . , , . , , , -, -. , - - .., . , , . . . , . , , , ,,, , , , .., , , , , ,. . , , , . - , . , - , , , . . , ,, , , , . , , . .., , , ,, , , , , ., . , , , . . - , . ,.., , , . . ,.., , , - . - ,,., . .-,. . , ., ,, . ., , , ., ,..,,., . -. . , , - . . ,, , ,. . , . . . , , . .., , , .., , , , . ,.. , ,- _- ., - , - --, -,-- , -, , , . , . , - - ,-,. , - , - ., ,. . , .. . ., . . .,, . ..., , .., .., . ,, ',,, , , - ., .. , , , , ,-, , , ,, _,,- .., , . , , , ., - , . ,, ,, . , .., , .., . . , .., , - .. , .., .., . , , .., ,. , . , . , . ., . . ,, .., . . , , , , , -, - -,- ..,- -, - , .- , , , .. , , . - - . , - , , , - -- , -- , ,- -, , - , , - - . , ., , . .., , , ,, . ,, , , , ,, ,, ,, , ,, ,, , , , , , , . , , , , . , , , , , , -, . , , , , . , . , , - -,, , , , , , , , - , , , , . . , , , - . , . , , , ..,- , , . - , , . , . , , , , , , , , . . , , . . , ,. , , , ..., , , , ... ..., , ..., ..., , , . , ..., , ..., , ,.., ,. , . .., , , ......, , ..., , , . ,.. . ., - , .., .., . , , ., , ,, , . . . , , , ., , , , , , . . , , - , , . . , ,.., , , ,. , , . , . , ,, ,..,, ., , , , . , , , , ,. , . - ., ., –. .., , , ,, , . , , .., , ,, , , ., , , , , ,. , . - , , ..., , , , , , . , ,. , , . .. , - ....,. . - ,..,. . . - ,., , . , ,.. . ..,,, , , , , ,. , , , ,, , ,.., , , , ,- , ., . , , , ., , , , , .. ,.. , -, ,- ,.,. ., . , . , - -, .., .., .., . -,- -, ., ,., . -,-. ..,. - ,-, ., ..,- ., .., ., .. -, , , .,., .. ., - .., ., , ., , - .., . . -, .., -, . ,., . - ., .. -, , , , ,. ,, , , , , , , - , . ,.., , , , - ,. , , ,.., , , , - , .. ., . - , , - , . , . .- . --, .- ,., . - . .. . , ,. , , ,, ,. ,, .,,,. , , , , , , ,.. ., , , , . - ,, , , , , , , , , , , , , , ., , ,, , . , , , - . .., ,.., - .- ..., . -, , . - - , –. .., ,.. . ,., . .., ., ,-,., . – ,.. ...,.. . –. ., –.., ,., . ., . ,..–. ., . . ,.., ., . .., ..., , , , , , ., , , , ,. , , .., .,,..,. , ., . – , ., . ,-.,.., . –. –. , ., . ,.., ,.., . ,., . . -, .., ,.., –. ., . ,.., . ,., ., ,. . –. . ., , ., . ,..,–. ,., ,. . ., . . ., – , . ..., ., ... –. ., ,. -. ,..,.., , , ,., . - .. , ... ., . .., . - , .., -. -. ,.., ., . , . . , , , .. , , . . , , . . , , , , , .. .., . , , . ,. , . , . . , . .., . , , , , ,, ,. . , . , , , . , . , .. . , . – - - ’ ’ ., - ’ ’ - .. ´, - - .. - - ´ .. , .. , - , - .. .., , , .. - . ,.. , , , .’-. .. , , -´ .. - ’ . . ,. , - . - . .. –’ ’ , .. , - .. -.. - , .-. .., - - - . ’ -. ., - .. ´, .. . . .. - - .. - ’ - -, - .. . .. , .. .., ´ . -, ’’ .. , . , .-. – - - . , - -.. . ., ,. ., . ,, , , , . – - , 1. - , -, 2 , , . , .–,, -- 7,, . 1 11 , , , 12 , , , . 1,14. -, - 1,1, - ,~- , , , , - - 1–1., - , 1. , - ,~- .1,1 ~ , , , , 2,21 . . , - - 2 11,. , , .2–24, , - , .. , , - ,- . , , .1. , . , ,- , , . - , , , , 1 ., . .. , , - .. - , - ., .- , , , — .. ,— .. , - , , . ,, , , ., .- , - - . ,, , .. - , , , ,.-1.., ,– , . –- , , – . .. - . , - - , . 1,1,17. , , . 2, , ,, - . , , - ., , . , . - .--. 22 1,17, - .. , - , .2,27. . , , - - .. - , 2. ’ . , .–, , - . , - - .-,, . ,1 - , .,. . , , , ,, .- - , . -,, , . - , , .,, . - .. , - - - -.,,.- , - - .. - , . , .,- . , , -,- - - .. , ,, .. , , -, - .. -, -- - .. . . , –- ~–- - ., . - . - .. , .- - .. , , , . , , , - -.. , -- - - , , -,.. 1 , - - - 1. .,. , - - . - , , - . , - - , , .. , - , ,... , ., . . . - -- - , - - .. . , -.- -- .,, - .,, , 1,17. , ., , , ,-. -- , .. . ,, , , - - , .. , - , -- -- - . -, - - - -.. 1–1. - , ., , , , ... ,, - -, ’ 27.. - , 1 , , . , , , , .. -’-, - . - - , , ,. , - - .,,. . - ,- - - - . ~ , ,,. , - - . .,, , , . , . , - - .- . - , - , - , , - - .. -, - . - - , - . - - , , -- - 11. , - , . - . - , -,, . -, , - - - - - , - .. - .. - ’ , ′ ′ . -- .. , ′ . ., . ., ′ - → .. , -, .. . ,- -, - ′., , - - - ,- ′ ′ ′ - . ′ ′ - ′ .. , , .. , - ., .. - ′ . - , , ,., . , . , ′ ., - .. , . .. .2, - - - - . -, ′., -. 2., .- , . 2 , . 2. , - - - -. , . ,1, ,-.2., - ., . -. .,,. .. , . , . , 2. , , , -, . - .. - , , . ,- - - ., , .,. - . , , - - , .. ,, ..,. - - , -. , .. . ,,, . , , , . , ---. , , , -. - , . , ,- , , -, -, - , . , , .. - . . - , . ,, , -, - ,, . . ,. , . - , 4.- . , . ,, . , , , , , ,. , , , , - - . . ,
ource oransm a.cae semuneonc aec, .. : omea scao seuence
Figure imgf000355_0001
eerrvvooaacceerruumm c caannaaccuumm s srraann :: - :
Figure imgf000356_0001
acrancaonmaumraonaarsa snos seransns sran ::
Figure imgf000357_0001
eraec snae wsaner mcaroomaa, conmmeunaeessr -om- : - :
Figure imgf000358_0001
co vaeesroamceroaru ano arrc,eau : :
Figure imgf000359_0001
ovne ru_.men: mcroa comm_une:srom : -
Figure imgf000360_0001
cu eees mncroosa cao,mmaunmoerse,rom a : :
Figure imgf000361_0001
:: - : : :
Figure imgf000362_0001
: - - : - : : : : : - - : : - : : : : : : : : :
Figure imgf000362_0002
: : : : : : : : : : - : : - ::
Figure imgf000362_0003
:: : : :: : :
Figure imgf000363_0001
Figure imgf000364_0001
woe_enom_:een so-_un- se_uceonvc_e. ,:
Figure imgf000365_0001
cumanu meaenomeenome assem,
Figure imgf000366_0001
: _roaroes _::--
Figure imgf000367_0001
cumanu meaenomeenome assem,
Figure imgf000368_0001
seomueac -nce-_ucson amn_ov:o,r wanos seraennome sou:n
Figure imgf000369_0001
cumanu meaenomeenome assem,
Figure imgf000370_0001
eanoem-ea- ausraens:s-ro,a cromoesee
Figure imgf000371_0001
uncu-ur-e a:e soae:
Figure imgf000372_0001
wroae m_eenaomene smneo-u_n- seu_ecnocve_
Figure imgf000373_0001
cumanu meaenomeenome assem,
Figure imgf000374_0001
cumanu meaenomeenome assem,
Figure imgf000375_0001
u. mea_eno:meenome_:
Figure imgf000376_0001
:_-:- __::
Figure imgf000377_0001
c wounmoaen:euno mme s_eoneo -numne - s_eenuoemncee a_scsoevm:,
Figure imgf000378_0001
enom-e :-_ro,aro _-_:.__:_v:es : _enomc : - : e_asm:acnosu_ercanoccenae_acer -,u wmoe
Figure imgf000379_0001
uacer sucomer suan. senue:nnce_co-n-_, woe
Figure imgf000380_0001
cumanu meaenomeenome assem,
Figure imgf000381_0001
coonsru:m, omena sorrmaoene ssou_n s:e-uen--ce-
Figure imgf000382_0001
aceroaesacerumsoaee_ :: - - :
Figure imgf000383_0001
roe. , .,,, . as c zc ozr ru
Figure imgf000384_0001
. . .
roe xs m ea a a a
Figure imgf000385_0001
. . . .
roe
Figure imgf000386_0001
roe ru
Figure imgf000386_0002
. . .
roe
Figure imgf000387_0001
. . .ene
Figure imgf000387_0002
. . . .
Figure imgf000388_0001
. . . .
are
Figure imgf000389_0001
. . . .
are
Figure imgf000390_0001
are
Figure imgf000390_0002
. . . .
are
Figure imgf000391_0001
. . . .
are
Figure imgf000392_0001
. . . .
are
Figure imgf000393_0001
are
Figure imgf000393_0002
. . . .
are
Figure imgf000394_0001
. . . .
are
Figure imgf000395_0001
. . . .
are
Figure imgf000396_0001
. . . .
are
Figure imgf000397_0001
. . . .
waweao
Figure imgf000398_0001
waweao
Figure imgf000399_0001
waweao
Figure imgf000400_0001
waweao
Figure imgf000401_0001
waweao
Figure imgf000402_0001
waweao
Figure imgf000403_0001
wa weao v
Figure imgf000404_0001
n eruem wa wa vs com com com com com com com com com com com
Figure imgf000405_0001
n eruem wa wa vs com com com com com com com com com com com
Figure imgf000406_0001
n eruem wa wa vs com com com com com com com c coomm com com com
Figure imgf000407_0001
n eruem wa wa vs com com com com com com com com com com com
Figure imgf000408_0001
n eruem wa wa vs com com com com com com com com com v
Figure imgf000409_0001
are
Figure imgf000410_0001
are '
Figure imgf000410_0002
. . .
areene nruncaerom' o omea nes re nes re nes re
Figure imgf000411_0001
. . .
areene nruncaerom nexusarn nes re nes re nes re
Figure imgf000412_0001
. . .
are
Figure imgf000413_0001
ene nruncaerom nexusarn nes re nes re nes re are
Figure imgf000413_0002
. . .
are
Figure imgf000414_0001
. . .are
Figure imgf000414_0002
. . .
are
Figure imgf000415_0001
are
Figure imgf000415_0002
. . . . , ..
ouarcecesc nsa aaanasaneasnoanooamazceauas aas ___ __n_nss
Figure imgf000416_0001
our_ce ____ __ ___ __ u_a __ __ __ _
Figure imgf000417_0001
.____ _ ________
ource ___ _ __ ___ __ __ ____ ___ __ __ __
Figure imgf000418_0002
.____ _________
Figure imgf000418_0001
our_c _e ___ _______ __ __ ___ ___ ___
Figure imgf000419_0002
_ __ ___ _______ _ _
Figure imgf000419_0001
ource ___ _ _ _ __ ___ _____ __ ___ __
Figure imgf000420_0002
_ ____ ___________
Figure imgf000420_0001
our__ce __ ___ _ ___ _ __ __ ___ __ __
Figure imgf000421_0002
.____ _ _____ __ _
Figure imgf000421_0001
our__ce _ ___ _ __ __ __ __ __ ___ __ _
Figure imgf000422_0002
.____ _ ________
Figure imgf000422_0001
our__ce
Figure imgf000423_0002
__ ._ ___ _ r , .
Figure imgf000423_0001
. sw oo swaa : _ _ __ swa :: __ .a _ ___ .... swa : _ .... swa uas … “" swa :: __ __ ____ …… “" swa : _ . “" swa : __ … “" swa : __ .. ____ …… “ “" swa : _ _ __ " swa : _ c … “ " swa : _ on__ ___-_ … “ " swa : _ … “ " sw a _ __ … “ " swaa :: __ .. __ _- … “ " swa : _- … “ " sw _ . __ … “ " swaa :: __ aa __ __ … “ " swa _ _ … “ " s : _ . _ _ … “ " swwaa :: __ . a _ __ … “ " swa : _ a _ ____- …… “ “ ""
swa : r_oo _ _ _ wa…e “oson swa : _ _ __ … " swa : _ a _ __ “ " swa : _ . _ … “ " swa : _ _- … “ " swa a _ __ … “ " swa : _ . _ _ … “ " sw : _ _ __ … “ " sa : _ . __ … “ " swwaa :: __ con__ ____ … “ " swa : _ _ - … “ " swa : _ _ _ … “ " swa a _ __ … “ " sw : _ . _ _- … “ " swaa :: __ .. ____- …… “ “ " swa : _ a _ __ " swa : _ a _ _ … “ " swa : _ _- … “ " swa a _ __ … “ " swa :: __ aa __ ___-_- …… “ " swa : _ _ __ “ " swa : _ _ _ … “ " swa : ns _ … “ " swa : nas- … “ " swa sas- … “ " s : _ _ __- … “ " swwaa :: a_as- _ _ _ …… “ “ ""
s swa : ro_o . __ wa…e “oson" swwaa :: __ . ___-_ …… “ “ ""
– como swa wao. wao. c como swa
Figure imgf000426_0001
coomo swa commo swa comoo s swa como swwa com a co swa coomo swa commo swa comoo swa como s swwa c como swaa coomo swa commo swa comoo s swa como swwa c como swaa como swa coommo swa comoo swa como s swwa c como swaa coomo swa commo swa comoo s swa como swwa com a co swa coomo swa commoo swa como s swa como swwaa c wao. wao. coommoo swa como s swwa comoa co swa commoo swa c como s swwaa coommo swa comoo s swwa com a co swa coommoo swa c como s swwaa coommo swa comoo s swwaa o. - roo
Figure imgf000427_0001
__ . _ __ _ . ___ __ __ ___ ___
. - , nneererusc-omea-ar,e c .. -x omex aa coec x an on anrocessn oaecaon 2 , .
Figure imgf000428_0001
ooen- comrooseon roen resn aoms , uceoe reusesues acoan rrosen2s uceoe . an . .m. . osn.eevnaosns on anes . a ° . oaon asrsoco score . oor roarmeers . amaca . avnrano oowree . saowe ..
., ene seuuee .. are arence aren -o- re re-o- -o- re re-o- nosarone
Figure imgf000429_0001
eanree saeurueeence aren -o- re re-o- -o- re re-o- nosarone
Figure imgf000430_0001
eanree saeurueeence aren -o- re re-o- -o- re re-o- nosarone
Figure imgf000431_0001
eanree saeurueeence aren -o- re re-o- -o- re re-o- nosarone
Figure imgf000432_0001
eanree saeurueeence aren -o- re re-o- -o- re re-o- nosarone
Figure imgf000433_0001
eanree saeurueeence aren -o- re re-o- -o- re re-o- nosarone
Figure imgf000434_0001
o osonoson re . .
Figure imgf000434_0002
Figure imgf000434_0003
e
Figure imgf000435_0001
roo. ene, nameue seuen–ce. : rm:er rm:er eusc : : : asc-,csc,ozrc,rusc,xsc- :: :: :: zcsc ::: : : : : : rusc : :: : : : :: am :: : : esc : : : asscc- :: :: : asc,aas- : : :: asca,a as sca-,a,s-a a,as as-a-as- ::: : : : :: : usc : : r : : : : :: : : : : :: ::
roo ene nameue seue:nce rm:er rmer: : :: :: :: ::
. ,.., .,..,.. . ,.., ,.., ,.......,–. . ,.,.,.,,,..,,,.., ,.., ,..,,.., ,., .,..,,.–.. ..,.,.,,,.,.,.,..,,.,,.,,.-., ,..,,..,, ... ., . . ,,..,.,,.,..,, ,,.-.,., ,., ,., ,., - ,..,...., . . -,.,.., ,.., ,.., ,.., ,., ,., ....,..,..., .-. ,..,,., ,., ,..,,..,. ,.,–.. . ,..,.., ,., ,..,,.., ,.., ,., - .. -,–.- -..,,..., .,.,,.,,.,,.,-,.-.,,.,,.,.,..,, ., . .,,...,.,,,..,., ,.., ,., ,.,,., ,..,,., ...,–. . .- ,..,,.,,., ,., ,..,.,.,,–,.... ,., ,..,.. ,...,.–. -..,-,,.,..,,.,,..,,.,.,..,,..,.,.., ,.., , ,–. - .. ,,.,. ,.., ,., ,., ,., ,.., ,., . , .-..,.,.,.,,.,,.,,.,,., ,., ,.,,.,,., - ....., –. . ,.,,., ,,.,.,,.,, -,., ,., ,., ,.., ,.,.-. - . .. .,. -,.,,., ,.. . -, –. . ,., ,., -,., ,., ,.., ,., ,..,,., ,.,,.,...,–. . ,..,,.., ,.., ,..,-,... ,–. . . ,,.,,., ,., ,., ,.,,., ,., ,., ,., ..,..., –. ..,,..,.,.,,., ,., ,.,,.,,.,,., ,., , .. -., . . ,., ,,..,, ,,..,, ,,..,, ,., ,., . ,,.,–... . -,.,,.,,.,,., ,,..,.., ,,...., ,.., ,., , . - ,.. . . .,.-.,,,–..,. ,.. .., ,,.,.,,..,,.., ,., ,.., ,., , . ,,.–.. . ,..,,..,,.., ,.., ,.., ,.., ,.., -,.., ,.,. ,,..–.. . ,,....,,.-., ,.., ,..,,., ,.., -.,. ,,.–... ..,,.,.,..,,.,.,.,,,.,..,.,.,.,-.., ,.., , ,–. .. ....,,.,.,.,,,.,..,,.., ,.., ,.., ,., , -,..,...-, –.....,,.,,- ,., - ,., ,., , . .., ,.., ,.., ,., ,.,. , -, - , . ,–.. ,.,,.,,.,,.,,., ,., ,., ,.., ,., .. .,,.,–... .–. . ..,. ,.,.,..,,.,,,..,., ,.,.,..,.,., ,.., ,.., ......, –. . ,,...,. ,., ,., ,., ,.,- ,., . ,–. - ..., , ,.., ,..,,., ,., ,.., ,.., , - ., ,., ,.,.. . , . *** , , , . . , ,, ., , .

Claims

. , , ’ ,’ , , . . ’ ,. , ’, . , . . , . . . ,
. ’, , . ’, . . , . , , . . , . . . , . ’ ’ ., . ’ . , . , , , , , , , , , ,, ,,,,,,,,, ,,,,,,,, ,. , .’ . , .’ . , . ,- . - . ’ ,. . ’, .’ . . , ’ . , . ’ . , . ,. , , . , . . , . , . . , , . - . , , . . -. , . -. , . . ,
. . , . . , . . , . . , . - . , - . . , -. . , .. , . , - - . . , , , , . . , , , , , . . , , , , , , . . - , , , . . , . . , ,-, , , , , , .. , , , , , ,,,,,, ,, ,, , , , , , ,, , , , , , , ,,,,,,,,, ,, ,, , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , ,, ,, ,,,,,,,,, ,, ,, , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , ,, ,, ,,,,,,,,, ,, , , , , , , , , , , , , , , , , , , , , , , , , , , , ,,, ,, ,., . , , , , , , , , , , , , , , , , , , , , , , , , ,, ,,,,,,,,,,,,, , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , ,,,,,,,, ,, ,, ,, ,, ,, , , , , , , _, ,. . , , ,, ,, ,,,,,,,,, , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , _ . . , . , , . - . - . . , - . . , . - .,
. ., . ,. . , ., . , ,- ,- - . . ,, . . -, - . . , , . . , , , . - . , . - . , . . ., ,. , . , , . ,.
. , - . . - . , . – . . , . .. , . ., . ,. . , . .. –, ,.. –, , . –, ., , , , ,
. – – . . , . . , . . , . . , . . – .– . . , . , . . , . ,. . , , ., , , , .,
. . ,. , , ,, , ,, - , - , , , , , , , , , , , , , , , , , , , , , - , , , , , , , , ’, , , , , , , ,,’, , , , , , , , , - , , ,, , , , , , , , , , - , , , , , ,-,’ , , ,, , , , , , , , , , , , , , , , ,, ,, , , , , , ,, , , , , , ,- , , , , , , ,, , . ,,. . , ,
PCT/US2024/057461 2023-11-29 2024-11-26 Engineered omega guide molecule and iscb compositions, systems, and methods of use thereof Pending WO2025117544A1 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US202363603923P 2023-11-29 2023-11-29
US63/603,923 2023-11-29
US202463703476P 2024-10-04 2024-10-04
US63/703,476 2024-10-04

Publications (1)

Publication Number Publication Date
WO2025117544A1 true WO2025117544A1 (en) 2025-06-05

Family

ID=93924967

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2024/057461 Pending WO2025117544A1 (en) 2023-11-29 2024-11-26 Engineered omega guide molecule and iscb compositions, systems, and methods of use thereof

Country Status (1)

Country Link
WO (1) WO2025117544A1 (en)

Citations (166)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA275339A (en) 1927-11-08 L. Sagebield Perle Electric smelting furnace
WO1992015322A1 (en) 1991-03-07 1992-09-17 The General Hospital Corporation Redirection of cellular immunity by receptor chimeras
CA2075515A1 (en) 1991-08-30 1993-03-01 Shohei Miyata Method for synthesizing stable single-stranded cdna in eucaryotes by means of a bacterial retron, products and uses therefor
US5210015A (en) 1990-08-06 1993-05-11 Hoffman-La Roche Inc. Homogeneous assay system using the nuclease activity of a nucleic acid polymerase
US5320958A (en) 1989-02-24 1994-06-14 University Of Medicine And Dentistry Of New Jersey Isolated bacterial reverse transcriptase
US5405775A (en) 1989-02-24 1995-04-11 The University Of Medicine And Dentistry Of New Jersey Retrons coding for hybrid DNA/RNA molecules
US5445934A (en) 1989-06-07 1995-08-29 Affymax Technologies N.V. Array of oligonucleotides on a solid substrate
US5563055A (en) 1992-07-27 1996-10-08 Pioneer Hi-Bred International, Inc. Method of Agrobacterium-mediated transformation of cultured soybean cells
WO1996039154A1 (en) 1995-06-06 1996-12-12 Isis Pharmaceuticals, Inc. Oligonucleotides having phosphorothioate linkages of high chiral purity
WO1997003211A1 (en) 1995-07-13 1997-01-30 Isis Pharmaceuticals, Inc. Antisense inhibition of hepatitis b virus replication
US5686281A (en) 1995-02-03 1997-11-11 Cell Genesys, Inc. Chimeric receptor molecules for delivery of co-stimulatory signals
WO1997049450A1 (en) 1996-06-24 1997-12-31 Genetronics, Inc. Electroporation-mediated intravascular delivery
US5780269A (en) 1989-02-24 1998-07-14 The University Of Medicine And Denistry Of New Jersey Hybrid molecules
WO1998052609A1 (en) 1997-05-19 1998-11-26 Nycomed Imaging As Sonodynamic therapy using an ultrasound sensitizer compound
US5843728A (en) 1991-03-07 1998-12-01 The General Hospital Corporation Redirection of cellular immunity by receptor chimeras
US5849563A (en) 1989-02-24 1998-12-15 The University Of Medecine And Dentistry Of New Jersey Eukaryotes expressing single stranded hybrid molecules
US5851828A (en) 1991-03-07 1998-12-22 The General Hospital Corporation Targeted cytolysis of HIV-infected cells by chimeric CD4 receptor-bearing cells
US5858358A (en) 1992-04-07 1999-01-12 The United States Of America As Represented By The Secretary Of The Navy Methods for selectively stimulating proliferation of T cells
US5869326A (en) 1996-09-09 1999-02-09 Genetronics, Inc. Electroporation employing user-configured pulsing scheme
US5906936A (en) 1988-05-04 1999-05-25 Yeda Research And Development Co. Ltd. Endowing lymphocytes with antibody specificity
US5912170A (en) 1991-03-07 1999-06-15 The General Hospital Corporation Redirection of cellular immunity by protein-tyrosine kinase chimeras
US6004811A (en) 1991-03-07 1999-12-21 The Massachussetts General Hospital Redirection of cellular immunity by protein tyrosine kinase chimeras
US6017737A (en) 1989-02-24 2000-01-25 The University Of Medicine And Denistry Of New Jersey E. coli msDNA synthesizing system, products and uses
US6040177A (en) 1994-08-31 2000-03-21 Fred Hutchinson Cancer Research Center High efficiency transduction of T lymphocytes using rapid expansion methods ("REM")
US6352694B1 (en) 1994-06-03 2002-03-05 Genetics Institute, Inc. Methods for inducing a population of T cells to proliferate using agents which recognize TCR/CD3 and ligands which stimulate an accessory molecule on the surface of the T cells
US6489458B2 (en) 1997-03-11 2002-12-03 Regents Of The University Of Minnesota DNA-based transposon system for the introduction of nucleic acid into DNA of a cell
WO2003020763A2 (en) 2001-08-31 2003-03-13 Avidex Limited Soluble t cell receptor
US6534055B1 (en) 1988-11-23 2003-03-18 Genetics Institute, Inc. Methods for selectively stimulating proliferation of T cells
WO2003057171A2 (en) 2002-01-03 2003-07-17 The Trustees Of The University Of Pennsylvania Activation and expansion of t-cells using an engineered multivalent signaling platform
WO2004015075A2 (en) 2002-08-08 2004-02-19 Dharmacon, Inc. Short interfering rnas having a hairpin structure containing a non-nucleotide loop
WO2004033685A1 (en) 2002-10-09 2004-04-22 Avidex Ltd Single chain recombinant t cell receptors
WO2004044004A2 (en) 2002-11-09 2004-05-27 Avidex Limited T cell receptor display
US6753162B1 (en) 1991-03-07 2004-06-22 The General Hospital Corporation Targeted cytolysis of HIV-infected cells by chimeric CD4 receptor-bearing cells
WO2004074322A1 (en) 2003-02-22 2004-09-02 Avidex Ltd Modified soluble t cell receptor
US6797514B2 (en) 2000-02-24 2004-09-28 Xcyte Therapies, Inc. Simultaneous stimulation and concentration of cells
US20040224402A1 (en) 2003-05-08 2004-11-11 Xcyte Therapies, Inc. Generation and isolation of antigen-specific T cells
US6867041B2 (en) 2000-02-24 2005-03-15 Xcyte Therapies, Inc. Simultaneous stimulation and concentration of cells
US6905680B2 (en) 1988-11-23 2005-06-14 Genetics Institute, Inc. Methods of treating HIV infected subjects
US6905874B2 (en) 2000-02-24 2005-06-14 Xcyte Therapies, Inc. Simultaneous stimulation and concentration of cells
WO2005114215A2 (en) 2004-05-19 2005-12-01 Avidex Ltd Method of improving t cell receptors
WO2005113595A2 (en) 2004-05-19 2005-12-01 Avidex Ltd High affinity ny-eso t cell receptor
US20050287127A1 (en) 2003-11-13 2005-12-29 Huawei Li Use of stem cells to generate inner ear cells
WO2006000830A2 (en) 2004-06-29 2006-01-05 Avidex Ltd Cells expressing a modified t cell receptor
US20060030837A1 (en) 2004-01-29 2006-02-09 The Charles Stark Draper Laboratory, Inc. Drug delivery apparatus
WO2006125962A2 (en) 2005-05-25 2006-11-30 Medigene Limited T cell receptors which specifically bind to vygfvracl-hla-a24
US7160682B2 (en) 1998-11-13 2007-01-09 Regents Of The University Of Minnesota Nucleic acid transfer vector for the introduction of nucleic acid into the DNA of a cell
US7175843B2 (en) 1994-06-03 2007-02-13 Genetics Institute, Llc Methods for selectively stimulating proliferation of T cells
US7206639B2 (en) 2002-03-15 2007-04-17 Sarcos Investments Lc Cochlear drug delivery system and method
US20070093878A1 (en) 2005-09-08 2007-04-26 Albert Edge Cochlear implants containing biological cells and uses thereof
WO2008038002A2 (en) 2006-09-29 2008-04-03 Medigene Limited T cell therapies
WO2008039818A2 (en) 2006-09-26 2008-04-03 Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Modified t cell receptors and related materials and methods
WO2008042156A1 (en) 2006-09-28 2008-04-10 Northwestern University Maximizing oligonucleotide loading on gold nanoparticle
US7446190B2 (en) 2002-05-28 2008-11-04 Sloan-Kettering Institute For Cancer Research Nucleic acids encoding chimeric T cell receptors
US7572631B2 (en) 2000-02-24 2009-08-11 Invitrogen Corporation Activation and expansion of T cells
US20100041033A1 (en) 2004-08-03 2010-02-18 The Regents Of The University Of California Site specific system for generating diversity protein sequences
US20100104509A1 (en) 2006-12-13 2010-04-29 Medarex, Inc. Human antibodies that bind cd19 and uses thereof
US7741465B1 (en) 1992-03-18 2010-06-22 Zelig Eshhar Chimeric receptor genes and cells transformed therewith
WO2010099296A1 (en) 2009-02-26 2010-09-02 Transposagen Biopharmaceuticals, Inc. Hyperactive piggybac transposases
WO2011008730A2 (en) 2009-07-13 2011-01-20 Somagenics Inc. Chemical modification of small hairpin rnas for inhibition of gene expression
US20110023139A1 (en) 2008-12-04 2011-01-27 Sigma-Aldrich Co. Genomic editing of genes involved in cardiovascular disease
US20110142917A1 (en) 2008-06-06 2011-06-16 Egvenia Alpert Compositions and methods for treatment of ear disorders
US7985739B2 (en) 2003-06-04 2011-07-26 The Board Of Trustees Of The Leland Stanford Junior University Enhanced sleeping beauty transposon system and methods for using the same
US8034334B2 (en) 2002-09-06 2011-10-11 The United States Of America As Represented By The Secretary, Department Of Health And Human Services Immunotherapy with in vitro-selected antigen-specific lymphocytes after non-myeloablative lymphodepleting chemotherapy
WO2011146862A1 (en) 2010-05-21 2011-11-24 Bellicum Pharmaceuticals, Inc. Methods for inducing selective apoptosis
WO2012058460A2 (en) 2010-10-27 2012-05-03 Baylor College Of Medicine Chimeric cd27 receptors for redirecting t cells to cd70-positive malignancies
WO2012079000A1 (en) 2010-12-09 2012-06-14 The Trustees Of The University Of Pennsylvania Use of chimeric antigen receptor-modified t cells to treat cancer
US20120159653A1 (en) 2008-12-04 2012-06-21 Sigma-Aldrich Co. Genomic editing of genes involved in macular degeneration
US8211422B2 (en) 1992-03-18 2012-07-03 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Chimeric receptor genes and cells transformed therewith
US8227432B2 (en) 2002-04-22 2012-07-24 Regents Of The University Of Minnesota Transposon system and methods of use
US20120244133A1 (en) 2011-03-22 2012-09-27 The United States of America, as represented by the Secretary, Department of Health and Methods of growing tumor infiltrating lymphocytes in gas-permeable containers
US20120328580A1 (en) 2008-02-07 2012-12-27 Albert Edge Compounds that enhance atoh1 expression
US8372951B2 (en) 2010-05-14 2013-02-12 National Tsing Hua University Cell penetrating peptides for intracellular delivery
US8399645B2 (en) 2003-11-05 2013-03-19 St. Jude Children's Research Hospital, Inc. Chimeric receptors with 4-1BB stimulatory signaling domain
WO2013039889A1 (en) 2011-09-15 2013-03-21 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services T cell receptors recognizing hla-a1- or hla-cw7-restricted mage
WO2013040371A2 (en) 2011-09-16 2013-03-21 Baylor College Of Medicine Targeting the tumor microenvironment using manipulated nkt cells
US20130071414A1 (en) 2011-04-27 2013-03-21 Gianpietro Dotti Engineered cd19-specific t lymphocytes that coexpress il-15 and an inducible caspase-9 based suicide gene for the treatment of b-cell malignancies
US8404658B2 (en) 2007-12-31 2013-03-26 Nanocor Therapeutics, Inc. RNA interference for the treatment of heart failure
WO2013044225A1 (en) 2011-09-22 2013-03-28 The Trustees Of The University Of Pennsylvania A universal immune receptor expressed by t cells for the targeting of diverse and multiple antigens
US8454972B2 (en) 2004-07-16 2013-06-04 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Method for inducing a multiclade immune response against HIV utilizing a multigene and multiclade immunogen
US20130183282A1 (en) 2010-05-12 2013-07-18 Cellectis Meganuclease variants cleaving a DNA target sequence from the rhodopsin gene and uses thereof
US20130185823A1 (en) 2012-01-16 2013-07-18 Academia Sinica Mesoporous silica nanoparticle-mediated delivery of dna into arabidopsis root
US20130202678A1 (en) 2008-07-29 2013-08-08 Academia Sinica Puf-a and related compounds for treatment of retinopathies and sight-threatening ophthalmologic disorders
WO2013154760A1 (en) 2012-04-11 2013-10-17 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Chimeric antigen receptors targeting b-cell maturation antigen
WO2013158141A1 (en) 2012-04-18 2013-10-24 Arrowhead Research Corporation Poly(acrylate) polymers for in vivo nucleic acid delivery
WO2013166321A1 (en) 2012-05-03 2013-11-07 Fred Hutchinson Cancer Research Center Enhanced affinity t cell receptors and methods for making the same
WO2013176915A1 (en) 2012-05-25 2013-11-28 Roman Galetto Methods for engineering allogeneic and immunosuppressive resistant t cell for immunotherapy
WO2014011987A1 (en) 2012-07-13 2014-01-16 The Trustees Of The University Of Pennsylvania Compositions and methods for regulating car t cells
US8637307B2 (en) 2002-01-03 2014-01-28 The Trustees Of The University Of Pennsylvania Activation and expansion of T-cells using an engineered multivalent signaling platform as a research tool
WO2014018863A1 (en) 2012-07-27 2014-01-30 The Board Of Trustees Of The University Of Illinois Engineering t-cell receptors
US8642295B2 (en) 2007-01-11 2014-02-04 Erasmus University Medical Center Circular chromosome conformation capture (4C)
WO2014047561A1 (en) 2012-09-21 2014-03-27 The Broad Institute Inc. Compositions and methods for labeling of agents
US8697854B2 (en) 2008-11-24 2014-04-15 Helmholtz Zentrum München Deutsches Forschungszentrum Für Gesundheit Und Umwelt Gmbh High affinity T cell receptor and use thereof
WO2014059173A2 (en) 2012-10-10 2014-04-17 Sangamo Biosciences, Inc. T cell modifying compounds and uses thereof
WO2014059255A1 (en) 2012-10-12 2014-04-17 The General Hospital Corporation Transcription activator-like effector (tale) - lysine-specific demethylase 1 (lsd1) fusion proteins
WO2014083173A1 (en) 2012-11-30 2014-06-05 Max-Delbrück-Centrum Für Molekulare Medizin (Mdc) Berlin-Buch Tumor specific t-cell receptors
WO2014093622A2 (en) 2012-12-12 2014-06-19 The Broad Institute, Inc. Delivery, engineering and optimization of systems, methods and compositions for sequence manipulation and therapeutic applications
WO2014093701A1 (en) 2012-12-12 2014-06-19 The Broad Institute, Inc. Functional genomics using crispr-cas systems, compositions, methods, knock out libraries and applications thereof
WO2014118272A1 (en) 2013-01-30 2014-08-07 Santaris Pharma A/S Antimir-122 oligonucleotide carbohydrate conjugates
WO2014133567A1 (en) 2013-03-01 2014-09-04 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods of producing enriched populations of tumor-reactive t cells from tumor
WO2014133568A1 (en) 2013-03-01 2014-09-04 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods of producing enriched populations of tumor reactive t cells from peripheral blood
WO2014134165A1 (en) 2013-02-26 2014-09-04 Memorial Sloan-Kettering Cancer Center Compositions and methods for immunotherapy
WO2014152432A2 (en) 2013-03-15 2014-09-25 The General Hospital Corporation Rna-guided targeting of genetic and epigenomic regulatory proteins to specific genomic loci
WO2014172606A1 (en) 2013-04-19 2014-10-23 The Brigham And Women's Hospital, Inc. Methods for modulating immune responses during chronic immune conditions by targeting metallothioneins
WO2014184744A1 (en) 2013-05-13 2014-11-20 Cellectis Methods for engineering highly active t cell for immunotherapy
WO2014191128A1 (en) 2013-05-29 2014-12-04 Cellectis Methods for engineering t cells for immunotherapy by using rna-guided cas nuclease system
WO2015035139A2 (en) * 2013-09-06 2015-03-12 Prisident And Fellows Of Harvard College Switchable cas9 nucleases and uses thereof
WO2015048577A2 (en) 2013-09-27 2015-04-02 Editas Medicine, Inc. Crispr-related methods and compositions
WO2015057834A1 (en) 2013-10-15 2015-04-23 The California Institute For Biomedical Research Peptidic chimeric antigen receptor t cell switches and uses thereof
WO2015057852A1 (en) 2013-10-15 2015-04-23 The California Institute For Biomedical Research Chimeric antigen receptor t cell switches and uses thereof
WO2015089419A2 (en) 2013-12-12 2015-06-18 The Broad Institute Inc. Delivery, use and therapeutic applications of the crispr-cas systems and compositions for targeting disorders and diseases using particle delivery components
WO2015089364A1 (en) 2013-12-12 2015-06-18 The Broad Institute Inc. Crystal structure of a crispr-cas system, and uses thereof
WO2015120096A2 (en) 2014-02-04 2015-08-13 Marc Better Methods for producing autologous t cells useful to treat b cell malignancies and other cancers and compositions thereof
WO2015142675A2 (en) 2014-03-15 2015-09-24 Novartis Ag Treatment of cancer using chimeric antigen receptor
WO2015161276A2 (en) 2014-04-18 2015-10-22 Editas Medicine, Inc. Crispr-cas-related methods, compositions and components for cancer immunotherapy
WO2015158671A1 (en) 2014-04-14 2015-10-22 Cellectis Bcma (cd269) specific chimeric antigen receptors for cancer immunotherapy
WO2015168404A1 (en) * 2014-04-30 2015-11-05 Massachusetts Institute Of Technology Toehold-gated guide rna for programmable cas9 circuitry with rna input
US9181527B2 (en) 2009-10-29 2015-11-10 The Trustees Of Dartmouth College T cell receptor-deficient T cell compositions
WO2015187528A1 (en) 2014-06-02 2015-12-10 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Chimeric antigen receptors targeting cd-19
US20150368342A1 (en) 2013-02-15 2015-12-24 The Regents Of The University Of California Chimeric antigen receptor and methods of use thereof
US20150368360A1 (en) 2013-02-06 2015-12-24 Anthrogenesis Corporation Modified t lymphocytes having improved specificity
WO2016000304A1 (en) 2014-06-30 2016-01-07 京东方科技集团股份有限公司 Virtual fitting method and virtual fitting system
US9233125B2 (en) 2010-12-14 2016-01-12 University Of Maryland, Baltimore Universal anti-tag chimeric antigen receptor-expressing T cells and methods of treating cancer
WO2016011210A2 (en) 2014-07-15 2016-01-21 Juno Therapeutics, Inc. Engineered cells for adoptive cell therapy
WO2016014789A2 (en) 2014-07-24 2016-01-28 Bluebird Bio, Inc. Bcma chimeric antigen receptors
US20160046724A1 (en) 2014-07-21 2016-02-18 The Trustees Of The University Of Pennsylvania Treatment of cancer using humanized anti-bcma chimeric antigen receptor
WO2016070061A1 (en) 2014-10-31 2016-05-06 The Trustees Of The University Of Pennsylvania Methods and compositions for modified t cells
US20160166613A1 (en) 2014-12-15 2016-06-16 Bellicum Pharmaceuticals, Inc. Methods for controlled elimination of therapeutic cells
US20160175359A1 (en) 2014-12-15 2016-06-23 Bellicum Pharmaceuticals, Inc. Methods for controlled activation or elimination of therapeutic cells
WO2016106236A1 (en) 2014-12-23 2016-06-30 The Broad Institute Inc. Rna-targeting system
WO2016161516A1 (en) 2015-04-10 2016-10-13 Feldan Bio Inc. Polypeptide-based shuttle agents for improving the transduction efficiency of polypeptide cargos to the cytosol of target eukaryotic cells, uses thereof, methods and kits relating to same
WO2016191756A1 (en) 2015-05-28 2016-12-01 Adrian Bot Methods of conditioning patients for t cell therapy
WO2016196388A1 (en) 2015-05-29 2016-12-08 Juno Therapeutics, Inc. Composition and methods for regulating inhibitory interactions in genetically engineered cells
WO2017004916A1 (en) 2015-07-08 2017-01-12 深圳市信维通信股份有限公司 8-shaped nfc antenna having rear metal housing
WO2017011804A1 (en) 2015-07-15 2017-01-19 Juno Therapeutics, Inc. Engineered cells for adoptive cell therapy
WO2017070395A1 (en) 2015-10-20 2017-04-27 Kite Pharma, Inc. Methods of preparing t cells for t cell therapy
WO2017090724A1 (en) 2015-11-25 2017-06-01 国立大学法人 群馬大学 Dna methylation editing kit and dna methylation editing method
US20170283504A1 (en) 2016-04-01 2017-10-05 Kite Pharma, Inc. Bcma binding molecules and methods of use thereof
WO2017211900A1 (en) 2016-06-07 2017-12-14 Max-Delbrück-Centrum für Molekulare Medizin Chimeric antigen receptor and car-t cells that bind bcma
WO2017223449A1 (en) * 2016-06-23 2017-12-28 President And Fellows Of Harvard College Conditional activation of nucleic acid-guided endonucleases
WO2018028647A1 (en) 2015-08-11 2018-02-15 Legend Biotech Usa Inc. Chimeric antigen receptors targeting bcma and methods of use thereof
WO2018053035A1 (en) 2016-09-13 2018-03-22 The Jackson Laboratory Targeted dna demethylation and methylation
US20180085444A1 (en) 2014-12-12 2018-03-29 Bluebird Bio, Inc. Bcma chimeric antigen receptors
WO2018148667A1 (en) 2017-02-10 2018-08-16 Memorial Sloan-Kettering Cancer Center Reprogramming cell aging
WO2019071048A1 (en) 2017-10-04 2019-04-11 The Broad Institute, Inc. Systems, methods, and compositions for targeted nucleic acid editing
WO2019084063A1 (en) 2017-10-23 2019-05-02 The Broad Institute, Inc. Systems, methods, and compositions for targeted nucleic acid editing
WO2019126774A1 (en) 2017-12-22 2019-06-27 The Broad Institute, Inc. Novel crispr enzymes and systems
WO2019126709A1 (en) 2017-12-22 2019-06-27 The Broad Institute, Inc. Cas12b systems, methods, and compositions for targeted dna base editing
WO2019126716A1 (en) 2017-12-22 2019-06-27 The Broad Institute, Inc. Cas12b systems, methods, and compositions for targeted rna base editing
WO2019126762A2 (en) 2017-12-22 2019-06-27 The Broad Institute, Inc. Cas12a systems, methods, and compositions for targeted rna base editing
WO2019136229A1 (en) 2018-01-05 2019-07-11 Prince Castle LLC Bun separation
WO2020191233A1 (en) 2019-03-19 2020-09-24 The Broad Institute, Inc. Methods and compositions for editing nucleotide sequences
US11001829B2 (en) 2014-09-25 2021-05-11 The Broad Institute, Inc. Functional screening with optimized functional CRISPR-Cas systems
WO2021102042A1 (en) 2019-11-19 2021-05-27 The Broad Institute, Inc. Retrotransposons and use thereof
WO2021138469A1 (en) 2019-12-30 2021-07-08 The Broad Institute, Inc. Genome editing using reverse transcriptase enabled and fully active crispr complexes
WO2021226558A1 (en) 2020-05-08 2021-11-11 The Broad Institute, Inc. Methods and compositions for simultaneous editing of both strands of a target double-stranded nucleotide sequence
WO2022017380A1 (en) 2020-07-21 2022-01-27 中国移动通信有限公司研究院 User ip address allocation management method and apparatus, and session management function entity
WO2022087494A1 (en) 2020-10-23 2022-04-28 The Broad Institute, Inc. Reprogrammable iscb nucleases and uses thereof
WO2022087235A1 (en) 2020-10-21 2022-04-28 Massachusetts Institute Of Technology Systems, methods, and compositions for site-specific genetic engineering using programmable addition via site-specific targeting elements (paste)
WO2022140577A2 (en) 2020-12-22 2022-06-30 Chroma Medicine, Inc. Compositions and methods for epigenetic editing
WO2023275601A1 (en) * 2021-07-02 2023-01-05 Vilnius University A novel rna-programmable system for targeting polynucleotides
WO2023097228A1 (en) 2021-11-23 2023-06-01 The Broad Institute, Inc. Reprogrammable iscb nucleases and uses thereof
WO2023097282A1 (en) * 2021-11-24 2023-06-01 Metagenomi, Inc. Endonuclease systems
WO2023114872A2 (en) * 2021-12-14 2023-06-22 The Broad Institute, Inc. Reprogrammable fanzor polynucleotides and uses thereof
WO2023215915A1 (en) * 2022-05-06 2023-11-09 Cornell University Use of iscb in genome editing
WO2023230483A2 (en) 2022-05-23 2023-11-30 The Broad Institute, Inc. Engineered chimeric iscb polypeptides and uses thereof
WO2024081728A2 (en) * 2022-10-11 2024-04-18 The Broad Institute, Inc. Reprogrammable tnpb polypeptides with maze domains and uses thereof

Patent Citations (197)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA275339A (en) 1927-11-08 L. Sagebield Perle Electric smelting furnace
US5912172A (en) 1988-05-04 1999-06-15 Yeda Research And Development Co. Ltd. Endowing lymphocytes with antibody specificity
US5906936A (en) 1988-05-04 1999-05-25 Yeda Research And Development Co. Ltd. Endowing lymphocytes with antibody specificity
US7232566B2 (en) 1988-11-23 2007-06-19 The United States As Represented By The Secretary Of The Navy Methods for treating HIV infected subjects
US6534055B1 (en) 1988-11-23 2003-03-18 Genetics Institute, Inc. Methods for selectively stimulating proliferation of T cells
US6905680B2 (en) 1988-11-23 2005-06-14 Genetics Institute, Inc. Methods of treating HIV infected subjects
US7144575B2 (en) 1988-11-23 2006-12-05 The Regents Of The University Of Michigan Methods for selectively stimulating proliferation of T cells
US6887466B2 (en) 1988-11-23 2005-05-03 Genetics Institute, Inc. Methods for selectively stimulating proliferation of T cells
US5883223A (en) 1988-11-23 1999-03-16 Gray; Gary S. CD9 antigen peptides and antibodies thereto
US5780269A (en) 1989-02-24 1998-07-14 The University Of Medicine And Denistry Of New Jersey Hybrid molecules
US6017737A (en) 1989-02-24 2000-01-25 The University Of Medicine And Denistry Of New Jersey E. coli msDNA synthesizing system, products and uses
US5320958A (en) 1989-02-24 1994-06-14 University Of Medicine And Dentistry Of New Jersey Isolated bacterial reverse transcriptase
US5436141A (en) 1989-02-24 1995-07-25 University Of Medicine And Dentistry Of New Jersey Method for synthesizing stable single-stranded CDNA in eukaryotes by means of a bacterial retron and products
US5405775A (en) 1989-02-24 1995-04-11 The University Of Medicine And Dentistry Of New Jersey Retrons coding for hybrid DNA/RNA molecules
US5849563A (en) 1989-02-24 1998-12-15 The University Of Medecine And Dentistry Of New Jersey Eukaryotes expressing single stranded hybrid molecules
US5445934A (en) 1989-06-07 1995-08-29 Affymax Technologies N.V. Array of oligonucleotides on a solid substrate
US5210015A (en) 1990-08-06 1993-05-11 Hoffman-La Roche Inc. Homogeneous assay system using the nuclease activity of a nucleic acid polymerase
US6410014B1 (en) 1991-03-07 2002-06-25 The General Hospital Corporation Redirection of cellular immunity by protein-tyrosine kinase chimeras
US6004811A (en) 1991-03-07 1999-12-21 The Massachussetts General Hospital Redirection of cellular immunity by protein tyrosine kinase chimeras
WO1992015322A1 (en) 1991-03-07 1992-09-17 The General Hospital Corporation Redirection of cellular immunity by receptor chimeras
US5851828A (en) 1991-03-07 1998-12-22 The General Hospital Corporation Targeted cytolysis of HIV-infected cells by chimeric CD4 receptor-bearing cells
US5843728A (en) 1991-03-07 1998-12-01 The General Hospital Corporation Redirection of cellular immunity by receptor chimeras
US6753162B1 (en) 1991-03-07 2004-06-22 The General Hospital Corporation Targeted cytolysis of HIV-infected cells by chimeric CD4 receptor-bearing cells
US5912170A (en) 1991-03-07 1999-06-15 The General Hospital Corporation Redirection of cellular immunity by protein-tyrosine kinase chimeras
US6392013B1 (en) 1991-03-07 2002-05-21 The General Hospital Corporation Redirection of cellular immunity by protein tyrosine kinase chimeras
US6284240B1 (en) 1991-03-07 2001-09-04 The General Hospital Corporation Targeted cytolysis of HIV-infected cells by chimeric CD4 receptor-bearing cells
CA2075515A1 (en) 1991-08-30 1993-03-01 Shohei Miyata Method for synthesizing stable single-stranded cdna in eucaryotes by means of a bacterial retron, products and uses therefor
US8211422B2 (en) 1992-03-18 2012-07-03 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Chimeric receptor genes and cells transformed therewith
US7741465B1 (en) 1992-03-18 2010-06-22 Zelig Eshhar Chimeric receptor genes and cells transformed therewith
US5858358A (en) 1992-04-07 1999-01-12 The United States Of America As Represented By The Secretary Of The Navy Methods for selectively stimulating proliferation of T cells
US5563055A (en) 1992-07-27 1996-10-08 Pioneer Hi-Bred International, Inc. Method of Agrobacterium-mediated transformation of cultured soybean cells
US6352694B1 (en) 1994-06-03 2002-03-05 Genetics Institute, Inc. Methods for inducing a population of T cells to proliferate using agents which recognize TCR/CD3 and ligands which stimulate an accessory molecule on the surface of the T cells
US7175843B2 (en) 1994-06-03 2007-02-13 Genetics Institute, Llc Methods for selectively stimulating proliferation of T cells
US6905681B1 (en) 1994-06-03 2005-06-14 Genetics Institute, Inc. Methods for selectively stimulating proliferation of T cells
US6040177A (en) 1994-08-31 2000-03-21 Fred Hutchinson Cancer Research Center High efficiency transduction of T lymphocytes using rapid expansion methods ("REM")
US5686281A (en) 1995-02-03 1997-11-11 Cell Genesys, Inc. Chimeric receptor molecules for delivery of co-stimulatory signals
WO1996039154A1 (en) 1995-06-06 1996-12-12 Isis Pharmaceuticals, Inc. Oligonucleotides having phosphorothioate linkages of high chiral purity
WO1997003211A1 (en) 1995-07-13 1997-01-30 Isis Pharmaceuticals, Inc. Antisense inhibition of hepatitis b virus replication
WO1997049450A1 (en) 1996-06-24 1997-12-31 Genetronics, Inc. Electroporation-mediated intravascular delivery
US5869326A (en) 1996-09-09 1999-02-09 Genetronics, Inc. Electroporation employing user-configured pulsing scheme
US7148203B2 (en) 1997-03-11 2006-12-12 Regents Of The University Of Minnesota Nucleic acid transfer vector for the introduction of nucleic acid into the DNA of a cell
US6489458B2 (en) 1997-03-11 2002-12-03 Regents Of The University Of Minnesota DNA-based transposon system for the introduction of nucleic acid into DNA of a cell
WO1998052609A1 (en) 1997-05-19 1998-11-26 Nycomed Imaging As Sonodynamic therapy using an ultrasound sensitizer compound
US7160682B2 (en) 1998-11-13 2007-01-09 Regents Of The University Of Minnesota Nucleic acid transfer vector for the introduction of nucleic acid into the DNA of a cell
US6797514B2 (en) 2000-02-24 2004-09-28 Xcyte Therapies, Inc. Simultaneous stimulation and concentration of cells
US6905874B2 (en) 2000-02-24 2005-06-14 Xcyte Therapies, Inc. Simultaneous stimulation and concentration of cells
US7572631B2 (en) 2000-02-24 2009-08-11 Invitrogen Corporation Activation and expansion of T cells
US6867041B2 (en) 2000-02-24 2005-03-15 Xcyte Therapies, Inc. Simultaneous stimulation and concentration of cells
WO2003020763A2 (en) 2001-08-31 2003-03-13 Avidex Limited Soluble t cell receptor
US8637307B2 (en) 2002-01-03 2014-01-28 The Trustees Of The University Of Pennsylvania Activation and expansion of T-cells using an engineered multivalent signaling platform as a research tool
WO2003057171A2 (en) 2002-01-03 2003-07-17 The Trustees Of The University Of Pennsylvania Activation and expansion of t-cells using an engineered multivalent signaling platform
US7206639B2 (en) 2002-03-15 2007-04-17 Sarcos Investments Lc Cochlear drug delivery system and method
US8227432B2 (en) 2002-04-22 2012-07-24 Regents Of The University Of Minnesota Transposon system and methods of use
US7446190B2 (en) 2002-05-28 2008-11-04 Sloan-Kettering Institute For Cancer Research Nucleic acids encoding chimeric T cell receptors
WO2004015075A2 (en) 2002-08-08 2004-02-19 Dharmacon, Inc. Short interfering rnas having a hairpin structure containing a non-nucleotide loop
US8034334B2 (en) 2002-09-06 2011-10-11 The United States Of America As Represented By The Secretary, Department Of Health And Human Services Immunotherapy with in vitro-selected antigen-specific lymphocytes after non-myeloablative lymphodepleting chemotherapy
WO2004033685A1 (en) 2002-10-09 2004-04-22 Avidex Ltd Single chain recombinant t cell receptors
WO2004044004A2 (en) 2002-11-09 2004-05-27 Avidex Limited T cell receptor display
WO2004074322A1 (en) 2003-02-22 2004-09-02 Avidex Ltd Modified soluble t cell receptor
US20040224402A1 (en) 2003-05-08 2004-11-11 Xcyte Therapies, Inc. Generation and isolation of antigen-specific T cells
US7985739B2 (en) 2003-06-04 2011-07-26 The Board Of Trustees Of The Leland Stanford Junior University Enhanced sleeping beauty transposon system and methods for using the same
US8399645B2 (en) 2003-11-05 2013-03-19 St. Jude Children's Research Hospital, Inc. Chimeric receptors with 4-1BB stimulatory signaling domain
US20050287127A1 (en) 2003-11-13 2005-12-29 Huawei Li Use of stem cells to generate inner ear cells
US20060030837A1 (en) 2004-01-29 2006-02-09 The Charles Stark Draper Laboratory, Inc. Drug delivery apparatus
WO2005113595A2 (en) 2004-05-19 2005-12-01 Avidex Ltd High affinity ny-eso t cell receptor
WO2005114215A2 (en) 2004-05-19 2005-12-01 Avidex Ltd Method of improving t cell receptors
WO2006000830A2 (en) 2004-06-29 2006-01-05 Avidex Ltd Cells expressing a modified t cell receptor
US8454972B2 (en) 2004-07-16 2013-06-04 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Method for inducing a multiclade immune response against HIV utilizing a multigene and multiclade immunogen
US20100041033A1 (en) 2004-08-03 2010-02-18 The Regents Of The University Of California Site specific system for generating diversity protein sequences
WO2006125962A2 (en) 2005-05-25 2006-11-30 Medigene Limited T cell receptors which specifically bind to vygfvracl-hla-a24
US20070093878A1 (en) 2005-09-08 2007-04-26 Albert Edge Cochlear implants containing biological cells and uses thereof
US8088379B2 (en) 2006-09-26 2012-01-03 The United States Of America As Represented By The Department Of Health And Human Services Modified T cell receptors and related materials and methods
WO2008039818A2 (en) 2006-09-26 2008-04-03 Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Modified t cell receptors and related materials and methods
WO2008042156A1 (en) 2006-09-28 2008-04-10 Northwestern University Maximizing oligonucleotide loading on gold nanoparticle
WO2008038002A2 (en) 2006-09-29 2008-04-03 Medigene Limited T cell therapies
US20100104509A1 (en) 2006-12-13 2010-04-29 Medarex, Inc. Human antibodies that bind cd19 and uses thereof
US8642295B2 (en) 2007-01-11 2014-02-04 Erasmus University Medical Center Circular chromosome conformation capture (4C)
US8404658B2 (en) 2007-12-31 2013-03-26 Nanocor Therapeutics, Inc. RNA interference for the treatment of heart failure
US20120328580A1 (en) 2008-02-07 2012-12-27 Albert Edge Compounds that enhance atoh1 expression
US20110142917A1 (en) 2008-06-06 2011-06-16 Egvenia Alpert Compositions and methods for treatment of ear disorders
US20130202678A1 (en) 2008-07-29 2013-08-08 Academia Sinica Puf-a and related compounds for treatment of retinopathies and sight-threatening ophthalmologic disorders
US8697854B2 (en) 2008-11-24 2014-04-15 Helmholtz Zentrum München Deutsches Forschungszentrum Für Gesundheit Und Umwelt Gmbh High affinity T cell receptor and use thereof
US20120159653A1 (en) 2008-12-04 2012-06-21 Sigma-Aldrich Co. Genomic editing of genes involved in macular degeneration
US20110023139A1 (en) 2008-12-04 2011-01-27 Sigma-Aldrich Co. Genomic editing of genes involved in cardiovascular disease
WO2010099296A1 (en) 2009-02-26 2010-09-02 Transposagen Biopharmaceuticals, Inc. Hyperactive piggybac transposases
WO2011008730A2 (en) 2009-07-13 2011-01-20 Somagenics Inc. Chemical modification of small hairpin rnas for inhibition of gene expression
US9181527B2 (en) 2009-10-29 2015-11-10 The Trustees Of Dartmouth College T cell receptor-deficient T cell compositions
US20130183282A1 (en) 2010-05-12 2013-07-18 Cellectis Meganuclease variants cleaving a DNA target sequence from the rhodopsin gene and uses thereof
US8372951B2 (en) 2010-05-14 2013-02-12 National Tsing Hua University Cell penetrating peptides for intracellular delivery
WO2011146862A1 (en) 2010-05-21 2011-11-24 Bellicum Pharmaceuticals, Inc. Methods for inducing selective apoptosis
WO2012058460A2 (en) 2010-10-27 2012-05-03 Baylor College Of Medicine Chimeric cd27 receptors for redirecting t cells to cd70-positive malignancies
US8906682B2 (en) 2010-12-09 2014-12-09 The Trustees Of The University Of Pennsylvania Methods for treatment of cancer
WO2012079000A1 (en) 2010-12-09 2012-06-14 The Trustees Of The University Of Pennsylvania Use of chimeric antigen receptor-modified t cells to treat cancer
US8911993B2 (en) 2010-12-09 2014-12-16 The Trustees Of The University Of Pennsylvania Compositions for treatment of cancer
US8916381B1 (en) 2010-12-09 2014-12-23 The Trustees Of The University Of Pennyslvania Methods for treatment of cancer
US8975071B1 (en) 2010-12-09 2015-03-10 The Trustees Of The University Of Pennsylvania Compositions for treatment of cancer
US9101584B2 (en) 2010-12-09 2015-08-11 The Trustees Of The University Of Pennsylvania Methods for treatment of cancer
US9102761B2 (en) 2010-12-09 2015-08-11 The Trustees Of The University Of Pennsylvania Compositions for treatment of cancer
US9102760B2 (en) 2010-12-09 2015-08-11 The Trustees Of The University Of Pennsylvania Compositions for treatment of cancer
US9233125B2 (en) 2010-12-14 2016-01-12 University Of Maryland, Baltimore Universal anti-tag chimeric antigen receptor-expressing T cells and methods of treating cancer
US20160129109A1 (en) 2010-12-14 2016-05-12 University Of Maryland, Baltimore Universal anti-tag chimeric antigen receptor-expressing t cells and methods of treating cancer
US20120244133A1 (en) 2011-03-22 2012-09-27 The United States of America, as represented by the Secretary, Department of Health and Methods of growing tumor infiltrating lymphocytes in gas-permeable containers
US20130071414A1 (en) 2011-04-27 2013-03-21 Gianpietro Dotti Engineered cd19-specific t lymphocytes that coexpress il-15 and an inducible caspase-9 based suicide gene for the treatment of b-cell malignancies
WO2013039889A1 (en) 2011-09-15 2013-03-21 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services T cell receptors recognizing hla-a1- or hla-cw7-restricted mage
WO2013040371A2 (en) 2011-09-16 2013-03-21 Baylor College Of Medicine Targeting the tumor microenvironment using manipulated nkt cells
WO2013044225A1 (en) 2011-09-22 2013-03-28 The Trustees Of The University Of Pennsylvania A universal immune receptor expressed by t cells for the targeting of diverse and multiple antigens
US20130185823A1 (en) 2012-01-16 2013-07-18 Academia Sinica Mesoporous silica nanoparticle-mediated delivery of dna into arabidopsis root
WO2013154760A1 (en) 2012-04-11 2013-10-17 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Chimeric antigen receptors targeting b-cell maturation antigen
WO2013158141A1 (en) 2012-04-18 2013-10-24 Arrowhead Research Corporation Poly(acrylate) polymers for in vivo nucleic acid delivery
WO2013166321A1 (en) 2012-05-03 2013-11-07 Fred Hutchinson Cancer Research Center Enhanced affinity t cell receptors and methods for making the same
WO2013176915A1 (en) 2012-05-25 2013-11-28 Roman Galetto Methods for engineering allogeneic and immunosuppressive resistant t cell for immunotherapy
WO2014011987A1 (en) 2012-07-13 2014-01-16 The Trustees Of The University Of Pennsylvania Compositions and methods for regulating car t cells
WO2014018863A1 (en) 2012-07-27 2014-01-30 The Board Of Trustees Of The University Of Illinois Engineering t-cell receptors
WO2014047561A1 (en) 2012-09-21 2014-03-27 The Broad Institute Inc. Compositions and methods for labeling of agents
WO2014059173A2 (en) 2012-10-10 2014-04-17 Sangamo Biosciences, Inc. T cell modifying compounds and uses thereof
WO2014059255A1 (en) 2012-10-12 2014-04-17 The General Hospital Corporation Transcription activator-like effector (tale) - lysine-specific demethylase 1 (lsd1) fusion proteins
WO2014083173A1 (en) 2012-11-30 2014-06-05 Max-Delbrück-Centrum Für Molekulare Medizin (Mdc) Berlin-Buch Tumor specific t-cell receptors
US20140357530A1 (en) 2012-12-12 2014-12-04 The Broad Institute Inc. Functional genomics using crispr-cas systems, compositions, methods, knock out libraries and applications thereof
WO2014093622A2 (en) 2012-12-12 2014-06-19 The Broad Institute, Inc. Delivery, engineering and optimization of systems, methods and compositions for sequence manipulation and therapeutic applications
WO2014093701A1 (en) 2012-12-12 2014-06-19 The Broad Institute, Inc. Functional genomics using crispr-cas systems, compositions, methods, knock out libraries and applications thereof
WO2014118272A1 (en) 2013-01-30 2014-08-07 Santaris Pharma A/S Antimir-122 oligonucleotide carbohydrate conjugates
US20150368360A1 (en) 2013-02-06 2015-12-24 Anthrogenesis Corporation Modified t lymphocytes having improved specificity
US20150368342A1 (en) 2013-02-15 2015-12-24 The Regents Of The University Of California Chimeric antigen receptor and methods of use thereof
WO2014134165A1 (en) 2013-02-26 2014-09-04 Memorial Sloan-Kettering Cancer Center Compositions and methods for immunotherapy
WO2014133567A1 (en) 2013-03-01 2014-09-04 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods of producing enriched populations of tumor-reactive t cells from tumor
WO2014133568A1 (en) 2013-03-01 2014-09-04 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods of producing enriched populations of tumor reactive t cells from peripheral blood
WO2014152432A2 (en) 2013-03-15 2014-09-25 The General Hospital Corporation Rna-guided targeting of genetic and epigenomic regulatory proteins to specific genomic loci
WO2014172606A1 (en) 2013-04-19 2014-10-23 The Brigham And Women's Hospital, Inc. Methods for modulating immune responses during chronic immune conditions by targeting metallothioneins
WO2014184744A1 (en) 2013-05-13 2014-11-20 Cellectis Methods for engineering highly active t cell for immunotherapy
WO2014191128A1 (en) 2013-05-29 2014-12-04 Cellectis Methods for engineering t cells for immunotherapy by using rna-guided cas nuclease system
WO2015035139A2 (en) * 2013-09-06 2015-03-12 Prisident And Fellows Of Harvard College Switchable cas9 nucleases and uses thereof
WO2015048577A2 (en) 2013-09-27 2015-04-02 Editas Medicine, Inc. Crispr-related methods and compositions
WO2015057852A1 (en) 2013-10-15 2015-04-23 The California Institute For Biomedical Research Chimeric antigen receptor t cell switches and uses thereof
WO2015057834A1 (en) 2013-10-15 2015-04-23 The California Institute For Biomedical Research Peptidic chimeric antigen receptor t cell switches and uses thereof
WO2015089364A1 (en) 2013-12-12 2015-06-18 The Broad Institute Inc. Crystal structure of a crispr-cas system, and uses thereof
WO2015089419A2 (en) 2013-12-12 2015-06-18 The Broad Institute Inc. Delivery, use and therapeutic applications of the crispr-cas systems and compositions for targeting disorders and diseases using particle delivery components
WO2015120096A2 (en) 2014-02-04 2015-08-13 Marc Better Methods for producing autologous t cells useful to treat b cell malignancies and other cancers and compositions thereof
WO2015142675A2 (en) 2014-03-15 2015-09-24 Novartis Ag Treatment of cancer using chimeric antigen receptor
WO2015158671A1 (en) 2014-04-14 2015-10-22 Cellectis Bcma (cd269) specific chimeric antigen receptors for cancer immunotherapy
WO2015161276A2 (en) 2014-04-18 2015-10-22 Editas Medicine, Inc. Crispr-cas-related methods, compositions and components for cancer immunotherapy
WO2015168404A1 (en) * 2014-04-30 2015-11-05 Massachusetts Institute Of Technology Toehold-gated guide rna for programmable cas9 circuitry with rna input
WO2015187528A1 (en) 2014-06-02 2015-12-10 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Chimeric antigen receptors targeting cd-19
WO2016000304A1 (en) 2014-06-30 2016-01-07 京东方科技集团股份有限公司 Virtual fitting method and virtual fitting system
WO2016011210A2 (en) 2014-07-15 2016-01-21 Juno Therapeutics, Inc. Engineered cells for adoptive cell therapy
US20160046724A1 (en) 2014-07-21 2016-02-18 The Trustees Of The University Of Pennsylvania Treatment of cancer using humanized anti-bcma chimeric antigen receptor
WO2016014789A2 (en) 2014-07-24 2016-01-28 Bluebird Bio, Inc. Bcma chimeric antigen receptors
US11001829B2 (en) 2014-09-25 2021-05-11 The Broad Institute, Inc. Functional screening with optimized functional CRISPR-Cas systems
WO2016070061A1 (en) 2014-10-31 2016-05-06 The Trustees Of The University Of Pennsylvania Methods and compositions for modified t cells
US20180085444A1 (en) 2014-12-12 2018-03-29 Bluebird Bio, Inc. Bcma chimeric antigen receptors
US20160166613A1 (en) 2014-12-15 2016-06-16 Bellicum Pharmaceuticals, Inc. Methods for controlled elimination of therapeutic cells
US20160175359A1 (en) 2014-12-15 2016-06-23 Bellicum Pharmaceuticals, Inc. Methods for controlled activation or elimination of therapeutic cells
WO2016106236A1 (en) 2014-12-23 2016-06-30 The Broad Institute Inc. Rna-targeting system
WO2016161516A1 (en) 2015-04-10 2016-10-13 Feldan Bio Inc. Polypeptide-based shuttle agents for improving the transduction efficiency of polypeptide cargos to the cytosol of target eukaryotic cells, uses thereof, methods and kits relating to same
WO2016191756A1 (en) 2015-05-28 2016-12-01 Adrian Bot Methods of conditioning patients for t cell therapy
WO2016196388A1 (en) 2015-05-29 2016-12-08 Juno Therapeutics, Inc. Composition and methods for regulating inhibitory interactions in genetically engineered cells
WO2017004916A1 (en) 2015-07-08 2017-01-12 深圳市信维通信股份有限公司 8-shaped nfc antenna having rear metal housing
WO2017011804A1 (en) 2015-07-15 2017-01-19 Juno Therapeutics, Inc. Engineered cells for adoptive cell therapy
WO2018028647A1 (en) 2015-08-11 2018-02-15 Legend Biotech Usa Inc. Chimeric antigen receptors targeting bcma and methods of use thereof
WO2017070395A1 (en) 2015-10-20 2017-04-27 Kite Pharma, Inc. Methods of preparing t cells for t cell therapy
WO2017090724A1 (en) 2015-11-25 2017-06-01 国立大学法人 群馬大学 Dna methylation editing kit and dna methylation editing method
US20170283504A1 (en) 2016-04-01 2017-10-05 Kite Pharma, Inc. Bcma binding molecules and methods of use thereof
WO2017211900A1 (en) 2016-06-07 2017-12-14 Max-Delbrück-Centrum für Molekulare Medizin Chimeric antigen receptor and car-t cells that bind bcma
WO2017223449A1 (en) * 2016-06-23 2017-12-28 President And Fellows Of Harvard College Conditional activation of nucleic acid-guided endonucleases
WO2018053035A1 (en) 2016-09-13 2018-03-22 The Jackson Laboratory Targeted dna demethylation and methylation
US20200003761A1 (en) 2017-02-10 2020-01-02 Memorial Sloan-Kettering Cancer Center Reprogramming cell aging
WO2018148667A1 (en) 2017-02-10 2018-08-16 Memorial Sloan-Kettering Cancer Center Reprogramming cell aging
WO2019071048A1 (en) 2017-10-04 2019-04-11 The Broad Institute, Inc. Systems, methods, and compositions for targeted nucleic acid editing
WO2019084063A1 (en) 2017-10-23 2019-05-02 The Broad Institute, Inc. Systems, methods, and compositions for targeted nucleic acid editing
WO2019126709A1 (en) 2017-12-22 2019-06-27 The Broad Institute, Inc. Cas12b systems, methods, and compositions for targeted dna base editing
WO2019126716A1 (en) 2017-12-22 2019-06-27 The Broad Institute, Inc. Cas12b systems, methods, and compositions for targeted rna base editing
WO2019126762A2 (en) 2017-12-22 2019-06-27 The Broad Institute, Inc. Cas12a systems, methods, and compositions for targeted rna base editing
WO2019126774A1 (en) 2017-12-22 2019-06-27 The Broad Institute, Inc. Novel crispr enzymes and systems
WO2019136229A1 (en) 2018-01-05 2019-07-11 Prince Castle LLC Bun separation
WO2020191246A1 (en) 2019-03-19 2020-09-24 The Broad Institute, Inc. Methods and compositions for editing nucleotide sequences
WO2020191234A1 (en) 2019-03-19 2020-09-24 The Broad Institute, Inc. Methods and compositions for editing nucleotide sequences
WO2020191239A1 (en) 2019-03-19 2020-09-24 The Broad Institute, Inc. Methods and compositions for editing nucleotide sequences
WO2020191242A1 (en) 2019-03-19 2020-09-24 The Broad Institute, Inc. Methods and compositions for editing nucleotide sequences
WO2020191243A1 (en) 2019-03-19 2020-09-24 The Broad Institute, Inc. Methods and compositions for editing nucleotide sequences
WO2020191245A1 (en) 2019-03-19 2020-09-24 The Broad Institute, Inc. Methods and compositions for editing nucleotide sequences
WO2020191248A1 (en) 2019-03-19 2020-09-24 The Broad Institute, Inc. Method and compositions for editing nucleotide sequences
WO2020191249A1 (en) 2019-03-19 2020-09-24 The Broad Institute, Inc. Methods and compositions for editing nucleotide sequences
WO2020191241A1 (en) 2019-03-19 2020-09-24 The Broad Institute, Inc. Methods and compositions for editing nucleotide sequences
WO2020191233A1 (en) 2019-03-19 2020-09-24 The Broad Institute, Inc. Methods and compositions for editing nucleotide sequences
WO2021102042A1 (en) 2019-11-19 2021-05-27 The Broad Institute, Inc. Retrotransposons and use thereof
WO2021138469A1 (en) 2019-12-30 2021-07-08 The Broad Institute, Inc. Genome editing using reverse transcriptase enabled and fully active crispr complexes
WO2021226558A1 (en) 2020-05-08 2021-11-11 The Broad Institute, Inc. Methods and compositions for simultaneous editing of both strands of a target double-stranded nucleotide sequence
WO2022017380A1 (en) 2020-07-21 2022-01-27 中国移动通信有限公司研究院 User ip address allocation management method and apparatus, and session management function entity
WO2022087235A1 (en) 2020-10-21 2022-04-28 Massachusetts Institute Of Technology Systems, methods, and compositions for site-specific genetic engineering using programmable addition via site-specific targeting elements (paste)
WO2022087494A1 (en) 2020-10-23 2022-04-28 The Broad Institute, Inc. Reprogrammable iscb nucleases and uses thereof
WO2022140577A2 (en) 2020-12-22 2022-06-30 Chroma Medicine, Inc. Compositions and methods for epigenetic editing
WO2023275601A1 (en) * 2021-07-02 2023-01-05 Vilnius University A novel rna-programmable system for targeting polynucleotides
WO2023097228A1 (en) 2021-11-23 2023-06-01 The Broad Institute, Inc. Reprogrammable iscb nucleases and uses thereof
WO2023097282A1 (en) * 2021-11-24 2023-06-01 Metagenomi, Inc. Endonuclease systems
WO2023114872A2 (en) * 2021-12-14 2023-06-22 The Broad Institute, Inc. Reprogrammable fanzor polynucleotides and uses thereof
WO2023215915A1 (en) * 2022-05-06 2023-11-09 Cornell University Use of iscb in genome editing
WO2023230483A2 (en) 2022-05-23 2023-11-30 The Broad Institute, Inc. Engineered chimeric iscb polypeptides and uses thereof
WO2024081728A2 (en) * 2022-10-11 2024-04-18 The Broad Institute, Inc. Reprogrammable tnpb polypeptides with maze domains and uses thereof

Non-Patent Citations (360)

* Cited by examiner, † Cited by third party
Title
"From Ultrasonics in Clinical Diagnosis", 1977, PUBL. CHURCHILL LIVINGSTONE
"Methods in Enzymology", 1995, ACADEMIC PRESS, INC., article "PCR 2: A Practical Approach"
ABHISHEK SINGHALVALENTINA BAGNACANIROBERTO CORRADINIPETER E. NIELSEN, ACS CHEMICAL BIOLOGY, vol. 9, no. 11, 2014, pages 2612 - 2620
ABUDAYYEH OO ET AL.: "A cytosine deaminase for programmable single-base RNA editing", SCIENCE, vol. 365, 26 July 2019 (2019-07-26), pages 382 - 386, XP055768225, DOI: 10.1126/science.aax7063
ADZUMAMIZUUCHI, CELL, vol. 53, 1988, pages 257 - 266
AGATHANGGELOU ET AL., AM.J.PATHOL., vol. 147, 1995, pages 1152 - 1160
AKINC A ET AL., MOLECULAR THERAPY, vol. 18, no. 7, 2010, pages 1357 - 1364
ALLERSON ET AL., J. MED. CHEM., vol. 48, 2005, pages 901 - 904
ALTAE-TRAN, H.KANNAN, S.DEMIRCIOGLU, F. E.OSHIRO, R.NETY, S. P.MCKAY, L. J.DLAKI6, M.INSKEEP, W. PMAKAROVA, K. S.MACRAE, R. K.: "The Widespread IS200/IS605 Transposon Family Encodes Diverse Programmable RNA-Guided Endonucleases", SCIENCE, vol. 374, 2021, pages 57 - 65, XP055901842, DOI: 10.1126/science.abj6856
ALTMAN ET AL., SCIENCE, vol. 274, no. 5284, 4 October 1996 (1996-10-04), pages 94 - 6
ANZALONE AV ET AL.: "Search-and-replace genome editing without double- strand breaks or donor DNA", NATURE, 21 October 2019 (2019-10-21)
ANZALONE ET AL.: "Search-and-replace genome editing without double-strand breaks or donor DNA", NATURE, vol. 576, no. 7785, 2019, pages 149 - 157, XP038006531, DOI: 10.1038/s41586-019-1711-4
BABA ET AL., J VIROL., vol. 82, 2008, pages 3843 - 3852
BAKER ET AL., CELL, vol. 65, 1991, pages 1003 - 1013
BALAGAAN: "J Gene Med", vol. 8, 2006, WILEY INTERSCIENCE, pages: 275 - 285
BARABAS, O.RONNING, D.R.GUYNET, C.HICKMAN, A.B.TONHOANG, B.CHANDLER, M.DYDA, F.: "Mechanism of IS200/ IS605 family DNA transposases: activation and transposon-directed target site selection", CELL, vol. 132, 2008, pages 208 - 220, XP055641870, DOI: 10.1016/j.cell.2007.12.029
BASKOTA ET AL., CELL., vol. 185, no. 2, 20 January 2022 (2022-01-20), pages 250 - 265
BATES K AND KOSTARELOS K., ADV DRUG DELIV REV, vol. 65, 2013, pages 2023 - 33
BATEY ET AL., NATURE, vol. 432, 2004, pages 411 - 415
BAWAGE SS ET AL., SYNTHETIC MRNA EXPRESSED CAS13A MITIGATES RNA VIRUS INFECTIONS
BEERLI RRSEGAL DJDREIER BBARBAS CF.: "3rd Toward controlling gene expression at will: specific regulation of the erbB-2/HER-2 promoter by using polydactyl zinc finger proteins constructed from modular building blocks", PROC NATL ACAD SCI U S A., vol. 95, 1998, pages 14628 - 14633, XP002924795, DOI: 10.1073/pnas.95.25.14628
BEHLKE ET AL., OLIGONUCLEOTIDES, vol. 18, 2008, pages 305 - 19
BERDEJA JG ET AL.: "Durable clinical responses in heavily pretreated patients with relapsed/refractory multiple myeloma: updated results from a multicenter study of bb2121 anti-Bcma CAR T cell therapy", BLOOD, vol. 130, 2017, pages 740, XP086629345, DOI: 10.1182/blood.V130.Suppl_1.740.740
BERNSTEIN DLLE LAY JERUANO EGKAESTNER KH: "TALE-mediated epigenetic suppression of CDKN2A increases replication in human fibroblasts", J CLIN INVEST., vol. 125, 2015, pages 1998 - 2006, XP055574014, DOI: 10.1172/JCI77321
BESSER ET AL., CLIN. CANCER RES, vol. 16, no. 9, 2010, pages 2646 - 55
BINLEY ET AL., HUMAN GENE THERAPY, vol. 23, September 2012 (2012-09-01), pages 980 - 991
BLACK JBADLER AFWANG HG ET AL.: "Targeted Epigenetic Remodeling of Endogenous Loci by CRISPR/Cas9-Based Transcriptional Activators Directly Converts Fibroblasts to Neuronal Cells", CELL STEM CELL., vol. 19, no. 3, 2016, pages 406 - 414, XP029711990, DOI: 10.1016/j.stem.2016.07.001
BONIMURANSKI ET AL., BLOOD, vol. 1, no. 12, 2008, pages 4746 - 54
BORTOLANZA ET AL., MOLECULAR THERAPY, vol. 19, no. 11, November 2011 (2011-11-01), pages 2055 - 2064
BRAMSEN ET AL., FRONT. GENET., vol. 3, 2012, pages 154
BREAKER, R.R., MOL CELL, vol. 43, 2011, pages 867 - 879
BUDDEE ET AL., PLOS ONE, 2013
BURNETTROSSI, CHEM BIOL., vol. 19, no. 1, 2012, pages 60 - 71
C. FESCHOTTE, MOL. BIOL. EVOL., vol. 21, no. 9, 2004, pages 1769 - 1780
CAMPOCHIARO ET AL., HUMAN GENE THERAPY, vol. 17, February 2006 (2006-02-01), pages 167 - 176
CANO-RODRIGUEZ DGJALTEMA RAJILDERDA LJ ET AL.: "Writing of H3K4Me3 overcomes epigenetic silencing in a sustained but context-dependent manner", NAT COMMUN., vol. 7, 2016, pages 12284
CAO ET AL., J CONTROLLED RELEASE, vol. 144, no. 2, June 2010 (2010-06-01), pages 203 - 212
CAPPELLO JHANDELSMAN KLODISH HF: "Sequence of Dictyostelium DIRS-1: an apparent retrotransposon with inverted terminal repeats and an internal circle junction sequence", CELL, vol. 43, 1985, pages 105 - 115, XP023910945, DOI: 10.1016/0092-8674(85)90016-9
CARTIER: "MINI-SYMPOSIUM: X-Linked Adrenoleukodystrophypa, Hematopoietic Stem Cell Transplantation and Hematopoietic Stem Cell Gene Therapy in X-Linked Adrenoleukodystrophy", BRAIN PATHOLOGY, vol. 20, 2010, pages 857 - 862
CASAS AM ET AL., PROC NATL ACAD SCI U S A., vol. 90, no. 23, 1 December 1993 (1993-12-01), pages 11212 - 11216
CAVAZZANA-CALVO: "Transfusion independence and HMGA2 activation after gene therapy of human β-thalassaemia", NATURE, vol. 467, 16 September 2010 (2010-09-16), pages 318 - 322, XP055258772, DOI: 10.1038/nature09328
CHAHLAVI ET AL., CANCER RES, vol. 65, 2005, pages 5428 - 5438
CHAVEZ A ET AL.: "Highly efficient Cas9-mediated transcriptional programming", NAT METHODS., vol. 12, 2015, pages 326 - 328, XP055694813, DOI: 10.1038/nmeth.3312
CHEN BGILBERT LACIMINI BASCHNITZBAUER JZHANG WLI GWPARK JBLACKBURN EHWEISSMAN JSQI LS: "Dynamic imaging of genomic loci in living human cells by an optimized CRISPR/Cas system", CELL, vol. 155, no. 7, 2013, pages 1479 - 91, XP093127685, DOI: 10.1016/j.cell.2013.12.001
CHEN ET AL., CELL, vol. 155, 2013, pages 1479 - 1491
CHEN ET AL., NAT COMMUN, vol. 9, 2018, pages 5065
CHEN ET AL., NATURE COMMUNICATIONS, vol. 8, 2017, pages 14958
CHEN ET AL.: "Enhanced prime editing systems by manipulating cellular determinants of editing outcomes", CELL, vol. 184, no. 22, 2021, pages 5635 - 5652, XP055915530, DOI: 10.1016/j.cell.2021.09.018
CHENG ET AL., CELL RES, vol. 26, 2016, pages 254 - 257
CHENLI, GENE, vol. 408, no. 1-2, 2008, pages 51 - 63
CHOI PSMEYERSON M., NAT COMMUN, vol. 5, 2014, pages 3728
CHOUDHURY ET AL., ONCOTARGET, vol. 7, no. 29, 19 July 2016 (2016-07-19), pages 46545 - 46556
CHRISTENSEN SM ET AL.: "RNA from the 5' end of the R2 retrotransposon controls R2 protein binding to and cleavage of its DNA target site", PROC NATL ACAD SCI U S A., vol. 103, no. 47, 21 November 2006 (2006-11-21), pages 17602 - 7, XP055659527, DOI: 10.1073/pnas.0605476103
CITORIK RJMIMEE MLU TK: "Sequence-specific antimicrobials using efficiently delivered RNA-guided nucleases", NAT BIOTECHNOL, vol. 32, 2014, pages 1141 - 1145, XP055545744, DOI: 10.1038/nbt.3011
COCHRANE ET AL., CHEM BIOL, vol. 14, 2007, pages 97 - 105
CONG LZHOU RKUO YCCUNNIFF MZHANG F.: "Comprehensive interrogation of natural TALE DNA-binding modules and transcriptional repressor domains", NAT COMMUN., vol. 3, 2012, pages 968, XP002700145, DOI: 10.1038/ncomms1962
COOPER ET AL., BLOOD, vol. 101, 2003, pages 1637 - 1644
COX DBT ET AL.: "RNA editing with CRISPR-Cas 13", SCIENCE., vol. 358, no. 6366, 24 November 2017 (2017-11-24), pages 1019 - 1027
CROWTHER ET AL.: "Genome-wide CRISPR-Cas9 screening reveals ubiquitous T cell cancer targeting via the monomorphic MHC class I-related protein MR1", NATURE IMMUNOLOGY, vol. 21, 2020, pages 178 - 185, XP037525542, DOI: 10.1038/s41590-019-0578-8
CSABA REVESZPETER HAMAR: "Gene Therapy Applications", 2011, article "Delivery Methods to Target RNAs in the Kidney"
D. LISCH, TRENDS IN PLANT SCI., vol. 7, no. 11, 2002, pages 498 - 504
DALKARA ET AL., SCI TRANSL MED, vol. 5, 2013
DANN ET AL., CELL, vol. 130, 2009, pages 878 - 892
D'ASTOLFO DSPAGLIERO RJPRAS A ET AL., CELL, vol. 161, 2015, pages 674 - 690
DAVEY MR ET AL., PLANT MOL BIOL., vol. 13, no. 3, September 1989 (1989-09-01), pages 273 - 85
DAWSON MAKOUZARIDES T.: "Cancer epigenetics: from mechanism to therapy", CELL, vol. 150, no. 1, 2012, pages 12 - 27, XP028400980, DOI: 10.1016/j.cell.2012.06.013
DELLINGER ET AL., J. AM. CHEM. SOC., vol. 133, 2011, pages 11540 - 11546
DENG ET AL., PNAS USA, vol. 112, no. 38, 2015, pages 11870 - 11875
DI STASI ET AL., THE NEW ENGLAND JOURNAL OF MEDICINE, vol. 365, 2011, pages 1735 - 1683
DIGIUSTO ET AL., SCI TRANSL MED, vol. 2, 2010
DRAKOPOULOU: "Review Article, The Ongoing Challenge of Hematopoietic Stem Cell-Based Gene Therapy for ø- Thalassemia", STEM CELLS INTERNATIONAL, vol. 2011, pages 10
DU X ET AL., BIOMATERIALS, vol. 35, 2014, pages 5580 - 90
DUDLEY ET AL., JOURNAL OF CLINICAL ONCOLOGY, vol. 23, no. 10, 2005, pages 2346 - 57
DUDLEY ET AL., SCIENCE, vol. 298, no. 5594, 2002, pages 850 - 4
DUMONCEAUX ET AL., MOLECULAR THERAPY, vol. 18, no. 5, May 2010 (2010-05-01), pages 881 - 887
DURFEE PN ET AL., ACS NANO, vol. 10, 2016, pages 8325 - 45
DURRANT ET AL., LARGE-SCALE DISCOVERY OF RECOMBINASES FOR INTEGRATING DNA INTO THE HUMAN GENOME
EDWARDSBATEY, J MOL BIOL, vol. 385, 2009, pages 938 - 948
EDWARDSFERRE-D'AMARE, STRUCTURE, vol. 14, 2006, pages 1459 - 1468
EICKBUSH TH ET AL.: "Integration, Regulation, and Long-Term Stability of R2 Retrotransposons", MICROBIOL SPECTR., vol. 3, no. 2, April 2015 (2015-04-01), XP055660172, DOI: 10.1128/microbiolspec.MDNA3-0011-2014
EL-ANDALOUSSI S ET AL., NAT PROTOC., vol. 7, no. 12, 2012, pages 2112 - 902
ESSEN, M. ET AL., J. IMMUNOL., vol. 173, 2004, pages 384 - 393
EULALIO ET AL., NATURE, vol. 492, 2012, pages 376
EYQUEM ET AL., NATURE, vol. 543, 2017, pages 113 - 117
FARZADFARD FPERLI SDLU TK: "Tunable and multifunctional eukaryotic transcription factors based on CRISPR/Cas", ACS SYNTH BIOL., vol. 2, 2013, pages 604 - 613, XP055194786, DOI: 10.1021/sb400081r
FENG ET AL., TRANSPLANTATION, vol. 87, no. 9, May 2009 (2009-05-01), pages 1283 - 1289
FRIEDMAN ET AL.: "Effective Targeting of Multiple BCMA-Expressing Hematological Malignancies by Anti-BCMA CAR T Cells", HUM GENE THER., 8 March 2018 (2018-03-08)
FU ET AL., NAT COMMUN, vol. 7, 2016, pages 11707
FU ET AL., TRANSGENIC RES., vol. 9, no. 1, February 2000 (2000-02-01), pages 11 - 9
FUREY, C.SCHER, G.YE, N. ET AL.: "Development of a nucleoside-modified mRNA vaccine against clade 2.3.4.4b H5 highly pathogenic avian influenza virus", NAT COMMUN, vol. 15, 2024, pages 4350
GALIZI ROBERTO ET AL: "Engineering CRISPR guide RNA riboswitches forin vivoapplications", CURRENT OPINION IN BIOTECHNOLOGY, LONDON, GB, vol. 55, 25 September 2018 (2018-09-25), pages 103 - 113, XP085596476, ISSN: 0958-1669, DOI: 10.1016/J.COPBIO.2018.08.007 *
GAO ZONGLIANG ET AL: "Improvement of the CRISPR-Cpf1 system with ribozyme-processed crRNA", RNA BIOLOGY, vol. 15, no. 12, 2 December 2018 (2018-12-02), pages 1458 - 1467, XP055935701, ISSN: 1547-6286, DOI: 10.1080/15476286.2018.1551703 *
GARST ET AL., J BIOL CHEM, vol. 283, 2008, pages 22347 - 22351
GAUDELLI ET AL.: "Directed evolution of adenine base editors with increased activity and therapeutic application", NATURE BIOTECH., vol. 38, 2020, pages 892 - 900, XP037187542, DOI: 10.1038/s41587-020-0491-6
GAUDELLI NM ET AL.: "Programmable base editing of A.T to G·C in genomic DNA without DNA cleavage", NATURE, vol. 551, 23 November 2017 (2017-11-23), pages 464 - 471
GEORGIADIS ET AL.: "Molecular Therapy", 6 March 2018, PRESS, article "Long Terminal Repeat CRISPR-CAR-Coupled ''Universal'' T Cells Mediate Potent Anti-leukemic Effects"
GILBERT ET AL., NAT STRUCT MOL BIOL, vol. 15, 2008, pages 1076 - 1083
GILLERON J. ET AL., NUCL. ACIDS RES., vol. 43, no. 16, 2015, pages 7984 - 8001
GOEDDEL: "GENE EXPRESSION TECHNOLOGY: METHODS IN ENZYMOLOGY", vol. 185, 1990, ACADEMIC PRESS
GOMAA AAKLUMPE HELUO MLSELLE KBARRANGOU RBEISEL CL: "Programmable removal of bacterial strains by use of genome-targeting composition, systems", MBIO, vol. 5, 2014, pages 00928 - 13
GOODWIN TJBUTLER MIPOULTER T: "Cryptons: a group of tyrosine-recombinase-encoding DNA transposons from pathogenic fungi", MICROBIOLOGY, vol. 149, 2003, pages 3099 - 3109
GRABUNDZIJA ET AL., NAT. COMMUN., vol. 9, 2018, pages 1278
GRECO ET AL.: "Improving the safety of cell therapy with the TK-suicide gene", FRONT. PHARMACOL., vol. 6, 2015, pages 95
GREEN, A.A. ET AL.: "Crystal Structure of Cas9 in Complex with Guide RNA and Target DNA", CELL, vol. 156, no. 5, 2014, pages 935 - 949
GREGORY DJZHANG YKOBZIK LFEDULOV AV: "Specific transcriptional enhancement of inducible nitric oxide synthase by targeted promoter demethylation", EPIGENETICS, vol. 8, 2013, pages 1205 - 1212
GRIMM, D. ET AL., J. VIROL., vol. 82, 2008, pages 5887 - 5911
GRZEBELUS ET AL., MOL. GENET. GENOMICS, vol. 275, no. 5, 2006, pages 450 - 459
GU ET AL., SCIENCE, vol. 359, 2018, pages 1050 - 1055
HAGSTROM ET AL., MOLECULAR THERAPY, vol. 10, no. 2, August 2004 (2004-08-01)
HAMAR ET AL., PROC NATL ACAD SCI, vol. 101, no. 41, October 2004 (2004-10-01), pages 14883 - 14888
HAN ET AL., GENOME BIOL. EVOL., vol. 6, no. 7, 2014, pages 1748 - 1757
HAN JS: "retrotransposons: mechanisms, recent developments, and unanswered questions", MOB DNA., vol. 1, no. 1, 12 May 2010 (2010-05-12), pages 15, XP021084898, DOI: 10.1186/1759-8753-1-15
HENDEL ET AL., NAT. BIOTECHNOL., vol. 33, no. 9, 2015, pages 985 - 989
HENDEL, NAT BIOTECHNOL., vol. 33, no. 9, 29 June 2015 (2015-06-29), pages 985 - 9
HENGJI ZHAN: "Engineering Cellular Signal Sensors based on CRISPR-sgRNA Reconstruction Approaches", INTERNATIONAL JOURNAL OF BIOLOGICAL SCIENCES, vol. 16, no. 8, 21 February 2020 (2020-02-21), pages 1441 - 1449, XP093159483, ISSN: 1449-2288, DOI: 10.7150/ijbs.42299 *
HICKE BJSTEPHENS AW: "Escort aptamers: a delivery service for diagnosis and therapy.", J CLIN INVEST, vol. 106, 2000, pages 923 - 928, XP002280743, DOI: 10.1172/JCI11324
HICKERSON ET AL., MOLECULAR THERAPY-NUCLEIC ACIDS, vol. 2, 2013, pages 129
HILTON IB ET AL.: "Epigenome editing by a CRISPR-Cas9-based acetyltransferase activates genes from promoters and enhancers", NAT BIOTECHNOL., 2015
HINRICHS CSROSENBERG SA: "Exploiting the curative potential of adoptive T-cell therapy for cancer", IMMUNOL REV, vol. 257, no. 1, 2014, pages 56 - 71, XP055249662, DOI: 10.1111/imr.12132
HIRANO SEIICHI ET AL: "Structure of the OMEGA nickase IsrB in complex with [omega]RNA and target DNA", NATURE, vol. 610, no. 7932, 12 October 2022 (2022-10-12), London, pages 575 - 581, XP093208203, ISSN: 0028-0836, DOI: 10.1038/s41586-022-05324-6 *
HOUOT ET AL.: "T-cell-based immunotherapy: adoptive cell transfer and checkpoint inhibition", CANCER IMMUNOL RES, vol. 3, no. 10, 2015, pages 1115 - 22, XP055437818, DOI: 10.1158/2326-6066.CIR-15-0190
HSU, P.SCOTT, D.WEINSTEIN, J.RAN, FA.KONERMANN, S.AGARWALA, V.LI, Y.FINE, E.WU, X.SHALEM, O., NAT BIOTECHNOL, 2013
HU, K.XU, K.WEN, J. ET AL.: "Helitron distribution in Brassicaceae and whole Genome Helitron density as a character for distinguishing plant species", BMC BIOINFORMATICS, vol. 20, 2019, pages 354
HUGHES ET AL., HUMAN GENE THERAPY, vol. 16, 2005, pages 457 - 472
HUNTER ET AL., BLOOD, vol. 104, no. 26, 2004, pages 4881
IOANNIDI ET AL., DRAG-AND-DROP GENOME INSERTION WITHOUT DNA CLEAVAGE WITH CRISPR-DIRECTED INTEGRASES
IRVING ET AL.: "Engineering Chimeric Antigen Receptor T-Cells for Racing in Solid Tumors: Don't Forget the Fuel", FRONT. IMMUNOL., 3 April 2017 (2017-04-03)
JENSONRIDDELL: "Design and implementation of adoptive therapy with chimeric antigen receptor-modified T cells", IMMUNOL REV., vol. 257, no. 1, 2014, pages 127 - 144
JI Q ET AL.: "Engineered zinc-finger transcription factors activate OCT4 (POUSF1), SOX2, KLF4, c-MYC (MYC) and miR302/367", NUCLEIC ACIDS RES., vol. 42, 2014, pages 6158 - 6167, XP055378599, DOI: 10.1093/nar/gku243
JIANG ET AL., MOLECULAR PHARMACEUTICS, vol. 6, no. 3, May 2009 (2009-05-01), pages 727 - 737
JIN ET AL.: "CD70, a novel target of CAR T-cell therapy for gliomas", NEURO ONCOL., vol. 20, no. 1, 10 January 2018 (2018-01-10), pages 55 - 65, XP055464384, DOI: 10.1093/neuonc/nox116
JOHNSON ET AL., BLOOD, vol. 114, no. 3, 2009, pages 535 - 46
JORDAN L. DOMAN ET AL.: "Evaluation and minimization of Cas9-independent off-target DNA editing by cytosine base editors", NAT BIOTECHNOL, 2020
JUNG ET AL., MOLECULAR THERAPY, vol. 21, no. 4, April 2013 (2013-04-01), pages 834 - 841
JUNKER ET AL., J UROL., vol. 173, 2005, pages 2150 - 2153
KALOS ET AL., SCIENCE TRANSLATIONAL MEDICINE, vol. 3, no. 95, 2011
KAMTA ET AL.: "Advancing Cancer Therapy with Present and Emerging Immuno-Oncology Approaches", FRONT. ONCOL., vol. 7, 2017, pages 64
KANG ET AL., MOL CELL, vol. 33, 2009, pages 784 - 790
KANG JGPARK JSKO JHKIM YS: "Regulation of gene expression by altered promoter methylation using a CRISPR/Cas9-mediated epigenetic editing system", SCI REP., vol. 9, no. 1, 2019, pages 11960, XP055688645, DOI: 10.1038/s41598-019-48130-3
KAPITONOV, V. ET AL., J. BACTERIOL., vol. 198, 2015, pages 797 - 807
KAWALE, A.A.BURMANN, B.M.: "Inherent backbone dynamics fine-tune the functional plasticity of Tudor domains", STRUCTURE, 2021
KEARNS NAPHAM HTABAK B ET AL.: "Functional annotation of native enhancers with a Cas9-histone demethylase fusion", NAT METHODS., vol. 12, no. 5, 2015, pages 401 - 403, XP055931429, DOI: 10.1038/nmeth.3325
KEEFE, ANTHONY D.SUPRIYA PAIANDREW ELLINGTON: "Aptamers as therapeutics.", NATURE REVIEWS DRUG DISCOVERY, vol. 9, no. 7, 2010, pages 537 - 550, XP055260503, DOI: 10.1038/nrd3141
KELLY ET AL., J. BIOTECH., vol. 233, 2016, pages 74 - 83
KINOUCHI ET AL., GENE THERAPY, vol. 15, 2008, pages 1126 - 1130
KLEIN RM ET AL., BIOTECHNOLOGY, vol. 24, 1992, pages 384 - 6
KLEINFERRE-D'AMARE, SCIENCE, vol. 314, no. 5796, 2006, pages 1752 - 1756
KLEINSTIVER BP ET AL.: "Engineered CRISPR-Cas9 nucleases with altered PAM specificities", NATURE, vol. 523, no. 7561, 23 July 2015 (2015-07-23), pages 481 - 5, XP055293257, DOI: 10.1038/nature14592
KNIGHT ET AL., SCIENCE, vol. 350, 2015, pages 823 - 826
KOBAYASHI ET AL., JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, vol. 308, no. 2, February 2004 (2004-02-01), pages 688 - 693
KOCHENDERFER ET AL., J IMMUNOTHER., vol. 32, no. 7, 2009, pages 689 - 702
KOGURE K ET AL., J CONTROL RELEASE, vol. 98, 2004, pages 317 - 23
KOMOR AC ET AL.: "Programmable editing of a target base in genomic DNA without double-stranded DNA cleavage", NATURE, vol. 533, no. 7603, 19 May 2016 (2016-05-19), pages 420 - 4, XP093078921, DOI: 10.1038/nature17946
KONERMANN S ET AL.: "Genome-scale transcriptional activation by an engineered CRISPR-Cas9 complex", NATURE, vol. 517, 2015, pages 583 - 588, XP093213286, DOI: 10.1038/nature14136
KONERMANN S ET AL.: "Optical control of mammalian endogenous transcription and epigenetic states", NATURE, vol. 500, 2013, pages 472 - 476, XP055696669, DOI: 10.1038/nature12466
KOOREMAN, NIGEL G. ET AL.: "Autologous iPSC-Based Vaccines Elicit Anti-tumor Responses In Vivo", CELL STEM CELL, vol. 22, pages 1 - 13
KULSHINA ET AL., NAT STRUCT MOL BIOL, vol. 16, 2009, pages 1218 - 1223
KUSHIBIKIA ET AL., J CONTROLLED RELEASE, vol. 105, no. 3, July 2005 (2005-07-01), pages 318 - 331
LAMBOWITZ AM ET AL.: "Group II Introns: Mobile Ribozymes that Invade DNA", COLD SPRING HARB PERSPECT BIOL., vol. 3, no. 8, August 2011 (2011-08-01), pages 003616, XP055514471, DOI: 10.1101/cshperspect.a003616
LAMPSON ET AL.: "Retrons, msDNA, and the bacterial genome", CYTOGENET GENOME RES, vol. 110, 2005, pages 491 - 499, XP055673617, DOI: 10.1159/000084982
LARSON ET AL., SURGERY, vol. 142, no. 2, August 2007 (2007-08-01), pages 262 - 269
LAUKOVA, L.KONEČNÁ, B.JANOVICOVA, L.VLKOVA, B.CELEC, P.: "Deoxyribonucleases and Their Applications in Biomedicine", BIOMOLECULES, vol. 10, 2020, pages 1036
LE MERCIER I ET AL.: "Beyond CTLA-4 and PD-1, the generation Z of negative checkpoint regulators", FRONT. IMMUNOL., vol. 6, 2015, pages 418
LEACHMAN ET AL., MOLECULAR THERAPY, vol. 18, no. 2, February 2010 (2010-02-01), pages 442 - 446
LEE ET AL., ELIFE, vol. 6, 2017, pages 25312
LEE K ET AL., NAT BIOMED ENG, vol. 1, 2017, pages 889 - 901
LEE: "Improved ex vivo expansion of adult hematopoietic stem cells by overcoming CUL4-mediated degradation of HOXB4.", BLOOD, vol. 121, no. 20, 16 May 2013 (2013-05-16), pages 4082 - 9
LEGUT ET AL.: "CRISPR-mediated TCR replacement generates superior anticancer transgenic T cells", BLOOD, vol. 131, no. 3, 2018, pages 311 - 322, XP055536727, DOI: 10.1182/blood-2017-05-787598
LENS ET AL., J IMMUNOL., vol. 174, 2005, pages 6212 - 6219
LEVY-NISSENBAUM, ETGAR ET AL.: "Nanotechnology and aptamers: applications in drug delivery.", TRENDS IN BIOTECHNOLOGY, vol. 26, no. 8, 2008, pages 442 - 449, XP022930419, DOI: 10.1016/j.tibtech.2008.04.006
LI ET AL., J. MOL. BIOL., vol. 430, no. 21, 2018, pages 4401 - 4418
LI ET AL., MOLECULAR THERAPY, vol. 17, no. 12, December 2009 (2009-12-01), pages 2067 - 2077
LI ET AL., NATURE BIOMEDICAL ENGINEERING, vol. 1, 2017, pages 0066
LI ET AL.: "Adoptive cell therapy with CD4+ T helper 1 cells and CD8+ cytotoxic T cells enhances complete rejection of an established tumor, leading to generation of endogenous memory responses to non-targeted tumor epitopes", CLIN TRANSL IMMUNOLOGY, vol. 6, no. 10, October 2017 (2017-10-01), pages 160
LI JMAHATA BESCOBAR M ET AL.: "Programmable human histone phosphorylation and gene activation using a CRISPR/Cas9-based chromatin kinase", NAT COMMUN., vol. 12, no. 1, 2021, pages 896
LI XU ET AL: "Empower multiplex cell and tissue-specific CRISPR-mediated gene manipulation with self-cleaving ribozymes and tRNA", NUCLEIC ACIDS RESEARCH, vol. 45, no. 5, 30 October 2016 (2016-10-30), GB, pages e28, XP055515116, ISSN: 0305-1048, DOI: 10.1093/nar/gkw1048 *
LINO CA ET AL.: "Delivering CRISPR: a review of the challenges and approaches", DRUG DELIVERY, vol. 25, no. 1, 2018, pages 1234 - 1257, XP055573342, DOI: 10.1080/10717544.2018.1474964
LIN-YANGA ET AL., PNAS, vol. 106, no. 10, 10 March 2009 (2009-03-10)
LIU PQ ET AL.: "Regulation of an endogenous locus using a panel of designed zinc finger proteins targeted to accessible chromatin regions. Activation of vascular endothelial growth factor", A. J BIOL CHEM., vol. 276, 2001, pages 11323 - 11334
LIU XSWU HJI X ET AL.: "Editing DNA Methylation in the Mammalian Genome", CELL, vol. 167, no. 1, 2016, pages 233 - 247, XP029748854, DOI: 10.1016/j.cell.2016.08.056
LUKAS OESINGHAUS ET AL: "Switching the activity of Cas12a using guide RNA strand displacement circuits", NATURE COMMUNICATIONS, vol. 10, no. 1, 7 May 2019 (2019-05-07), XP055738806, DOI: 10.1038/s41467-019-09953-w *
LUO DSALTZMAN WM., NAT BIOTECHNOL, vol. 18, 2000, pages 893 - 5
LUO GF ET AL., SCI REP, vol. 4, 2014, pages 6064
MA ET AL., ANAL CHEM, vol. 89, 2017, pages 12896 - 12901
MA ET AL., J CELL BIOL, vol. 214, 2016, pages 529 - 537
MA ET AL., NAT BIOTECHNOL, vol. 34, 2016, pages 528 - 530
MA ET AL., PROC NATL ACAD SCI U S A, vol. 112, 2015, pages 3002 - 3007
MAEDER MLLINDER SJCASCIO VMFU YHO QHJOUNG JK: "CRISPR RNA-guided activation of endogenous human genes", NAT METHODS., vol. 10, no. 10, 2013, pages 977 - 979, XP055291599, DOI: 10.1038/nmeth.2598
MAHER ET AL., NATURE BIOTECHNOLOGY, vol. 20, 2002, pages 70 - 75
MALEK ET AL., TOXICOLOGY AND APPLIED PHARMACOLOGY, vol. 236, no. 1, April 2009 (2009-04-01), pages 97 - 108
MALIK HS ET AL.: "The age and evolution of non-LTR retrotransposable elements", MOL BIOL EVOL., vol. 16, no. 6, June 1999 (1999-06-01), pages 793 - 805
MANOHARAN, M. CURR. OPIN. CHEM. BIOL., vol. 8, 2004, pages 570 - 9
MARTEN H. HOFKERJAN VAN DEURSEN, TRANSGENIC MOUSE METHODS AND PROTOCOLS, 2011
MARTIN-OROZCO N ET AL.: "T helper 17 cells promote cytotoxic T cell activation in tumor immunity", IMMUNITY, vol. 31, no. 5, 20 November 2009 (2009-11-20), pages 787 - 98
MAUS ET AL.: "Adoptive Immunotherapy for Cancer or Viruses", ANNUAL REVIEW OF IMMUNOLOGY, vol. 32, 2014, pages 189 - 225, XP002781210
MAXWELL ET AL., PROC. NATL. ACAD. SCI. USA, vol. 84, 1987, pages 699 - 703
METTANANDA ET AL.: "Editing an α-globin enhancer in primary human hematopoietic stem cells as a treatment for β-thalassemia", NAT COMMUN., vol. 8, no. 1, 4 September 2017 (2017-09-04), pages 424
MIKHAYLOVA ET AL., ANCER GENE THERAPY, vol. 16, no. 3, March 2011 (2011-03-01), pages 217 - 226
MILLINGTON-WARD ET AL., MOLECULAR THERAPY, vol. 19, no. 4, April 2011 (2011-04-01), pages 642 - 649
MINAKHINA S ET AL.: "Tn5053 family transposons are res site hunters sensing plasmidal res sites occupied by cognate resolvases", MOL MICROBIOL., vol. 33, no. 5, September 1999 (1999-09-01), pages 1059 - 68
MISKEY ET AL., NUCLEIC ACID RES., vol. 31, no. 23, 2003, pages 6873 - 6881
MIYAGISHI ET AL., NATURE BIOTECH., vol. 20, 2002
MOLITORIS ET AL., J AM SOC NEPHROL, vol. 20, 2009, pages 1754 - 1764
MOLITORIS ET AL., J AM SOC NEPHROL, vol. 20, no. 8, August 2009 (2009-08-01), pages 1754 - 1764
MORLOT ET AL., J. BIOL. CHEM., vol. 280, 2005, pages 15984 - 91
MOROCZ ET AL., JOURNAL OF MAGNETIC RESONANCE IMAGING, vol. 8, no. 1, 1998, pages 136 - 142
MOUHIEDDINEGHOBRIAL: "Immunotherapy in Multiple Myeloma: The Era of CAR T Cell Therapy", HEMATOLOGIST, vol. 15, pages 20180500
MOUSSATOV ET AL., ULTRASONICS, vol. 36, no. 8, 1998, pages 893 - 900
MOUT R, ACS NANO, vol. 11, 2017, pages 2452 - 8
MUKHERJEA ET AL., ANTIOXIDANTS & REDOX SIGNALING, no. 5, 2010
MURANSKI P ET AL.: "Tumor-specific Thl7-polarized cells eradicate large established melanoma", BLOOD, vol. 112, no. 2, 15 July 2008 (2008-07-15), pages 362 - 73, XP055503075, DOI: 10.1182/blood-2007-11-120998
NAIGAMWALLA ET AL., JOURNAL OF MOLECULAR BIOLOGY, vol. 282, 1998, pages 265 - 274
NAIR, JK ET AL., JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, vol. 136, no. 49, 2014, pages 16958 - 16961
NAKAGAWA ET AL., NAT. BIOTECHNOL., vol. 26, 2008, pages 101 - 106
NAKAMURA T ET AL., ACC CHEM RES, vol. 45, 2012, pages 1113 - 21
NAKAMURA, Y. ET AL.: "Codon usage tabulated from the international DNA sequence databases: status for the year 2000", NUCL. ACIDS RES., vol. 28, 2000, pages 292, XP002941557, DOI: 10.1093/nar/28.1.292
NAT METHODS, vol. 15, 2018, pages 928 - 931
NICHOLSON ET AL., MOLECULAR IMMUNOLOGY, vol. 34, 1997, pages 1157 - 1165
NICOLAS ET AL., MICROBIOL SPECTR., vol. 3, no. 4, 2015
NINICHUK ET AL., AM J PATHOL, vol. 172, no. 3, March 2008 (2008-03-01), pages 628 - 637
NISHIMASU ET AL.: "Crystal structure of Cas9 in complex with guide RNA and target DNA", CELL, 2014
NOWAK ET AL., NUCLEIC ACIDS RES, vol. 44, no. 20, 2016, pages 9555 - 9564
NOWOTNYMARCIN ET AL.: "Specific recognition of RNA/DNA hybrid and enhancement of human RNase H1 activity by HBD.", THE EMBO JOURNAL, vol. 27, no. 7, 2008, pages 1172 - 81, XP093164453, DOI: 10.1038/emboj.2008.44
NUDLER, E.MIRONOV, A.S., TRENDS BIOCHEM SCI, vol. 29, 2004, pages 11 - 17
OKITA ET AL., NATURE, vol. 448, 2007, pages 260 - 262
ORTHWEIN ET AL.: "Daniel Durocher's lab at the Mount Sinai Hospital in Ottawa, Canada", NATURE, vol. 16142, 9 December 2015 (2015-12-09)
OSTERGAARD ET AL., BIOCONJUGATE CHEM., vol. 26, no. 8, 2015, pages 1451 - 1455
PAIGE, JEREMY S.KAREN Y. WUSAMIE R. JAFFREY: "RNA mimics of green fluorescent protein.", SCIENCE, vol. 333, no. 6042, 2011, pages 642 - 646
PARK ET AL.: "CD70 as a target for chimeric antigen receptor T cells in head and neck squamous cell carcinoma", ORAL ONCOL., vol. 78, March 2018 (2018-03-01), pages 145 - 150, XP085353974, DOI: 10.1016/j.oraloncology.2018.01.024
PARKER ET AL., J. IMMUNOL., vol. 152, 1994, pages 163
PARKS AR, PLASMID, vol. 61, no. 1, January 2009 (2009-01-01), pages 1 - 14
PARTRIDGE SR ET AL.: "Mobile Genetic Elements Associated with Antimicrobial Resistance", CLIN MICROBIOL REV, vol. 31, no. 4, 1 August 2018 (2018-08-01)
PELLESTOR, F.PAULASOVA, P.: "The peptide nucleic acids (PNAs), powerful tools for molecular genetics and cytogenetics", EUR J HUM GENET, vol. 12, 2004, pages 694 - 700
PENG ET AL., RSC CHEM. BIOL., vol. 2, 2021, pages 1370
PEREZ-PINERA P ET AL.: "Synergistic and tunable human gene activation by combinations of synthetic transcription factors", NAT METHODS., vol. 10, 2013, pages 239 - 242, XP055206832, DOI: 10.1038/nmeth.2361
PFLUEGER C.TAN D.SWAIN T.NGUYEN T.PFLUEGER J.NEFZGER C.POLO J.M.FORD E.LISTER R.: "A modular dCas9-SunTag DNMT3A epigenome editing system overcomes pervasive off-target activity of direct fusion dCas9-DNMT3A constructs", GENOME RES., vol. 28, 2018, pages 1193 - 1206, XP055975093, DOI: 10.1101/gr.233049.117
PHELPS KJ ET AL.: "Recognition of duplex RNA by the deaminase domain of the RNA editing enzyme ADAR2", NUCLEIC ACIDS RES., vol. 43, no. 2, January 2015 (2015-01-01), pages 1123 - 32
POIROT ET AL.: "Multiplex genome edited T-cell manufacturing platform for ''off-the-shelf'' adoptive T-cell immunotherapies", CANCER RES, vol. 75, no. 18, 2015, pages 3853, XP055568648, DOI: 10.1158/0008-5472.CAN-14-3321
PURSCHKE ET AL., PROC NATL ACAD SCI, vol. 103, no. 13, March 2006 (2006-03-01), pages 5173 - 5178
Q. ZHANG ET AL., PLOS ONE, vol. 5, no. 7, July 2010 (2010-07-01), pages 1 - 13
QASIM ET AL.: "Molecular remission of infant B-ALL after infusion of universal TALEN gene-edited CAR T cells", SCI TRANSL MED., vol. 9, no. 374, 25 January 2017 (2017-01-25), XP055850736, DOI: 10.1126/scitranslmed.aaj2013
QI ET AL., GENE THERAPY, 2013, pages 1 - 9
RAGDARM ET AL., PNAS, vol. 112, 2015, pages 11870 - 11875
RAJASAGI ET AL.: "Systematic identification of personal tumor-specific neoantigens in chronic lymphocytic leukemia", BLOOD, vol. 124, no. 3, 17 July 2014 (2014-07-17), pages 453 - 62, XP055322841, DOI: 10.1182/blood-2014-04-567933
RAMOS ET AL., STEM CELLS, vol. 28, no. 6, 2010, pages 1107 - 15
RASILA ET AL., PLOS ONE, vol. 7, no. 5, 2012, pages E37922
REJALI ET AL., HEAR RES., vol. 228, no. 1-2, June 2007 (2007-06-01), pages 180 - 7
REN ET AL., CELL RES., vol. 24, 2014, pages 1146 - 1149
REN ET AL., CLIN CANCER RES, vol. 23, no. 9, 2017, pages 2255 - 2266
REN ET AL.: "Multiplex genome editing to generate universal CAR T cells resistant to PD1 inhibition", CLIN CANCER RES., vol. 23, no. 9, 1 May 2017 (2017-05-01), pages 2255 - 2266, XP055565027, DOI: 10.1158/1078-0432.CCR-16-1300
RESTIFO ET AL.: "Adoptive immunotherapy for cancer: harnessing the T cell response", NAT. REV. IMMUNOL., vol. 12, no. 4, 2015, pages 269 - 281, XP055034896, DOI: 10.1038/nri3191
RICHTER MF ET AL.: "Phage-assisted evolution of an adenine base editor with improved Cas domain compatibility and activity", NAT BIOTECHNOL, 2020
RIVENBARK AG ET AL.: "Epigenetic reprogramming of cancer cells via targeted DNA methylation", EPIGENETICS, vol. 7, 2012, pages 350 - 360, XP002756482, DOI: 10.4161/epi.19507
ROSENBERGRESTIFO: "Adoptive cell transfer as personalized immunotherapy for human cancer", SCIENCE, vol. 348, no. 6230, 2015, pages 62 - 68, XP055256712, DOI: 10.1126/science.aaa4967
ROSIN ET AL., MOLECULAR THERAPY, vol. 19, no. 12, December 2011 (2011-12-01), pages 1286 - 2200
RUBIN ET AL., GENETICS, vol. 158, no. 3, 2001, pages 949 - 957
SAHAY G. ET AL., NATURE BIOTECHNOLOGY, vol. 31, 2013, pages 653 - 658
SAITO MAKOTO ET AL: "Fanzor is a eukaryotic programmable RNA-guided endonuclease", NATURE, vol. 620, no. 7974, 28 June 2023 (2023-06-28), London, pages 660 - 668, XP093252294, ISSN: 0028-0836, DOI: 10.1038/s41586-023-06356-2 *
SALTPLONTKE, DRUG DISCOVERY TODAY, vol. 10, 2005, pages 1299 - 1306
SAMBROOKBOEHRINGER MANNHEIM ET AL.: "Nonradioactive In Situ Hybridization Application Manual", 1989
SAMBROOKFRITSCHMANIATIS: "Molecular Cloning: A Laboratory Manual", 2012, HUMANA PRESS, article "Oligonucleotide Synthesis: Methods and Applications", pages: 288
SCARINGE ET AL., J. AM. CHEM. SOC., vol. 120, 1998, pages 11820 - 11821
SCARINGE, METHODS ENZYMOL., vol. 317, 2000, pages 3 - 18
SCHOLTHOF ET AL., ANNU REV PHYTOPATHOL., vol. 34, 1996, pages 299 - 323
SCHROEDER A ET AL., J INTERN MED., vol. 267, no. 1, January 2010 (2010-01-01), pages 9 - 21
SCHULERHU ET AL.: "Structural basis for RNA-guided DNA cleavage by IscB-OMEGA guide molecule and mechanistic comparison with Cas9", SCIENCE, 2022
SCIENCE., vol. 343, no. 6166, 3 January 2014 (2014-01-03), pages 84 - 87
SEGAL ET AL.: "Mammalian retrovirus-like protein PEG10 packages its own mRNA and can be pseudo-typed for mRNA delivery", 373 SCIENCE, 2021, pages 882 - 889
SEGEL, M.LASH, B.SONG, J.LADHA, A.LIU, C. C.JIN, X.MEKHEDOV, S. L.MACRAE, R. K.KOONIN, E. V.ZHANG, F.: "Mammalian Retrovirus-like Protein PEG10 Packages Its Own MRNA and Can Be Pseudotyped for MRNA Delivery", SCIENCE, vol. 373, 2021, pages 882 - 889, XP055919110, DOI: 10.1126/science.abg6155
SERGANOV ET AL., CHEM BIOL, vol. 11, 2004, pages 1729 - 1741
SERGANOV ET AL., NATURE, vol. 441, 2006, pages 1167 - 1171
SERGANOV ET AL., NATURE, vol. 455, 2008, pages 1263 - 1267
SERGANOV ET AL., NATURE, vol. 458, 2009, pages 233 - 237
SERGANOV, A.NUDLER, E.: "CRISPR-mediated modular RNA-guided regulation of transcription in eukaryotes", CELL, vol. 154, 2013, pages 442 - 451
SHALEM, O.SANJANA, NE.HARTENIAN, E.SHI, X.SCOTT, DA.MIKKELSON, T.HECKL, D.EBERT, BL.ROOT, DE.DOENCH, JG.: "Genome-Scale CRISPR-Cas Knockout Screening in Human Cells.", SCIENCE
SHAO ET AL., ACS SYNTH BIOL, 2017
SHARIFIYE: "MyDGR: a server for identification and characterization of diversity-generating retroelements", NUCLEIC ACIDS RES., vol. 47, no. W1, 2 July 2019 (2019-07-02), pages 289 - 294
SHARMA ET AL., MEDCHEMCOMM, vol. 5, 2014, pages 1454 - 1471
SHERWOOD, A.V.HENKIN, T.M., ANNU REV MICROBIOL, vol. 70, 2016, pages 361 - 374
SHIMIZU ET AL., J AM SOC NEPHROL, vol. 21, 2010, pages 622 - 633
SHIMIZU ET AL., J AM SOC NEPHROLOGY, vol. 21, no. 4, April 2010 (2010-04-01), pages 622 - 633
SHUKLA ET AL., CHEMMEDCHEM, vol. 5, 2010, pages 328 - 49
SIDDIQUE AN ET AL.: "Targeted methylation and gene silencing of VEGF-A in human cells by using a designed Dnmt3a-Dnmt3L single-chain fusion protein with increased DNA methylation activity", J MOL BIOL., vol. 425, 2013, pages 479 - 491, XP055623261, DOI: 10.1016/j.jmb.2012.11.038
SIERIG G ET AL., INFECT IMMUN, vol. 71, 2003, pages 446 - 55
SINGHAL ET AL., CANCER RES, vol. 69, no. 10, May 2009 (2009-05-01), pages 4244 - 4251
SINZELLE ET AL., PNAS, vol. 105, no. 12, 2007, pages 4715 - 4720
SLETTEN ET AL., ANGEW. CHEM. INT. ED., vol. 48, 2009, pages 6974 - 6998
SMITH MCTHORPE HM: "Diversity in the serine recombinases.", MOL MICROBIOL., vol. 44, 2002, pages 299 - 307, XP008070129, DOI: 10.1046/j.1365-2958.2002.02891.x
SNOWDEN AWGREGORY PDCASE CCPABO CO: "Gene-specific targeting of H3K9 methylation is sufficient for initiating repression in vivo", CURR BIOL., vol. 12, 2002, pages 2159 - 2166, XP009157323, DOI: 10.1016/S0960-9822(02)01391-X
SOMASUNTHARAM ET AL., BIOMATERIALS, vol. 34, 2013, pages 7790
SONG ET AL., STEM CELLS DEV., vol. 24, no. 9, 1 May 2015 (2015-05-01), pages 1053 - 65
SPITALE ET AL., J BIOL CHEM, vol. 284, 2009, pages 11012 - 11016
STEPPER PKUNGULOVSKI GJURKOWSKA RZ ET AL.: "Efficient targeted DNA methylation with chimeric dCas9-Dnmt3a-Dnmt3L methyltransferase", NUCLEIC ACIDS RES., vol. 45, no. 4, 2017, pages 1703 - 1713, XP055459985, DOI: 10.1093/nar/gkw1112
STRICHCHERTOW, J. CLIN. MICROBIO., vol. 57, 2019, pages 01307 - 18
SUN W ET AL., ANGEW CHEM INT ED ENGL., vol. 54, no. 41, 5 October 2015 (2015-10-05), pages 12029 - 33
SUN W ET AL., J AM CHEM SOC., vol. 136, no. 42, 22 October 2014 (2014-10-22), pages 14722 - 5
SURETTE ET AL., J. BIOL. CHEM., vol. 266, 1991, pages 3118 - 3124
SURETTECHACONAS, J. BIOL CHEM., vol. 266, 1991, pages 17306 - 17313
SYDING LANICKL PKASPAREK PSEDLACEK R: "CRISPR/Cas9 Epigenome Editing Potential for Rare Imprinting Diseases: A Review", CELLS, vol. 9, no. 4, 2020, pages 993
TAKAHASHI ET AL., CELL, vol. 131, no. 5, 2007, pages 834 - 835
TAKAHASHIYAMANAKA, CELL, vol. 126, 2006, pages 663 - 76
TANEBAUM ET AL., CELL, vol. 159, 2014, pages 635 - 646
TENG KW ET AL., ELIFE, vol. 6, 2017, pages 25460
THAKORE PID'IPPOLITO AMSONG L ET AL.: "Highly specific epigenome editing by CRISPR-Cas9 repressors for silencing of distal regulatory elements", NAT METHODS., vol. 12, no. 12, 2015, pages 1143 - 1149, XP055623949, DOI: 10.1038/nmeth.3630
THOMAS J.PRITHAM E. J.: "Helitrons, the eukaryotic rolling-circle transposable elements", MICROBIOL. SPECTR., vol. 3, no. 2, 2015, pages 893 - 926
THOMPSON ET AL., NUCLEIC ACID THERAPEUTICS, vol. 22, no. 4, 2012
TIJSSEN: "Laboratory Techniques In Biochemistry And Molecular Biology-Hybridization With Nucleic Acid Probes Part 1", 1993, ELSEVIER, article "Overview of principles of hybridization and the strategy of nucleic acid probe assay"
TRANHUUHUE ET AL., ACUSTICA, vol. 83, no. 6, 1997, pages 1103 - 1106
TUERK CGOLD L: "Systematic evolution of ligands by exponential enrichment: RNA ligands to bacteriophage T4 DNA polymerase.", SCIENCE, vol. 249, 1990, pages 505 - 510, XP000647748, DOI: 10.1126/science.2200121
UNO Y ET AL., HUM GENE THER., vol. 22, no. 6, June 2011 (2011-06-01), pages 711 - 9
W.S. REZNIKOFF., ANNU REV. MICROBIOL., vol. 47, 1993, pages 945 - 963
WAHLGREN, NUCLEIC ACIDS RESEARCH, vol. 40, no. 17, 2012
WALEV I ET AL., PROC NATL ACAD SCI U S A, vol. 98, 2001, pages 3185 - 90
WANG ET AL., ACS SYNTH. BIOL., vol. 8, no. 5, 2019, pages 1079 - 1088
WANG ET AL., GENE THERAPY, vol. 13, no. 14, July 2006 (2006-07-01), pages 1097 - 1103
WANG ET AL., SCI REP, vol. 6, 2016, pages 26857
WANG ET AL., SCIENCE, vol. 365, no. 6459, 2020, pages 1301 - 1305
WANG J, QUAKE SR., PROC NATL ACAD SCI, vol. 111, 2014, pages 13157 - 62
WANG, K.WANG, H.LI, C.YIN, Z.XIAO, R.LI, Q.XIANG, Y.WANG, W.HUANG, J.CHEN, L.: "Genomic Profiling of Native R Loops with a DNA-RNA Hybrid Recognition Sensor", SCIENCE ADVANCES, 2021, pages 7
WATSON HA ET AL.: "SHP-1: the next checkpoint target for cancer immunotherapy?", BIOCHEM SOC TRANS., vol. 44, no. 2, 15 April 2016 (2016-04-15), pages 356 - 62, XP055469547, DOI: 10.1042/BST20150251
WATTS ET AL., DRUG. DISCOV. TODAY, vol. 13, 2008, pages 842 - 55
WATTS: "Hematopoietic Stem Cell Expansion and Gene Therapy", CYTOTHERAPY, vol. 13, no. 10, 2011, pages 1164 - 1171, XP055620372, DOI: 10.3109/14653249.2011.620748
WECHSLER ET AL., ANNUAL MEETING AND EXPOSITION OF THE AMERICAN SOCIETY OF HEMATOLOGY, 6 December 2015 (2015-12-06)
WICKER ET AL., PLANT PHYSIOL., vol. 132, no. 1, 2003, pages 52 - 63
WILKINSON ET AL.: "Structure of the R2 non-LTR retrotransposon initiating a target-primed reverse transcription", SCIENCE, vol. 380, no. 6642, 2023, pages 301 - 308
WILLIAMSRAYMOND J.: "Restriction endonuclease.", MOLECULAR BIOTECHNOLOGY, vol. 23, no. 3, 2003, pages 225 - 243
WOLFRUM ET AL., NATURE BIOTECHNOLOGY, vol. 25, no. 10, September 2007 (2007-09-01), pages 1149 - 1157
WU ET AL., NUCLEIC ACIDS RES, 2018
WU JW ET AL., NAT BIOTECHNOL., vol. 33, no. 11, November 2015 (2015-11-01), pages 1162 - 4
WU Y ET AL., CELL RES, vol. 25, 2015, pages 67 - 79
WU, CELL STEM CELL, vol. 13, 2013, pages 659 - 62
WUCHACONAS, J. BIOL. CHEM., vol. 267, 1992, pages 9552 - 9558
WUCHACONAS, J. BIOL. CHEM., vol. 269, 1994, pages 28829 - 28833
XIA CFBOADO RJPARDRIDGE WM: "Antibody-mediated targeting of siRNA via the human insulin receptor using avidin-biotin technology.", MOL PHARM., vol. 6, no. 3, May 2009 (2009-05-01), pages 747 - 51, XP055088899, DOI: 10.1021/mp800194y
XIA ET AL., NUCLEIC ACIDS RES., vol. 31, no. 17, 2003, pages 100
XIE ET AL.: "Genome Research gr.173427.114", 2014, COLD SPRING HARBOR LABORATORY PRESS, article "Seamless gene correction of β-thalassaemia mutations in patient-specific iPSCs using CRISPR/Cas9 and piggyback"
XU ET AL., CELL DISCOV., vol. 2, 3 May 2016 (2016-05-03), pages 16009
XU ET AL., SCI REP., vol. 5, 9 July 2015 (2015-07-09), pages 12065
Y. ZHANG ET AL., J AM SOC NEPHROL, vol. 17, no. 4, April 2006 (2006-04-01), pages 1090 - 1101
YAN ET AL.: "Discovery and characterization of the evolution, variation and functions of diversity-generating retroelements using thousands of genomes and metagenomes", BMC GENOMICS, vol. 20, 2019, pages 595
YE ET AL., PROTEIN CELL, vol. 8, 2017, pages 853 - 855
YE L ET AL., PROC NATL ACAD SCI USA, vol. 111, 2014, pages 9591 - 6
YE Y ET AL., BIOMATER SCI., 28 April 2020 (2020-04-28)
YEO NCCHAVEZ ALANCE-BYRNE A ET AL.: "An enhanced CRISPR repressor for targeted mammalian gene regulation", NAT METHODS., vol. 15, no. 8, 2018, pages 611 - 616, XP093069177, DOI: 10.1038/s41592-018-0048-5
YIANNIS A SAVVA ET AL.: "The ADAR protein family", GENOME BIOL., vol. 13, no. 12, 2012, pages 252, XP093159128, DOI: 10.1186/gb-2012-13-12-252
YU, J. ET AL., SCIENCE, vol. 318, no. 5858, 2007, pages 1917 - 1920
YUAN ET AL., AM J PHYSIOL RENAL PHYSIOL, vol. 295, 2008, pages 605 - 617
ZACHARAKIS ET AL., NAT MED., vol. 24, no. 6, June 2018 (2018-06-01), pages 724 - 730
ZAMORA, AM J RESPIR CRIT CARE MED, vol. 183, 2011, pages 531 - 538
ZHANG ET AL., GENETICS., vol. 166, no. 2, 2004, pages 971 - 986
ZHANG ET AL., MOL THER., vol. 7, no. 1, January 2003 (2003-01-01), pages 11 - 8
ZHANG Y.: "Transcriptional regulation by histone ubiquitination and deubiquitination", GENES DEV., vol. 17, no. 22, 2003, pages 2733 - 2740
ZHAO ET AL., BIOMATERIALS, vol. 100, 2016, pages 172 - 183
ZHAO ET AL., NAT GENET, vol. 38, 2006, pages 1341 - 7
ZHENG ET AL., AM J PATHOL, vol. 173, no. 4, October 2008 (2008-10-01), pages 973 - 980
ZHENG ET AL., PNAS, vol. 109, no. 30, 24 July 2012 (2012-07-24), pages 11975 - 11980
ZHOU ET AL., BLOOD, 2014
ZHOUJIEHUAJOHN J. ROSSI: "Aptamer-targeted cell-specific RNA interference.", SILENCE, vol. 1, no. 1, 2010, pages 4, XP021070609
ZOU W ET AL., HUM GENE THER., vol. 22, no. 4, April 2011 (2011-04-01), pages 465 - 75
ZUCKERMANN M ET AL., NAT COMMUN, vol. 6, 2015, pages 7391

Similar Documents

Publication Publication Date Title
Behera et al. Bimetallic nanoparticles: Green synthesis, applications, and future perspectives
WO2025117544A1 (en) Engineered omega guide molecule and iscb compositions, systems, and methods of use thereof
Oka et al. Ether‐linked analogue of 2‐arachidonoylglycerol (noladin ether) was not detected in the brains of various mammalian species
Denchev et al. Checklist of the larger basidiomycetes in Bulgaria
BR112022023582A2 (en) LEWIS/BRONSTED BINARY ACID/BASE AND NICKEL PHOSPHITE CATALYST SYSTEM (CO-CATALYST) FOR DIRECT ELECTROCHEMICAL REDUCTION OF CO2 TO HYDROCARBONS
Nogami et al. Highly Selective and Efficient Electrocatalytic Semihydrogenation of Diphenylacetylene in a PEM Reactor with Pt–Pd Alloy Cathode Catalysts
Chae et al. Exploring the critical role of binders in electrochemical CO2 reduction reactions
CN105602175B (en) A kind of cross-linked polyolefin Insulation Material and its preparation method and application
Qian et al. Mapping legaltech adoption and skill demand
Nilsen et al. Cortinarius atropileatus sp. nov.(Cortinariaceae) from New Zealand
Tin et al. Enhancement of chlorine resistance on RO membrane by surface modification with epoxy glue
Wang et al. Improvement of the performance of fuel cells anodes with Sm3+ doped CeO2
WO2025255373A2 (en) Fatty acid and cyclized derivatives of the immunomodulatory peptide rp-182 with improved anti-tumor activity, compositions, and methods of use thereof
Calvo et al. Needs and emerging opportunities of electron beam accelerators on radiation processing technology for industrial and environmental applications in South America
Rose et al. A novel, graphical representation of the classical radar range equation
Wolfson et al. Transfer hydrogenation of a carbonyl compound in glycerol-based solvent mixtures
Ahmed et al. Epoxy–novolac interpenetrating network adhesive for bonding of plasma-nitrided titanium
US9944571B2 (en) One-pot process using heterogeneous catalyst
US20250304783A1 (en) Plant-Based Tar Compound
Zinner et al. The phylogenetic position of “Papio ruhei”–a unique baboon taxon from Somalia
López-González et al. Electrochemical Evaluation of Rhus Vernicifera Biocathodes for Oxygen Reduction Reaction in Neutral Media with Application in Air-Breathing Hybrid Microfluidic Fuel Cells
Dagousset Elaboration of liquid and gel electrolytes for supercapacitor applications over a wide temperature range
Dubus High and very high energy gamma-ray emission from binaries
RU2667843C1 (en) Method of reconstruction of insulating surface of cathode-polarizable metal structures and structures (variants) and electroactive monomer immobilized as gel substance and method of providing polymeric organic compound with capability of electrodeposition from water solutions on cathode
Radhakrishnan et al. The electrochemical reduction of CO2 to value-added products

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 24827493

Country of ref document: EP

Kind code of ref document: A1